

The antibody aducanumab reduces AÎ² plaques in Alzhe

Nature

537, 50-56

DOI: [10.1038/nature19323](https://doi.org/10.1038/nature19323)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Aging, Dementia, and Alzheimer Disease. , 2015, , 99-131.		2
2	Amyloid-beta immunotherapy: the hope for Alzheimer disease?. Colombia Medica, 2016, , 203-212.	0.7	55
3	Integrated Approaches to Drug Discovery for Oxidative Stress-Related Retinal Diseases. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-9.	1.9	12
4	Biotic/Abiotic Stress-Driven Alzheimer's Disease. Frontiers in Cellular Neuroscience, 2016, 10, 269.	1.8	24
5	Checkpoints to the Brain: Directing Myeloid Cell Migration to the Central Nervous System. International Journal of Molecular Sciences, 2016, 17, 2030.	1.8	12
6	Emerging drugs to reduce abnormal β -amyloid protein in Alzheimer's disease patients. Expert Opinion on Emerging Drugs, 2016, 21, 377-391.	1.0	54
7	Towards Personalized Intervention for Alzheimer's Disease. Genomics, Proteomics and Bioinformatics, 2016, 14, 289-297.	3.0	19
8	Antibody-Based Drugs and Approaches Against Amyloid- β Species for Alzheimer's Disease Immunotherapy. Drugs and Aging, 2016, 33, 685-697.	1.3	48
9	The Future for Dementia Research: a Perspective from the Journal of Molecular Neuroscience. Journal of Molecular Neuroscience, 2016, 60, 410-411.	1.1	0
10	Attack on amyloid- β protein. Nature, 2016, 537, 36-37.	13.7	42
11	Cometary dust under the microscope. Nature, 2016, 537, 37-38.	13.7	4
12	Translational biomarkers: from discovery and development to clinical practice. Drug Discovery Today: Technologies, 2016, 21-22, 3-10.	4.0	13
13	The Head and the Heart. Journal of the American College of Cardiology, 2016, 68, 2408-2411.	1.2	6
14	Anti- $A\beta$ antibody treatment shows promise in Alzheimer disease. Nature Reviews Neurology, 2016, 12, 555-555.	4.9	3
15	Aducanumab reduces $A\beta$ plaques in Alzheimer's disease. Movement Disorders, 2016, 31, 1631-1631.	2.2	5
16	Lobar cerebral microbleeds signal early cognitive impairment. Nature Reviews Neurology, 2016, 12, 680-682.	4.9	26
17	Immunotherapy with Aducanumab Restores Calcium Homeostasis in Tg2576 Mice. Journal of Neuroscience, 2016, 36, 12549-12558.	1.7	80
18	Advances in $A\beta$ plaque detection and the value of knowing: overcoming challenges to improving patient outcomes in Alzheimer's disease. Neurodegenerative Disease Management, 2016, 6, 491-497.	1.2	3

#	ARTICLE	IF	CITATIONS
19	The road to restoring neural circuits for the treatment of Alzheimer's disease. <i>Nature</i> , 2016, 539, 187-196.	13.7	426
20	Depletion of TDP-43 decreases fibril and plaque β -amyloid and exacerbates neurodegeneration in an Alzheimer's mouse model. <i>Acta Neuropathologica</i> , 2016, 132, 859-873.	3.9	43
21	The impact of fraudulent and irreproducible data to the translational research crisis – solutions and implementation. <i>Journal of Neurochemistry</i> , 2016, 139, 253-270.	2.1	41
22	Hope for anti-amyloid antibodies surges, yet again. <i>Nature Biotechnology</i> , 2016, 34, 1082-1083.	9.4	5
23	Amyloid Cascade into Clarity. <i>Immunity</i> , 2016, 45, 717-718.	6.6	15
24	China Brain Project: Basic Neuroscience, Brain Diseases, and Brain-Inspired Computing. <i>Neuron</i> , 2016, 92, 591-596.	3.8	207
25	Literature Search and Review. <i>Assay and Drug Development Technologies</i> , 2016, 14, 511-517.	0.6	0
26	Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease. <i>Current Opinion in Lipidology</i> , 2017, 28, 60-67.	1.2	123
27	Two decades of new drug discovery and development for Alzheimer's disease. <i>RSC Advances</i> , 2017, 7, 6046-6058.	1.7	60
28	Update on Alzheimer's Disease Therapy and Prevention Strategies. <i>Annual Review of Medicine</i> , 2017, 68, 413-430.	5.0	402
29	Astrocytic transporters in Alzheimer's disease. <i>Biochemical Journal</i> , 2017, 474, 333-355.	1.7	19
30	Paving the Way for New Clinical Trials for Alzheimer's Disease. <i>Biological Psychiatry</i> , 2017, 81, 88-89.	0.7	4
31	Association between β and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A ^{11}C -PBB3-PET study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 11-20.	1.2	66
32	Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β -Amyloid in an Animal Model of Alzheimer's Disease. <i>Molecular Therapy</i> , 2017, 25, 153-164.	3.7	13
33	T cell responses in the central nervous system. <i>Nature Reviews Immunology</i> , 2017, 17, 179-194.	10.6	219
35	Identification of Inhibitors of CD36-Amyloid Beta Binding as Potential Agents for Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1232-1241.	1.7	35
36	APP Modulates β -Induced Activation of Microglia in Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2017, 37, 238-240.	1.7	1
37	Putting AD treatments and biomarkers to the test. <i>Nature Reviews Neurology</i> , 2017, 13, 74-76.	4.9	14

#	ARTICLE	IF	CITATIONS
38	Modulators of IgG penetration through the blood-brain barrier: Implications for Alzheimer's disease immunotherapy. <i>Human Antibodies</i> , 2017, 25, 131-146.	0.6	14
39	Familial Mutations May Switch Conformational Preferences in β -Synuclein Fibrils. <i>ACS Chemical Neuroscience</i> , 2017, 8, 837-849.	1.7	27
40	Aberrant proteolytic processing and therapeutic strategies in Alzheimer disease. <i>Advances in Biological Regulation</i> , 2017, 64, 33-38.	1.4	30
41	Peptide regulation of cofilin activity in the CNS: A novel therapeutic approach for treatment of multiple neurological disorders. , 2017, 175, 17-27.		43
42	The prion model for progression and diversity of neurodegenerative diseases. <i>Lancet Neurology</i> , The, 2017, 16, 323-332.	4.9	92
43	Concentrations of antibodies against β -amyloid 40/42 monomer and oligomers in Chinese intravenous immunoglobulins. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 138, 277-282.	1.4	5
44	Clearance of cerebral $A\beta$ in Alzheimer's disease: reassessing the role of microglia and monocytes. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 2167-2201.	2.4	199
45	Designer protein disaggregases to counter neurodegenerative disease. <i>Current Opinion in Genetics and Development</i> , 2017, 44, 1-8.	1.5	68
46	HuCNS-SC Human NSCs Fail to Differentiate, Form Ectopic Clusters, and Provide No Cognitive Benefits in a Transgenic Model of Alzheimer's Disease. <i>Stem Cell Reports</i> , 2017, 8, 235-248.	2.3	50
47	Diagnostic pathology of Alzheimer's disease from routine microscopy to immunohistochemistry and experimental correlations. <i>Annals of Diagnostic Pathology</i> , 2017, 28, 24-29.	0.6	8
48	Merck ends trial of potential Alzheimer's drug verubecestat. <i>BMJ: British Medical Journal</i> , 2017, 356, j845.	2.4	46
49	Brain barriers and brain fluid research in 2016: advances, challenges and controversies. <i>Fluids and Barriers of the CNS</i> , 2017, 14, 4.	2.4	1
50	Reestablishing microglia function: good news for Alzheimer's therapy?. <i>EMBO Journal</i> , 2017, 36, 565-567.	3.5	2
51	Future Directions in Imaging Neurodegeneration. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 9.	2.0	13
52	Acidity and Acid-Sensing Ion Channels in the Normal and Alzheimer's Disease Brain. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 1137-1144.	1.2	28
53	The role of histidines in amyloid β fibril assembly. <i>FEBS Letters</i> , 2017, 591, 1167-1175.	1.3	36
54	Islet amyloid polypeptide: Another key molecule in Alzheimer's pathogenesis?. <i>Progress in Neurobiology</i> , 2017, 153, 100-120.	2.8	64
55	Tau and Cortical Thickness in Alzheimer Disease. <i>JAMA Neurology</i> , 2017, 74, 390.	4.5	5

#	ARTICLE	IF	CITATIONS
56	Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. <i>Alzheimer's and Dementia</i> , 2017, 13, 454-467.	0.4	58
57	Microglia Function in the Central Nervous System During Health and Neurodegeneration. <i>Annual Review of Immunology</i> , 2017, 35, 441-468.	9.5	1,450
58	Immune Regulation of Antibody Access to Neuronal Tissues. <i>Trends in Molecular Medicine</i> , 2017, 23, 227-245.	3.5	48
59	Significant Improvement in Cognition in Mild to Moderately Severe Dementia Cases Treated with Transcranial Plus Intranasal Photobiomodulation: Case Series Report. <i>Photomedicine and Laser Surgery</i> , 2017, 35, 432-441.	2.1	184
60	Optimal Reference Region to Measure Longitudinal Amyloid- β^2 Change with ¹⁸ F-Florbetaben PET. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1300-1306.	2.8	49
61	Focused ultrasound as a novel strategy for Alzheimer disease therapeutics. <i>Annals of Neurology</i> , 2017, 81, 611-617.	2.8	33
62	A brief essay on non-pharmacological treatment of Alzheimer's disease. <i>Reviews in the Neurosciences</i> , 2017, 28, 587-597.	1.4	15
63	Chemical Composition and Acetylcholinesterase Inhibitory Activity of Essential Oils from <i>Piper</i> Species. <i>Journal of Agricultural and Food Chemistry</i> , 2017, 65, 3702-3710.	2.4	48
64	Mechanisms of vascular disease in dementia: what does industry want to know?. <i>Clinical Science</i> , 2017, 131, 799-802.	1.8	4
65	Small static electric field strength promotes aggregation-prone structures in amyloid- β^2 (29-42). <i>Journal of Chemical Physics</i> , 2017, 146, 145101.	1.2	17
66	AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy. <i>Journal of Experimental Medicine</i> , 2017, 214, 1227-1238.	4.2	45
67	Pharmacological and Toxicological Properties of the Potent Oral β^3 -Secretase Modulator BPN-15606. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 362, 31-44.	1.3	36
68	Modulation of innate immunity of patients with Alzheimer's disease by omega-3 fatty acids. <i>FASEB Journal</i> , 2017, 31, 3229-3239.	0.2	37
69	Emerging amyloid and tau targeting treatments for Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 697-711.	1.4	11
70	Galantamine. <i>ChemTexts</i> , 2017, 3, 1.	1.0	14
71	Alzheimer's Disease II. <i>Topics in Medicinal Chemistry</i> , 2017, , .	0.4	2
72	The Anti-Amyloid- β^2 and Neuroprotective Properties of a Novel Tricyclic Pyrone Molecule. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 559-574.	1.2	10
73	Dysregulated Metabolism of the Amyloid- β^2 Protein and Therapeutic Approaches in Alzheimer Disease. <i>Journal of Cellular Biochemistry</i> , 2017, 118, 4183-4190.	1.2	34

#	ARTICLE	IF	CITATIONS
74	A novel pathway for amyloids self-assembly in aggregates at nanomolar concentration mediated by the interaction with surfaces. <i>Scientific Reports</i> , 2017, 7, 45592.	1.6	44
75	Using PET for therapy monitoring in oncological clinical trials: challenges ahead. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 32-40.	3.3	4
76	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 1251-1260.	0.4	47
77	Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non-Alzheimer Disease Dementias. <i>PET Clinics</i> , 2017, 12, 351-359.	1.5	21
78	Advancing Drug Discovery and Development Using Molecular Imaging (ADDMI): an Interest Group of the World Molecular Imaging Society and an Inaugural Session on Positron Emission Tomography (PET). <i>Molecular Imaging and Biology</i> , 2017, 19, 348-356.	1.3	4
79	Curcumin Dictates Divergent Fates for the Central Salt Bridges in Amyloid- β 40 and Amyloid- β 42. <i>Biophysical Journal</i> , 2017, 112, 1597-1608.	0.2	16
80	UBA311, a novel UBITH [®] amyloid β peptide vaccine for mild Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 262-272.	1.8	104
81	Aducanumab Therapy Ameliorates Calcium Overload in a Mouse Model of Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2017, 37, 4430-4432.	1.7	14
82	Prolonged changes in amyloid- β metabolism after a severe traumatic brain injury. <i>NeuroReport</i> , 2017, 28, 250-252.	0.6	6
83	Structural and functional analyses of pyroglutamate-amyloid- β -specific antibodies as a basis for Alzheimer immunotherapy. <i>Journal of Biological Chemistry</i> , 2017, 292, 12713-12724.	1.6	24
84	Antibody blood-brain barrier efflux is modulated by glycan modification. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2017, 1861, 2228-2239.	1.1	17
86	Alzheimer's disease: How metal ions define β -amyloid function. <i>Coordination Chemistry Reviews</i> , 2017, 351, 127-159.	9.5	120
87	Alzheimer's Disease and ncRNAs. <i>Advances in Experimental Medicine and Biology</i> , 2017, 978, 337-361.	0.8	64
88	Inhibition of the Aggregation and Toxicity of the Minimal Amyloidogenic Fragment of Tau by Its Pro-substituted Analogues. <i>Chemistry - A European Journal</i> , 2017, 23, 9618-9624.	1.7	23
90	Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases. <i>Neuron</i> , 2017, 94, 1056-1070.	3.8	216
91	Dihydropyrimidine-Thiones and Cloquinol Synergize To Target β -Amyloid Cellular Pathologies through a Metal-Dependent Mechanism. <i>ACS Chemical Neuroscience</i> , 2017, 8, 2039-2055.	1.7	17
93	Alzheimer's disease: time to focus on the brain, not just molecules. <i>Brain</i> , 2017, 140, 251-253.	3.7	18
94	Methods of probing the interactions between small molecules and disordered proteins. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 3225-3243.	2.4	56

#	ARTICLE	IF	CITATIONS
95	Selective targeting of primary and secondary nucleation pathways in A β ²⁴² aggregation using a rational antibody scanning method. <i>Science Advances</i> , 2017, 3, e1700488.	4.7	116
96	β -Secretase Modulators as A β ²⁴² -Lowering Pharmacological Agents to Treat Alzheimer's Disease. <i>Topics in Medicinal Chemistry</i> , 2017, , 87-118.	0.4	6
97	Phage display and kinetic selection of antibodies that specifically inhibit amyloid self-replication. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 6444-6449.	3.3	60
98	Alzheimer's disease: where next for anti-amyloid therapies?. <i>Brain</i> , 2017, 140, 853-855.	3.7	57
99	miR-34a knockout attenuates cognitive deficits in APP/PS1 mice through inhibition of the amyloidogenic processing of APP. <i>Life Sciences</i> , 2017, 182, 104-111.	2.0	61
100	Amyotrophic lateral sclerosis. <i>Lancet, The</i> , 2017, 390, 2084-2098.	6.3	867
101	Alzheimer's disease drug development pipeline: 2017. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 367-384.	1.8	331
102	Alzheimer Disease. <i>Mayo Clinic Proceedings</i> , 2017, 92, 978-994.	1.4	57
103	Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: A systematic critical update. <i>NeuroImage: Clinical</i> , 2017, 15, 247-263.	1.4	60
104	The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 767-775.	1.4	4
105	Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 1-10.	1.2	28
106	Affibody molecules as engineered protein drugs. <i>Experimental and Molecular Medicine</i> , 2017, 49, e306-e306.	3.2	155
107	Biodistribution and Radiation Dosimetry for the Tau Tracer ¹⁸ F-THK-5351 in Healthy Human Subjects. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1498-1503.	2.8	21
108	Microfluidic neural probes: in vivo tools for advancing neuroscience. <i>Lab on A Chip</i> , 2017, 17, 1406-1435.	3.1	70
109	Validation of the Semiquantitative Static SUVR Method for ¹⁸ F-AV45 PET by Pharmacokinetic Modeling with an Arterial Input Function. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1483-1489.	2.8	29
110	ErbB2 regulates autophagic flux to modulate the proteostasis of APP-CTFs in Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E3129-E3138.	3.3	57
111	Dissociable diffusion MRI patterns of white matter microstructure and connectivity in Alzheimer's disease spectrum. <i>Scientific Reports</i> , 2017, 7, 45131.	1.6	43
112	Antibodies inhibit transmission and aggregation of polyQ dipeptide repeat proteins. <i>EMBO Molecular Medicine</i> , 2017, 9, 687-702.	3.3	70

#	ARTICLE	IF	CITATIONS
113	Cortical Superficial Siderosis in Different Types of Cerebral Small Vessel Disease. <i>Stroke</i> , 2017, 48, 1404-1407.	1.0	40
114	An intranasally delivered peptide drug ameliorates cognitive decline in Alzheimer transgenic mice. <i>EMBO Molecular Medicine</i> , 2017, 9, 703-715.	3.3	54
115	Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 645-665.	1.2	139
116	Integrated analysis of genetic, behavioral, and biochemical data implicates neural stem cell-induced changes in immunity, neurotransmission and mitochondrial function in Dementia with Lewy Body mice. <i>Acta Neuropathologica Communications</i> , 2017, 5, 21.	2.4	8
117	DNA repair in the trinucleotide repeat disorders. <i>Lancet Neurology</i> , The, 2017, 16, 88-96.	4.9	75
118	Alzheimer's disease and other dementias: update on research. <i>Lancet Neurology</i> , The, 2017, 16, 4-5.	4.9	19
119	Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of A β ²⁴² and A β ²⁴⁰ peptides by β -secretase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E476-E485.	3.3	277
120	Research update on Alzheimer's disease and introduction to the Expert Review of Neurotherapeutics special issue. <i>Expert Review of Neurotherapeutics</i> , 2017, 17, 1-2.	1.4	2
121	Alzheimer's disease: experimental models and reality. <i>Acta Neuropathologica</i> , 2017, 133, 155-175.	3.9	513
122	Young microglia restore amyloid plaque clearance of aged microglia. <i>EMBO Journal</i> , 2017, 36, 583-603.	3.5	124
123	Safety and Efficacy of Anti-Amyloid- β Immunotherapy in Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>Journal of Neuroimmune Pharmacology</i> , 2017, 12, 194-203.	2.1	53
124	A dysfunctional blood-brain barrier and cerebral small vessel disease. <i>Neurology</i> , 2017, 88, 420-421.	1.5	27
125	The Amyloid- β Peptide in Amyloid Formation Processes: Interactions with Blood Proteins and Naturally Occurring Metal Ions. <i>Israel Journal of Chemistry</i> , 2017, 57, 674-685.	1.0	21
126	From A β Filament to Fibril: Molecular Mechanism of Surface-Activated Secondary Nucleation from All-Atom MD Simulations. <i>Journal of Physical Chemistry B</i> , 2017, 121, 671-682.	1.2	34
127	Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer's and cat allergy. <i>Npj Vaccines</i> , 2017, 2, 30.	2.9	78
128	Prion-like Protein Seeding and the Pathobiology of Alzheimer's Disease. , 2017, , 57-82.		0
130	Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology. <i>BioDrugs</i> , 2017, 31, 503-519.	2.2	121
131	A systemic view of Alzheimer disease - insights from amyloid- β metabolism beyond the brain. <i>Nature Reviews Neurology</i> , 2017, 13, 612-623.	4.9	581

#	ARTICLE	IF	CITATIONS
132	A mimotope of A β oligomers may also behave as a β -sheet inhibitor. FEBS Letters, 2017, 591, 3615-3624.	1.3	7
133	Identification of a Novel 1,2,3,4-Tetrahydrobenzo[<i>b</i>][1,6]naphthyridine Analogue as a Potent Phosphodiesterase 5 Inhibitor with Improved Aqueous Solubility for the Treatment of Alzheimer's Disease. Journal of Medicinal Chemistry, 2017, 60, 8858-8875.	2.9	47
134	Tau-based therapies in neurodegeneration: opportunities and challenges. Nature Reviews Drug Discovery, 2017, 16, 863-883.	21.5	193
135	Self-Assembly Pathways of β -Sheet-Rich Amyloid- β (A β) ₄₀ Dimers: Markov State Model Analysis on Millisecond Hybrid-Resolution Simulations. Journal of Chemical Theory and Computation, 2017, 13, 5731-5744.	2.3	45
136	Disruption of amyloid precursor protein ubiquitination selectively increases amyloid β (A β) ₄₀ levels via presenilin 2-mediated cleavage. Journal of Biological Chemistry, 2017, 292, 19873-19889.	1.6	20
137	Molecular imaging in early diagnosis, differential diagnosis and follow-up of patients with neurodegenerative diseases. Clinical and Translational Imaging, 2017, 5, 465-471.	1.1	8
138	Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae. Nature Communications, 2017, 8, 1000.	5.8	103
139	Current status and future challenges for molecular imaging. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2017, 375, 20170023.	1.6	22
140	Peptidomimetics That Inhibit and Partially Reverse the Aggregation of A β ₄₂ . Biochemistry, 2017, 56, 4840-4849.	1.2	15
141	Dissecting Amyloid Beta Deposition Using Distinct Strains of the Neurotropic Parasite Toxoplasma gondii as a Novel Tool. ASN Neuro, 2017, 9, 175909141772491.	1.5	30
142	Lessons from Anti-Amyloid- β Immunotherapies in Alzheimer Disease: Aiming at a Moving Target. Neurodegenerative Diseases, 2017, 17, 242-250.	0.8	34
143	The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 982-994.	0.9	162
144	Pseudo-peptide amyloid- β blocking inhibitors: molecular dynamics and single molecule force spectroscopy study. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2017, 1865, 1707-1718.	1.1	15
145	Neuropathology of White Matter Lesions, Blood-Brain Barrier Dysfunction, and Dementia. Stroke, 2017, 48, 2799-2804.	1.0	85
146	Mechanisms of recognition of amyloid- β (A β) monomer, oligomer, and fibril by homologous antibodies. Journal of Biological Chemistry, 2017, 292, 18325-18343.	1.6	53
147	Combination of A β Suppression and Innate Immune Activation in the Brain Significantly Attenuates Amyloid Plaque Deposition. American Journal of Pathology, 2017, 187, 2886-2894.	1.9	7
148	Molecular Insights into Human Serum Albumin as a Receptor of Amyloid- β in the Extracellular Region. Journal of the American Chemical Society, 2017, 139, 15437-15445.	6.6	61
149	A Toxic Conformer of A β ₄₂ with a Turn at 22-23 is a Novel Therapeutic Target for Alzheimer's Disease. Scientific Reports, 2017, 7, 11811.	1.6	23

#	ARTICLE	IF	CITATIONS
150	Review: Neuropathology and behavioural features of transgenic murine models of Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2017, 43, 553-570.	1.8	46
152	Vaccination strategies in tauopathies and synucleinopathies. <i>Journal of Neurochemistry</i> , 2017, 143, 467-488.	2.1	30
153	Small-molecule PET Tracers for Imaging Proteinopathies. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 553-575.	2.5	91
154	Dementia prevention, intervention, and care. <i>Lancet, The</i> , 2017, 390, 2673-2734.	6.3	4,228
155	A Review of Biomarkers for Neurodegenerative Disease: Will They Swing Us Across the Valley?. <i>Neurology and Therapy</i> , 2017, 6, 5-13.	1.4	34
156	A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood. <i>Neurology and Therapy</i> , 2017, 6, 15-24.	1.4	211
157	Hydroxy-substituted trans -cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2017, 139, 378-389.	2.6	21
158	Phase II clinical trials of anti-amyloid β antibodies: When is enough, enough?. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 402-409.	1.8	69
159	Clinical Applications of Small-molecule PET Radiotracers: Current Progress and Future Outlook. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 429-453.	2.5	25
160	A human scFv antibody that targets and neutralizes high molecular weight pathogenic amyloid β oligomers. <i>Journal of Neurochemistry</i> , 2017, 142, 934-947.	2.1	27
161	Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 393-401.	1.8	47
162	Alzheimer's disease CSF biomarkers: clinical indications and rational use. <i>Acta Neurologica Belgica</i> , 2017, 117, 591-602.	0.5	90
163	Early functional network alterations in asymptomatic elders at risk for Alzheimer's disease. <i>Scientific Reports</i> , 2017, 7, 6517.	1.6	64
164	The effects of metal ion contaminants on the double stranded DNA helix and diseases. <i>Journal of Environmental Science and Health - Part A Toxic/Hazardous Substances and Environmental Engineering</i> , 2017, 52, 1030-1040.	0.9	11
165	Cross-Sectional Relationships of Physical Activity and Sedentary Behavior With Cognitive Function in Older Adults With Probable Mild Cognitive Impairment. <i>Physical Therapy</i> , 2017, 97, 975-984.	1.1	80
166	Prevention of Alzheimer's Disease: Lessons Learned and Applied. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 2128-2133.	1.3	67
167	Augmenting Amyloid PET Interpretations With Quantitative Information Improves Consistency of Early Amyloid Detection. <i>Clinical Nuclear Medicine</i> , 2017, 42, 577-581.	0.7	37
168	Impact of aging immune system on neurodegeneration and potential immunotherapies. <i>Progress in Neurobiology</i> , 2017, 157, 2-28.	2.8	39

#	ARTICLE	IF	CITATIONS
169	Dissecting the behaviour of β -amyloid peptide variants during oligomerization and fibrillation. <i>Journal of Peptide Science</i> , 2017, 23, 810-817.	0.8	5
171	Resveratrol for Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> , 2017, 1403, 142-149.	1.8	198
172	Amyloid in Alzheimer's Disease: Guilty Beyond Reasonable Doubt?. <i>Trends in Pharmacological Sciences</i> , 2017, 38, 849-851.	4.0	22
173	Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 1131-1136.	1.9	44
174	APP mouse models for Alzheimer's disease preclinical studies. <i>EMBO Journal</i> , 2017, 36, 2473-2487.	3.5	530
175	Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound $A\beta$ oligomers. <i>Molecular Biology of the Cell</i> , 2017, 28, 2623-2636.	0.9	88
176	The companion dog as a unique translational model for aging. <i>Seminars in Cell and Developmental Biology</i> , 2017, 70, 141-153.	2.3	42
177	A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 622-635.	1.8	59
178	Allosteric nanobodies uncover a role of hippocampal mGlu2 receptor homodimers in contextual fear consolidation. <i>Nature Communications</i> , 2017, 8, 1967.	5.8	66
179	Meeting Report: Tissue-based Image Analysis. <i>Toxicologic Pathology</i> , 2017, 45, 983-1003.	0.9	9
180	Specification of Physiologic and Disease States by Distinct Proteins and Protein Conformations. <i>Cell</i> , 2017, 171, 1001-1014.	13.5	39
181	PSEN1 Mutant iPSC-Derived Model Reveals Severe Astrocyte Pathology in Alzheimer's Disease. <i>Stem Cell Reports</i> , 2017, 9, 1885-1897.	2.3	239
182	Immunotherapies for Alzheimer's Disease. , 2017, , 267-279.		1
183	HIV-1 counteracts an innate restriction by amyloid precursor protein resulting in neurodegeneration. <i>Nature Communications</i> , 2017, 8, 1522.	5.8	42
184	Adult-Onset Epilepsy in Presymptomatic Alzheimer's Disease: A Retrospective Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1267-1274.	1.2	57
185	Has molecular imaging delivered to drug development?. <i>Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences</i> , 2017, 375, 20170112.	1.6	4
186	Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer's disease. <i>Nature Communications</i> , 2017, 8, 1403.	5.8	54
188	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology</i> , The, 2017, 16, 661-676.	4.9	464

#	ARTICLE	IF	CITATIONS
189	Implications of peptide assemblies in amyloid diseases. <i>Chemical Society Reviews</i> , 2017, 46, 6492-6531.	18.7	262
190	Physico-Pathologic Mechanisms Involved in Neurodegeneration: Misfolded Protein-Plasma Membrane Interactions. <i>Neuron</i> , 2017, 95, 33-50.	3.8	83
191	Quantitative positron emission tomography in brain research. <i>Brain Research</i> , 2017, 1670, 220-234.	1.1	38
193	APOE Genotype Differentially Modulates Effects of Anti-A β , Passive Immunization in APP Transgenic Mice. <i>Molecular Neurodegeneration</i> , 2017, 12, 12.	4.4	25
194	Evaluation of a DNA A β 242 vaccine in adult rhesus monkeys (<i>Macaca mulatta</i>): antibody kinetics and immune profile after intradermal immunization with full-length DNA A β 242 trimer. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 30.	3.0	17
195	A vaccine with A β 2 oligomer-specific mimotope attenuates cognitive deficits and brain pathologies in transgenic mice with Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 41.	3.0	9
196	Kinetic Analysis Reveals the Identity of A β -Metal Complex Responsible for the Initial Aggregation of A β in the Synapse. <i>ACS Chemical Neuroscience</i> , 2017, 8, 1970-1979.	1.7	22
197	Emerging ocular biomarkers of Alzheimer disease. <i>Clinical and Experimental Ophthalmology</i> , 2017, 45, 54-61.	1.3	46
198	Biomarkers for the Early Detection and Progression of Alzheimer's Disease. <i>Neurotherapeutics</i> , 2017, 14, 35-53.	2.1	128
199	Large Soluble Oligomers of Amyloid β -Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate. <i>Journal of Neuroscience</i> , 2017, 37, 152-163.	1.7	262
200	Rejecting the Alzheimer's disease vaccine development for the wrong reasons. <i>Drug Discovery Today</i> , 2017, 22, 609-614.	3.2	8
201	Alzheimer's disease in people with Down's syndrome: the prospects for and the challenges of developing preventative treatments. <i>Journal of Neurology</i> , 2017, 264, 804-813.	1.8	43
202	Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. <i>Progress in Biophysics and Molecular Biology</i> , 2017, 123, 16-41.	1.4	64
203	Hybrid Antioxidant and Metal Sequestering Small Molecules Targeting the Molecular Features of Alzheimer's Disease. <i>Comments on Inorganic Chemistry</i> , 2017, 37, 146-167.	3.0	2
204	Computational approach for the assessment of inhibitory potency against beta-amyloid aggregation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 212-216.	1.0	16
205	Dysregulation of neuronal calcium homeostasis in Alzheimer's disease – A therapeutic opportunity?. <i>Biochemical and Biophysical Research Communications</i> , 2017, 483, 998-1004.	1.0	172
206	Combined Socio-Behavioral Evaluation Improves the Differential Diagnosis Between the Behavioral Variant of Frontotemporal Dementia and Alzheimer's Disease: In Search of Neuropsychological Markers. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 761-772.	1.2	21
207	Efficacy and safety of anti-amyloid immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 931-942.	1.7	69

#	ARTICLE	IF	CITATIONS
208	Pre-critical fluctuations and what they disclose about heterogeneous crystal nucleation. <i>Nature Communications</i> , 2017, 8, 2257.	5.8	55
209	In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease. <i>Frontiers in Pharmacology</i> , 2017, 8, 20.	1.6	140
210	Increased Physical Fitness Is Associated with Higher Executive Functioning in People with Dementia. <i>Frontiers in Public Health</i> , 2017, 5, 346.	1.3	13
211	A Comparison of Lysosomal Enzymes Expression Levels in Peripheral Blood of Mild- and Severe-Alzheimer's Disease and MCI Patients: Implications for Regenerative Medicine Approaches. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1806.	1.8	36
212	Stop Alzheimer's before it starts. <i>Nature</i> , 2017, 547, 153-155.	13.7	189
213	The Montreal Cognitive Assessment: Normative Data from a Large Swedish Population-Based Cohort. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 893-901.	1.2	133
214	Novel Treatment Strategies Using TiO ₂ -Nanowired Delivery of Histaminergic Drugs and Antibodies to Tau With Cerebrolysin for Superior Neuroprotection in the Pathophysiology of Alzheimer's Disease. <i>International Review of Neurobiology</i> , 2017, 137, 123-165.	0.9	23
215	Old Maids: Aging and Its Impact on Microglia Function. <i>International Journal of Molecular Sciences</i> , 2017, 18, 769.	1.8	163
216	Subcortical Shape Changes, Hippocampal Atrophy and Cortical Thinning in Future Alzheimer's Disease Patients. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 38.	1.7	43
217	Neuropsychological Testing and Machine Learning Distinguish Alzheimer's Disease from Other Causes for Cognitive Impairment. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 114.	1.7	31
218	Protein-Remodeling Factors As Potential Therapeutics for Neurodegenerative Disease. <i>Frontiers in Neuroscience</i> , 2017, 11, 99.	1.4	27
219	Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy. <i>Frontiers in Neuroscience</i> , 2017, 11, 680.	1.4	108
220	Therapeutic Potential of Secreted Amyloid Precursor Protein APPs [±] . <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 30.	1.4	91
221	Stabilization and structural analysis of a membrane-associated hIAPP aggregation intermediate. <i>ELife</i> , 2017, 6, .	2.8	61
222	Aromatherapy and Aromatic Plants for the Treatment of Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer's Disease: Clinical Evidence and Possible Mechanisms. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-8.	0.5	32
224	Evaluation of Cholinergic Deficiency in Preclinical Alzheimer's Disease Using Pupillometry. <i>Journal of Ophthalmology</i> , 2017, 2017, 1-8.	0.6	29
225	Detecting At-Risk Alzheimer's Disease Cases. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 97-105.	1.2	42
226	New drugs in psychiatry: focus on new pharmacological targets. <i>F1000Research</i> , 2017, 6, 397.	0.8	23

#	ARTICLE	IF	CITATIONS
227	Amyloid-Related Imaging Abnormalities in An Aged Squirrel Monkey with Cerebral Amyloid Angiopathy. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 519-530.	1.2	22
228	Immunotherapy for the Treatment of Alzheimer's Disease. , 2017, , 331-359.		0
229	Drug candidates in clinical trials for Alzheimer's disease. <i>Journal of Biomedical Science</i> , 2017, 24, 47.	2.6	330
230	Practical considerations for choosing a mouse model of Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2017, 12, 89.	4.4	305
231	Restoring synaptic plasticity and memory in mouse models of Alzheimer's disease by PKR inhibition. <i>Molecular Brain</i> , 2017, 10, 57.	1.3	43
232	The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 85.	3.0	52
233	A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 95.	3.0	396
234	Disease modification and Neuroprotection in neurodegenerative disorders. <i>Translational Neurodegeneration</i> , 2017, 6, 25.	3.6	68
235	Chronic Verubecestat Treatment Suppresses Amyloid Accumulation in Advanced Aged Tg2576-A β PPswe Mice Without Inducing Microhemorrhage. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1393-1413.	1.2	24
236	Alzheimer's disease and osteoporosis. <i>Tzu Chi Medical Journal</i> , 2017, 29, 138.	0.4	27
237	When Patient Engagement and Research Ethics Collide: Lessons from a Dementia Forum. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1-10.	1.2	36
238	The emerging role of PET imaging in dementia. <i>F1000Research</i> , 2017, 6, 1830.	0.8	43
239	Progress and Challenges in the Development of PET Ligands to Aid CNS Drug Discovery. , 2017, , 20-64.		4
240	Molecular Mechanisms of Synaptic Plasticity and Memory and Their Dysfunction in Alzheimer's Disease. , 2017, , 65-135.		1
242	CNS inflammation and neurodegeneration. <i>Journal of Clinical Investigation</i> , 2017, 127, 3577-3587.	3.9	351
243	The past, present, and future of disease-modifying therapies for Alzheimer's disease. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2017, 93, 757-771.	1.6	31
244	Reader response: A phase 3 trial of IV immunoglobulin for Alzheimer disease. <i>Neurology</i> , 2018, 90, 144-145.	1.5	3
245	Dale Schenk One Year Anniversary: Fighting to Preserve the Memories. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1-13.	1.2	7

#	ARTICLE	IF	CITATIONS
246	Targeting Alzheimer's Disease at the Right Time and the Right Place: Validation of a Personalized Approach to Diagnosis and Treatment. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S23-S31.	1.2	11
247	Transthyretin Mimetics as Anti- β -Amyloid Agents: A Comparison of Peptide and Protein Approaches. <i>ChemMedChem</i> , 2018, 13, 968-979.	1.6	23
248	Is there a role for MR-guided focused ultrasound in Parkinson's disease?. <i>Movement Disorders</i> , 2018, 33, 575-579.	2.2	6
249	Biomarkers for Preclinical Alzheimer's Disease. <i>Neuromethods</i> , 2018, , .	0.2	5
250	Electromagnetic signatures of the preclinical and prodromal stages of Alzheimer's disease. <i>Brain</i> , 2018, 141, 1470-1485.	3.7	109
251	Prospects for strain-specific immunotherapy in Alzheimer's disease and tauopathies. <i>Npj Vaccines</i> , 2018, 3, 9.	2.9	45
252	Effect of solvent selectivity on crystallization-driven fibril growth kinetics of diblock copolymers. <i>Polymer</i> , 2018, 138, 359-362.	1.8	23
253	Quantitative Characterization of Metastability and Heterogeneity of Amyloid Aggregates. <i>Biophysical Journal</i> , 2018, 114, 800-811.	0.2	9
254	Scores Obtained from a Simple Cognitive Test of Visuospatial Episodic Memory Performed Decades before Death Are Associated with the Ultimate Presence of Alzheimer Disease Pathology. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 45, 79-90.	0.7	9
255	Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid- β . <i>Scientific Reports</i> , 2018, 8, 6412.	1.6	182
256	Mechanistic insights into the inhibition and size effects of graphene oxide nanosheets on the aggregation of an amyloid- β peptide fragment. <i>Nanoscale</i> , 2018, 10, 8989-8997.	2.8	31
257	Computational Analysis for the Rational Design of Anti-Amyloid Beta ($A\beta$) Antibodies. <i>Journal of Physical Chemistry B</i> , 2018, 122, 4521-4536.	1.2	8
258	Next generation antibody drugs: pursuit of the 'high-hanging fruit'. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 197-223.	21.5	595
259	Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S3-S22.	1.2	108
260	Have there been improvements in Alzheimer's disease drug discovery over the past 5 years?. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 523-538.	2.5	51
261	A Rational Structured Epitope Defines a Distinct Subclass of Toxic Amyloid-beta Oligomers. <i>ACS Chemical Neuroscience</i> , 2018, 9, 1591-1606.	1.7	21
262	Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials. <i>Movement Disorders</i> , 2018, 33, 528-536.	2.2	17
263	Amyloid blood biomarker detects Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2018, 10, .	3.3	145

#	ARTICLE	IF	CITATIONS
264	Intracellular tracing of amyloid vaccines through direct fluorescent labelling. <i>Scientific Reports</i> , 2018, 8, 2437.	1.6	7
265	BIOLOGY OF AGING. <i>ACSM's Health and Fitness Journal</i> , 2018, 22, 17-27.	0.3	0
266	Precision pharmacology for Alzheimer's disease. <i>Pharmacological Research</i> , 2018, 130, 331-365.	3.1	79
267	Competitive homo- and hetero- self-assembly of amyloid- β 1-42 and 1-40 in the early stage of fibrillation. <i>International Journal of Mass Spectrometry</i> , 2018, 428, 15-21.	0.7	10
268	Novel targets in Alzheimer's disease: A special focus on microglia. <i>Pharmacological Research</i> , 2018, 130, 402-413.	3.1	46
269	Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. <i>Neurology</i> , 2018, 90, e877-e886.	1.5	28
270	Vascular cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18003.	18.1	358
271	Quantitative Measurement of β -Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms. <i>Journal of Visualized Experiments</i> , 2018, , .	0.2	1
272	High performance plasma amyloid- β biomarkers for Alzheimer's disease. <i>Nature</i> , 2018, 554, 249-254.	13.7	1,180
273	Editors' note: A phase 3 trial of IV immunoglobulin for Alzheimer disease. <i>Neurology</i> , 2018, 90, 144-144.	1.5	1
274	Novel Translational Research Methodology and the Prospect to a Better Understanding of Neurodegenerative Disease. <i>Neurodegenerative Diseases</i> , 2018, 18, 1-4.	0.8	4
275	Author response: A phase 3 trial of IV immunoglobulin for Alzheimer disease. <i>Neurology</i> , 2018, 90, 145-145.	1.5	1
276	Depletion of amyloid- β peptides from solution by sequestration within fibril-seeded hydrogels. <i>Protein Science</i> , 2018, 27, 1218-1230.	3.1	6
277	Prion-like properties of disease-relevant proteins in amyotrophic lateral sclerosis. <i>Journal of Neural Transmission</i> , 2018, 125, 591-613.	1.4	16
278	The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease. <i>Journal of Pathology</i> , 2018, 245, 85-100.	2.1	180
279	Crocin improved amyloid beta induced long-term potentiation and memory deficits in the hippocampal CA1 neurons in freely moving rats. <i>Synapse</i> , 2018, 72, e22026.	0.6	41
280	Accurate Etiological Diagnosis of Dementia Contributes to Better Clinical Care. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 827-829.	1.3	0
281	Editors' note: Clinical Reasoning: Labyrinthine hemorrhage: An unusual etiology for peripheral vertigo. <i>Neurology</i> , 2018, 90, 146-146.	1.5	0

#	ARTICLE	IF	CITATIONS
282	Author response: Clinical Reasoning: Labyrinthine hemorrhage: An unusual etiology for peripheral vertigo. <i>Neurology</i> , 2018, 90, 146-147.	1.5	0
283	Reader response: Clinical Reasoning: Labyrinthine hemorrhage: An unusual etiology for peripheral vertigo. <i>Neurology</i> , 2018, 90, 146-146.	1.5	0
284	Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2018, 378, 321-330.	13.9	795
285	Amyloid-Beta Solubility in the Treatment of Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2018, 378, 391-392.	13.9	39
286	El Alzheimer, la enfermedad ignorada. <i>Medicina Clínica</i> , 2018, 150, 432-433.	0.3	3
287	An overview of the possible therapeutic role of SUMOylation in the treatment of Alzheimer's disease. <i>Pharmacological Research</i> , 2018, 130, 420-437.	3.1	16
288	Melatonin protects against A β -induced neurotoxicity in primary neurons via miR-132/PTEN/AKT/FOXO3a pathway. <i>BioFactors</i> , 2018, 44, 609-618.	2.6	38
289	Immunotherapy for neurodegenerative diseases: the Alzheimer's disease paradigm. <i>Current Opinion in Chemical Engineering</i> , 2018, 19, 59-67.	3.8	8
291	Imaging A β and tau in early stage Alzheimer's disease with [18F]AV45 and [18F]AV1451. <i>EJNMMI Research</i> , 2018, 8, 19.	1.1	14
292	The physics of polymer chain-folding. <i>Physics Reports</i> , 2018, 747, 1-50.	10.3	126
293	Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2018, 378, 1691-1703.	13.9	512
294	Elephants, Parkinson's Disease, and Proof-of-Concept Clinical Trials. <i>Movement Disorders</i> , 2018, 33, 697-700.	2.2	29
295	Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic. <i>Movement Disorders</i> , 2018, 33, 684-696.	2.2	140
296	Prions, prionoids and protein misfolding disorders. <i>Nature Reviews Genetics</i> , 2018, 19, 405-418.	7.7	218
297	Brain Inflammation Connects Cognitive and Non-Cognitive Symptoms in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S313-S327.	1.2	31
298	ABBY. <i>Neurology</i> , 2018, 90, e1889-e1897.	1.5	188
299	In Vivo Molecular Imaging for Biomedical Analysis and Therapies. <i>Analytical Sciences</i> , 2018, 34, 273-277.	0.8	14
300	Targeting Amyloid- β Precursor Protein, APP, Splicing with Antisense Oligonucleotides Reduces Toxic Amyloid- β Production. <i>Molecular Therapy</i> , 2018, 26, 1539-1551.	3.7	27

#	ARTICLE	IF	CITATIONS
301	Longitudinal tau PET in ageing and Alzheimer's disease. <i>Brain</i> , 2018, 141, 1517-1528.	3.7	309
302	Tongluo Xingnao effervescent tablet reverses memory deficit and reduces plaque load in APP ^{swE} /PS1 ^{dE9} mice. <i>Experimental and Therapeutic Medicine</i> , 2018, 15, 4005-4013.	0.8	5
303	Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1199-1209.	1.2	69
304	Temporal unfolding of declining episodic memory on the Free and Cued Selective Reminding Test in the prodementia phase of Alzheimer's disease: Implications for clinical trials. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 161-171.	1.2	36
305	Simultaneous quantitative susceptibility mapping and Flutemetamol-PET suggests local correlation of iron and A β -amyloid as an indicator of cognitive performance at high age. <i>NeuroImage</i> , 2018, 174, 308-316.	2.1	70
306	CRISPR/Cas9 Mediated Disruption of the Swedish APP Allele as a Therapeutic Approach for Early-Onset Alzheimer's Disease. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 11, 429-440.	2.3	116
307	Zinc ion rapidly induces toxic, off-pathway amyloid-A β oligomers distinct from amyloid-A β derived diffusible ligands in Alzheimer's disease. <i>Scientific Reports</i> , 2018, 8, 4772.	1.6	104
308	Molecular imaging: What is right and what is an illusion?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 217-220.	1.2	11
309	Anti-A β drug candidates in clinical trials and plasmonic nanoparticle-based drug-screen for Alzheimer's disease. <i>Analyst</i> , 2018, 143, 2204-2212.	1.7	19
310	Alzheimer's Disease, Oligomers, and Inflammation. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1261-1276.	1.2	141
311	Amyloid β -accumulators. <i>Neurology</i> , 2018, 90, 759-760.	1.5	9
312	Metabolic Dysfunction in Alzheimer's Disease: From Basic Neurobiology to Clinical Approaches. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S405-S426.	1.2	66
313	Bridging Type 2 Diabetes and Alzheimer's Disease: Assembling the Puzzle Pieces in the Quest for the Molecules With Therapeutic and Preventive Potential. <i>Medicinal Research Reviews</i> , 2018, 38, 261-324.	5.0	55
314	The Arc Gene Confers Genetic Susceptibility to Alzheimer's Disease in Han Chinese. <i>Molecular Neurobiology</i> , 2018, 55, 1217-1226.	1.9	30
315	Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibition Impairs Synaptic Plasticity via Seizure Protein 6. <i>Biological Psychiatry</i> , 2018, 83, 428-437.	0.7	80
316	Targeting Fyn Kinase in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2018, 83, 369-376.	0.7	108
317	Innate immunity in Alzheimer's disease: the relevance of animal models?. <i>Journal of Neural Transmission</i> , 2018, 125, 827-846.	1.4	16
318	Reduced TRPC6 mRNA levels in the blood cells of patients with Alzheimer's disease and mild cognitive impairment. <i>Molecular Psychiatry</i> , 2018, 23, 767-776.	4.1	48

#	ARTICLE	IF	CITATIONS
319	Microglia-Mediated Neuroprotection, TREM2 , and Alzheimer's Disease: Evidence From Optical Imaging. <i>Biological Psychiatry</i> , 2018, 83, 377-387.	0.7	84
320	Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease. <i>Clinical Pharmacokinetics</i> , 2018, 57, 315-333.	1.6	66
321	Oxidative stress and the amyloid beta peptide in Alzheimer's disease. <i>Redox Biology</i> , 2018, 14, 450-464.	3.9	1,411
322	Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease. <i>NeuroImage: Clinical</i> , 2018, 17, 452-464.	1.4	126
323	Alzheimer's disease. <i>European Journal of Neurology</i> , 2018, 25, 59-70.	1.7	1,624
324	Lymphatic drainage system of the brain: A novel target for intervention of neurological diseases. <i>Progress in Neurobiology</i> , 2018, 163-164, 118-143.	2.8	158
325	Anti-Amyloid- β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise. <i>Biological Psychiatry</i> , 2018, 83, 311-319.	0.7	408
326	Epilepsy as a Network Disorder (2): What can we learn from other network disorders such as dementia and schizophrenia, and what are the implications for translational research?. <i>Epilepsy and Behavior</i> , 2018, 78, 302-312.	0.9	17
327	Alpha7 nicotinic acetylcholine receptor-specific agonist DMXBA (GTS-21) attenuates $A\beta$ accumulation through suppression of neuronal β -secretase activity and promotion of microglial amyloid- β phagocytosis and ameliorates cognitive impairment in a mouse model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 62, 197-209.	1.5	44
328	Adsorptive filtration systems for effective removal of blood amyloid β : a potential therapy for Alzheimer's disease. <i>Journal of Artificial Organs</i> , 2018, 21, 220-229.	0.4	8
329	Amyloid- β and tau complexity " towards improved biomarkers and targeted therapies. <i>Nature Reviews Neurology</i> , 2018, 14, 22-39.	4.9	303
330	Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease. <i>Journal of Ethnopharmacology</i> , 2018, 215, 42-73.	2.0	105
331	Synergistic Inhibitory Effect of GQDs's Tramiprosate Covalent Binding on Amyloid Aggregation. <i>ACS Chemical Neuroscience</i> , 2018, 9, 817-823.	1.7	40
332	Cathepsin B links oxidative stress to the activation of NLRP3 inflammasome. <i>Experimental Cell Research</i> , 2018, 362, 180-187.	1.2	85
333	Amyloid β oligomers ($A\beta$ Os) in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2018, 125, 177-191.	1.4	114
334	Organizing biochemistry in space and time using prion-like self-assembly. <i>Current Opinion in Systems Biology</i> , 2018, 8, 16-24.	1.3	16
335	Could blocking the formation of amyloid channels rescue Alzheimer's phenotype?. <i>EMBO Molecular Medicine</i> , 2018, 10, 7-9.	3.3	3
336	NABi, a novel β -sheet breaker, inhibits $A\beta$ aggregation and neuronal toxicity: Therapeutic implications for Alzheimer's disease. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2018, 1862, 71-80.	1.1	3

#	ARTICLE	IF	CITATIONS
337	Insulin expression in cultured astrocytes and the decrease by amyloid β . <i>Neurochemistry International</i> , 2018, 119, 171-177.	1.9	29
338	Discovery of an Orally Bioavailable Benzofuran Analogue That Serves as a β -Amyloid Aggregation Inhibitor for the Potential Treatment of Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 396-402.	2.9	30
339	Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes. <i>Clinical and Translational Science</i> , 2018, 11, 147-152.	1.5	224
340	Alzheimer's disease as oligomeropathy. <i>Neurochemistry International</i> , 2018, 119, 57-70.	1.9	90
341	Modulation of β - and γ -Secretases as Early Prevention Against Alzheimer's Disease. <i>Biological Psychiatry</i> , 2018, 83, 320-327.	0.7	54
342	Making the final cut: pathogenic amyloid- β peptide generation by β -secretase. <i>Cell Stress</i> , 2018, 2, 292-310.	1.4	100
343	Removal of blood amyloid- β ; with hemodialysis reduced brain amyloid- β ; confirmed by brain imaging: a case report. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 2931-2937.	1.0	10
344	Present and Future Therapies for Alzheimer's Disease. , 2018, , .		0
346	6. Diagnostische Methoden. , 2018, , 187-352.		0
347	4. Risikofaktoren und Prävention. , 2018, , 123-156.		0
348	Cognitive-Enhancing Effect of a Hydroethanolic Extract of <i>Crinum macowanii</i> against Memory Impairment Induced by Aluminum Chloride in BALB/c Mice. <i>Behavioural Neurology</i> , 2018, 2018, 1-10.	1.1	7
349	Active full-length DNA A β 242 immunization in 3xTg-AD mice reduces not only amyloid deposition but also tau pathology. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 115.	3.0	36
350	Signs and Artifacts in Amyloid PET. <i>Radiographics</i> , 2018, 38, 2123-2133.	1.4	42
351	Decoding the synaptic dysfunction of bioactive human AD brain soluble A β to inspire novel therapeutic avenues for Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2018, 6, 121.	2.4	46
352	Epitomic Characterization of the Specificity of the Anti-Amyloid A β Monoclonal Antibodies 6E10 and 4G8. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1235-1244.	1.2	45
354	Presuming the Promotion of the Common Good by Large-Scale Health Research. , 0, , 155-182.		1
355	Age-Related Increase of Insulin-Degrading Enzyme Is Inversely Correlated with Cognitive Function in APP ^{swe} /PS1 ^{dE9} Mice. <i>Medical Science Monitor</i> , 2018, 24, 2446-2455.	0.5	10
356	Immunotherapeutic and pharmacological approaches for the treatment of Alzheimer's disease. <i>Bioscience Horizons</i> , 2018, 11, .	0.6	2

#	ARTICLE	IF	CITATIONS
357	Therapeutic effect of Rho kinase inhibitor FSDâ€™C10 in a mouse model of Alzheimer's disease. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 3929-3938.	0.8	10
358	Alzheimer's disease: The right drug, the right time. <i>Science</i> , 2018, 362, 1250-1251.	6.0	114
359	Advances in developing novel therapeutic strategies for Alzheimerâ€™s disease. <i>Molecular Neurodegeneration</i> , 2018, 13, 64.	4.4	189
360	Direct CNS delivery of proteins using thermosensitive liposome-in-gel carrier by heterotopic mucosal engrafting. <i>PLoS ONE</i> , 2018, 13, e0208122.	1.1	17
361	A web-based diagnostic reference centre for the European Reference Network â€œEpiCareâ€ recommendations of the eNeuropathology working group. <i>Epileptic Disorders</i> , 2018, 20, 339-345.	0.7	2
362	Current state of Alzheimerâ€™s fluid biomarkers. <i>Acta Neuropathologica</i> , 2018, 136, 821-853.	3.9	370
363	SAR228810: an antibody for protofibrillar amyloid Î² peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA). <i>Alzheimer's Research and Therapy</i> , 2018, 10, 117.	3.0	14
364	Stem Cell-Derived Gametes and Uterus Transplants. , 0, , 37-51.		0
365	A human-derived antibody targets misfolded SOD1 and ameliorates motor symptoms in mouse models of amyotrophic lateral sclerosis. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	56
366	Genomics: New Light on Alzheimerâ€™s Disease Research. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3771.	1.8	14
367	Probing the Occurrence of Soluble Oligomers through Amyloid Aggregation Scaling Laws. <i>Biomolecules</i> , 2018, 8, 108.	1.8	10
368	Inhibiting amyloid-Î² cytotoxicity through its interaction with the cell surface receptor LirB2 by structure-based design. <i>Nature Chemistry</i> , 2018, 10, 1213-1221.	6.6	46
369	Recent progress of drug nanoformulations targeting to brain. <i>Journal of Controlled Release</i> , 2018, 291, 37-64.	4.8	134
370	Synaptosomes. <i>Neuromethods</i> , 2018, , .	0.2	3
371	Neurodegenerative Diseases: Regenerative Mechanisms and Novel Therapeutic Approaches. <i>Brain Sciences</i> , 2018, 8, 177.	1.1	139
372	Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimerâ€™s disease (BLAZE). <i>Alzheimer's Research and Therapy</i> , 2018, 10, 96.	3.0	109
373	What have we learned recently from transgenic mouse models about neurodegeneration? The most promising discoveries of this millennium. <i>Pharmacological Reports</i> , 2018, 70, 1105-1115.	1.5	7
374	Alzheimerâ€™s disease (AD) therapeutics â€œ 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality. <i>Biochemical Pharmacology</i> , 2018, 158, 359-375.	2.0	59

#	ARTICLE	IF	CITATIONS
375	A bispecific immunotweezer prevents soluble PrP oligomers and abolishes prion toxicity. PLoS Pathogens, 2018, 14, e1007335.	2.1	21
376	BACE inhibitors in clinical development for the treatment of Alzheimer's disease. Expert Review of Neurotherapeutics, 2018, 18, 847-857.	1.4	66
377	Peripheral immune system in aging and Alzheimer's disease. Molecular Neurodegeneration, 2018, 13, 51.	4.4	143
378	The identity and function of microglia in neurodegeneration. Nature Immunology, 2018, 19, 1048-1058.	7.0	241
379	Converging pathways in neurodegeneration, from genetics to mechanisms. Nature Neuroscience, 2018, 21, 1300-1309.	7.1	325
380	Early affective changes and increased connectivity in preclinical Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 471-479.	1.2	40
381	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. Alzheimer's Research and Therapy, 2018, 10, 112.	3.0	46
382	The effects of fluorescent labels on A β ₄₂ aggregation detected by fluorescence correlation spectroscopy. Biopolymers, 2018, 109, e23237.	1.2	9
383	The glymphatic pathway in neurological disorders. Lancet Neurology, The, 2018, 17, 1016-1024.	4.9	831
384	Grasping at straws: the failure of solanezumab to modify mild Alzheimer's disease. Expert Opinion on Biological Therapy, 2018, 18, 1189-1192.	1.4	17
385	Prediction of Cerebral Amyloid With Common Information Obtained From Memory Clinic Practice. Frontiers in Aging Neuroscience, 2018, 10, 309.	1.7	21
386	Phyto-Therapeutic and Nanomedicinal Approaches to Cure Alzheimer's Disease: Present Status and Future Opportunities. Frontiers in Aging Neuroscience, 2018, 10, 284.	1.7	99
387	Anti-amyloid Therapy of Alzheimer's Disease: Current State and Prospects. Biochemistry (Moscow), 2018, 83, 1057-1067.	0.7	29
388	Microglial signatures and their role in health and disease. Nature Reviews Neuroscience, 2018, 19, 622-635.	4.9	599
389	Passive A β Immunotherapy: Current Achievements and Future Perspectives. Molecules, 2018, 23, 1068.	1.7	41
390	The Effect of 40-Hz Light Therapy on Amyloid Load in Patients with Prodromal and Clinical Alzheimer's Disease. International Journal of Alzheimer's Disease, 2018, 2018, 1-5.	1.1	28
391	Targeting Amyloid Aggregation: An Overview of Strategies and Mechanisms. International Journal of Molecular Sciences, 2018, 19, 2677.	1.8	103
392	Blood-brain barrier integrity in a mouse model of Alzheimer's disease with or without acute 3D6 immunotherapy. Neuropharmacology, 2018, 143, 1-9.	2.0	27

#	ARTICLE	IF	CITATIONS
393	Nanodisc-Forming Scaffold Protein Promoted Retardation of Amyloid-Beta Aggregation. Journal of Molecular Biology, 2018, 430, 4230-4244.	2.0	49
394	TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease. Journal of Experimental Medicine, 2018, 215, 2247-2264.	4.2	50
395	Passive Immunotherapy in Alzheimer's Disease. , 0, , .		2
396	Extending the functional characteristics of naturally occurring autoantibodies against A β -Amyloid, Prion Protein and I α -Synuclein. PLoS ONE, 2018, 13, e0202954.	1.1	16
397	Bringing Induced Pluripotent Stem Cell Technology to the Bedside. JMA Journal, 2018, 1, 6-14.	0.6	9
398	Dihydrochalcone molecules destabilize Alzheimer's amyloid-A β protofibrils through binding to the protofibril cavity. Physical Chemistry Chemical Physics, 2018, 20, 17208-17217.	1.3	32
399	AP180 N-Terminal Homology (ANTH) and Epsin N-Terminal Homology (ENTH) Domains: Physiological Functions and Involvement in Disease. Advances in Experimental Medicine and Biology, 2018, 1111, 55-76.	0.8	6
400	Total chemical synthesis and biophysical properties of a designed soluble 24 kDa amyloid analogue. Chemical Science, 2018, 9, 5594-5599.	3.7	6
401	Dissociation of cerebrospinal fluid amyloid-A β and tau levels in patients with prolonged posttraumatic disorders of consciousness. Brain Injury, 2018, 32, 1056-1060.	0.6	14
402	Inhibition of tau-derived hexapeptide aggregation and toxicity by a self-assembled cyclic peptide conformational inhibitor. Chemical Communications, 2018, 54, 5980-5983.	2.2	33
403	Improved synaptic and cognitive function in aged 3 \times Tg-AD mice with reduced amyloid-A β after immunotherapy with a novel recombinant 6A β 215-TF chimeric vaccine. Clinical Immunology, 2018, 193, 12-23.	1.4	4
405	Cyclic trimer of human cystatin C, an amyloidogenic protein - molecular dynamics and experimental studies. Journal of Applied Physics, 2018, 123, 174701.	1.1	3
406	Mechanisms of protein toxicity in neurodegenerative diseases. Cellular and Molecular Life Sciences, 2018, 75, 3159-3180.	2.4	103
407	PET/CT of Dementia. American Journal of Roentgenology, 2018, 211, 246-259.	1.0	18
408	Alzheimer's Disease Model System Using Drosophila. Advances in Experimental Medicine and Biology, 2018, 1076, 25-40.	0.8	33
409	Clinical Research on Alzheimer's Disease: Progress and Perspectives. Neuroscience Bulletin, 2018, 34, 1111-1118.	1.5	100
410	The Microglial Response to Neurodegenerative Disease. Advances in Immunology, 2018, 139, 1-50.	1.1	22
411	ASIC Implementation of a Nonlinear Dynamical Model for Hippocampal Prosthesis. Neural Computation, 2018, 30, 2472-2499.	1.3	2

#	ARTICLE	IF	CITATIONS
412	Intradermal active full-length DNA A β 242 immunization via electroporation leads to high anti-A β 2 antibody levels in wild-type mice. <i>Journal of Neuroimmunology</i> , 2018, 322, 15-25.	1.1	5
413	Current progress, challenges and future prospects of diagnostic and therapeutic interventions in Alzheimer's disease. <i>RSC Advances</i> , 2018, 8, 23780-23804.	1.7	105
414	Spontaneous Fluctuations Can Guide Drug Design Strategies for Structurally Disordered Proteins. <i>Biochemistry</i> , 2018, 57, 4206-4213.	1.2	10
416	A Novel scFv Anti-A β 2 Antibody Reduces Pathological Impairments in APP/PS1 Transgenic Mice via Modulation of Inflammatory Cytokines and A β 2-related Enzymes. <i>Journal of Molecular Neuroscience</i> , 2018, 66, 1-9.	1.1	2
417	Polyphenols Derived from Lychee Seed Suppress A β 2 (1-42)-Induced Neuroinflammation. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2109.	1.8	31
418	Structural aspects of Alzheimer's disease immunotherapy targeted against amyloid-beta peptide. <i>Bratislava Medical Journal</i> , 2018, 119, 201-204.	0.4	5
419	Modeling endophilin-mediated A β 2 disposal in glioma cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2018, 1865, 1385-1396.	1.9	7
420	Early A β 2-HBc virus-like particles immunization had better effects on preventing the deficit of learning and memory abilities and reducing cerebral A β 2 load in PDAPP mice. <i>Vaccine</i> , 2018, 36, 5258-5264.	1.7	1
421	Efficient clearance of A β 2 protofibrils in A β 2PP-transgenic mice treated with a brain-penetrating bifunctional antibody. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 49.	3.0	49
422	Remarkably Efficient Blood-brain Barrier Crossing Polyfluorene-Chitosan Nanoparticle Selectively Tweaks Amyloid Oligomer in Cerebrospinal Fluid and A β 21-40. <i>ACS Omega</i> , 2018, 3, 8059-8066.	1.6	19
423	Neuro-Immuno-Gene- and Genome-Editing-Therapy for Alzheimer's Disease: Are We There Yet?. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 321-344.	1.2	17
424	Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound. <i>Nature Communications</i> , 2018, 9, 2336.	5.8	618
425	Intercellular Spread of Protein Aggregates in Neurodegenerative Disease. <i>Annual Review of Cell and Developmental Biology</i> , 2018, 34, 545-568.	4.0	99
426	Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain. <i>CNS Drugs</i> , 2018, 32, 849-861.	2.7	38
427	The Role of Genetics in Advancing Precision Medicine for Alzheimer's Disease—A Narrative Review. <i>Frontiers in Medicine</i> , 2018, 5, 108.	1.2	61
428	Mechanisms of Risk Reduction in the Clinical Practice of Alzheimer's Disease Prevention. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 96.	1.7	33
429	Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 100.	1.7	20
430	The Physiological Roles of Amyloid- β 2 Peptide Hint at New Ways to Treat Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 118.	1.7	226

#	ARTICLE	IF	CITATIONS
431	The Relation Between Brain Amyloid Deposition, Cortical Atrophy, and Plasma Biomarkers in Amnesic Mild Cognitive Impairment and Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 175.	1.7	48
432	Potential Utility of Retinal Imaging for Alzheimer's Disease: A Review. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 188.	1.7	52
433	The Quest for an Alzheimer Therapy. <i>Frontiers in Neurology</i> , 2018, 9, 108.	1.1	19
434	Safety and Efficacy of Scanning Ultrasound Treatment of Aged APP23 Mice. <i>Frontiers in Neuroscience</i> , 2018, 12, 55.	1.4	50
435	Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 254.	1.4	17
436	Rate of β -amyloid accumulation varies with baseline amyloid burden: Implications for anti-amyloid drug trials. <i>Alzheimer's and Dementia</i> , 2018, 14, 1387-1396.	0.4	16
437	Spatial navigation deficits " overlooked cognitive marker for preclinical Alzheimer disease?. <i>Nature Reviews Neurology</i> , 2018, 14, 496-506.	4.9	293
438	Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 689-707.	1.2	15
439	Perioperative implications of common and newer psychotropic medications used in clinical practice. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2018, 32, 187-202.	1.7	12
440	The Implication of the Brain Insulin Receptor in Late Onset Alzheimer's Disease Dementia. <i>Pharmaceuticals</i> , 2018, 11, 11.	1.7	45
441	Notch3 ^{ECD} immunotherapy improves cerebrovascular responses in CADASIL mice. <i>Annals of Neurology</i> , 2018, 84, 246-259.	2.8	26
442	Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. <i>Nature Reviews Endocrinology</i> , 2018, 14, 591-604.	4.3	689
443	An in vitro paradigm to assess potential anti-A β antibodies for Alzheimer's disease. <i>Nature Communications</i> , 2018, 9, 2676.	5.8	50
444	Chiral supramolecular coordination cages as high-performance inhibitors against amyloid- β aggregation. <i>Chemical Communications</i> , 2018, 54, 8725-8728.	2.2	16
445	A Randomized Phase 2 Study of an Anti- β -Amyloid β Monoclonal Antibody in Geographic Atrophy Secondary to Age-Related Macular Degeneration. <i>Ophthalmology Retina</i> , 2018, 2, 1028-1040.	1.2	43
446	Recent advancements toward therapeutic vaccines against Alzheimer's disease. <i>Expert Review of Vaccines</i> , 2018, 17, 707-721.	2.0	46
447	The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 797-819.	1.2	38
448	In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 859-873.	1.2	10

#	ARTICLE	IF	CITATIONS
449	Alzheimer's disease: Only prevention makes sense. <i>European Journal of Clinical Investigation</i> , 2018, 48, e13005.	1.7	41
450	Tau oligomers mediate β -synuclein toxicity and can be targeted by immunotherapy. <i>Molecular Neurodegeneration</i> , 2018, 13, 13.	4.4	60
451	The Properties of Amyloid- β Fibrils Are Determined by their Path of Formation. <i>Journal of Molecular Biology</i> , 2018, 430, 1940-1949.	2.0	17
452	Antiamyloidogenic Chemical/Biochemical-Based Designed Nanoparticle as Artificial Chaperone for Efficient Inhibition of Protein Aggregation. <i>Biomacromolecules</i> , 2018, 19, 1721-1731.	2.6	35
453	Safety, tolerability and immunogenicity of an active anti-A β 240 vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 12.	3.0	72
454	Impact of amyloid-beta changes on cognitive outcomes in Alzheimer's disease: analysis of clinical trials using a quantitative systems pharmacology model. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 14.	3.0	27
455	Alzheimer's disease hypothesis and related therapies. <i>Translational Neurodegeneration</i> , 2018, 7, 2.	3.6	385
456	Sex-Dependent Differences in Spontaneous Autoimmunity in Adult 3xTg-AD Mice. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1191-1205.	1.2	18
457	The Brain Health Registry: An internet-based platform for recruitment, assessment, and longitudinal monitoring of participants for neuroscience studies. <i>Alzheimer's and Dementia</i> , 2018, 14, 1063-1076.	0.4	91
458	Japanese and North American Alzheimer's Disease Neuroimaging Initiative studies: Harmonization for international trials. <i>Alzheimer's and Dementia</i> , 2018, 14, 1077-1087.	0.4	83
459	Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region. <i>Expert Opinion on Drug Delivery</i> , 2018, 15, 589-617.	2.4	74
460	Degenerative or Debilitative Neurologic Syndromes. <i>Nursing Clinics of North America</i> , 2018, 53, 447-457.	0.7	2
461	Low-dose CT for the spatial normalization of PET images: A validation procedure for amyloid-PET semi-quantification. <i>NeuroImage: Clinical</i> , 2018, 20, 153-160.	1.4	21
462	Comparison of Blood Lead Levels in Patients With Alzheimer's Disease and Healthy People. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2018, 33, 541-547.	0.9	29
463	Identification of novel immune-relevant drug target genes for Alzheimer's Disease by combining ontology inference with network analysis. <i>CNS Neuroscience and Therapeutics</i> , 2018, 24, 1253-1263.	1.9	32
464	Dysregulation of Neuronal Iron Homeostasis as an Alternative Unifying Effect of Mutations Causing Familial Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 533.	1.4	41
465	Finding useful biomarkers for Parkinson's disease. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	125
466	Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 660-688.	21.5	370

#	ARTICLE	IF	CITATIONS
467	Gene therapy for neurological disorders: progress and prospects. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 641-659.	21.5	222
468	Antibody-Based In Vivo PET Imaging Detects Amyloid- β Reduction in Alzheimer Transgenic Mice After BACE-1 Inhibition. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1885-1891.	2.8	32
469	Role of Amyloid- β and Tau Proteins in Alzheimer's Disease: Confuting the Amyloid Cascade. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S611-S631.	1.2	102
470	The Amyloid- β Oligomer Hypothesis: Beginning of the Third Decade. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S567-S610.	1.2	572
471	Latent classes of mild cognitive impairment are associated with clinical outcomes and neuropathology: Analysis of data from the National Alzheimer's Coordinating Center. <i>Neurobiology of Disease</i> , 2018, 117, 62-71.	2.1	17
472	Alzheimer's disease: An ignored condition. <i>Medicina Clínica (English Edition)</i> , 2018, 150, 432-433.	0.1	2
473	Everything but amyloid: new thinking prompts FDA revamp. <i>Nature Biotechnology</i> , 2018, 36, 483-484.	9.4	8
474	Tau Conformation as a Target for Disease-Modifying Therapy: The Role of Truncation. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S535-S546.	1.2	29
475	Translating Human Genetics into Novel Drug Targets. <i>Methods in Molecular Biology</i> , 2018, 1793, 277-290.	0.4	2
476	Prophylactic and Therapeutic Applications of Catalytic Immunoglobulin Gene Delivery in a Mouse Model of Alzheimer's Disease. , 2018, , 139-161.		1
477	Multimodal imaging-based therapeutic fingerprints for optimizing personalized interventions: Application to neurodegeneration. <i>NeuroImage</i> , 2018, 179, 40-50.	2.1	33
478	What autoantibodies tell us about the pathogenesis of Parkinson's disease. <i>Journal of Neurochemistry</i> , 2018, 145, 433-435.	2.1	6
479	Neurodegenerative Diseases as Protein Folding Disorders. , 2018, , 243-267.		0
480	The development of a stochastic mathematical model of Alzheimer's disease to help improve the design of clinical trials of potential treatments. <i>PLoS ONE</i> , 2018, 13, e0190615.	1.1	26
481	Vaccination strategies. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 153, 419-430.	1.0	5
482	Early differentiation of dementia with Lewy bodies and Alzheimer's disease: Heart rate variability at mild cognitive impairment stage. <i>Clinical Neurophysiology</i> , 2018, 129, 1570-1578.	0.7	25
483	Therapeutic strategies for targeting neurodegenerative protein misfolding disorders. <i>Current Opinion in Chemical Biology</i> , 2018, 44, 66-74.	2.8	23
484	Estudios farmacogenéticos en la enfermedad de Alzheimer. <i>Neurología</i> , 2022, 37, 287-303.	0.3	5

#	ARTICLE	IF	CITATIONS
485	The shape effect of reconstituted high-density lipoprotein nanocarriers on brain delivery and A β clearance. <i>Nano Research</i> , 2018, 11, 5615-5628.	5.8	6
486	Impact of Reference and Target Region Selection on Amyloid PET SUV Ratios in the Phase 1b PRIME Study of Aducanumab. <i>Journal of Nuclear Medicine</i> , 2019, 60, 100-106.	2.8	43
487	Ocular amyloid imaging at the crossroad of Alzheimer's disease and age-related macular degeneration: implications for diagnosis and therapy. <i>Journal of Neurology</i> , 2019, 266, 1566-1577.	1.8	23
488	Anti-prion Protein Antibody 6D11 Restores Cellular Proteostasis of Prion Protein Through Disrupting Recycling Propagation of PrP ^{Sc} and Targeting PrP ^{Sc} for Lysosomal Degradation. <i>Molecular Neurobiology</i> , 2019, 56, 2073-2091.	1.9	13
489	Urinary and plasmatic metabolomics strategy to explore the holistic mechanism of lignans in <i>S. chinensis</i> in treating Alzheimer's disease using UPLC-Q-TOF-MS. <i>Food and Function</i> , 2019, 10, 5656-5668.	2.1	26
490	EDITORIAL: FAILURE AFTER FAILURE. WHAT NEXT IN AD DRUG DEVELOPMENT?. <i>Journal of prevention of Alzheimer's disease</i> , The, 2019, 6, 1-1.	1.5	18
491	Scanning ultrasound in the absence of blood-brain barrier opening is not sufficient to clear A β -amyloid plaques in the APP23 mouse model of Alzheimer's disease. <i>Brain Research Bulletin</i> , 2019, 153, 8-14.	1.4	26
492	Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 68.	3.0	44
493	Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases. <i>CNS Drugs</i> , 2019, 33, 883-904.	2.7	23
494	Unilateral Focused Ultrasound-Induced Blood-Brain Barrier Opening Reduces Phosphorylated Tau from The rTg4510 Mouse Model. <i>Theranostics</i> , 2019, 9, 5396-5411.	4.6	63
496	Targeting the transferrin receptor for brain drug delivery. <i>Progress in Neurobiology</i> , 2019, 181, 101665.	2.8	204
497	Exosomal DNA Aptamer Targeting A β -Synuclein Aggregates Reduced Neuropathological Deficits in a Mouse Parkinson's Disease Model. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 17, 726-740.	2.3	77
498	Designing an Interactive Device to Slow Progression of Alzheimer's Disease. <i>Lecture Notes in Computer Science</i> , 2019, , 546-562.	1.0	0
499	Preventing dementia by preventing stroke: The Berlin Manifesto. <i>Alzheimer's and Dementia</i> , 2019, 15, 961-984.	0.4	200
500	Could changing the course of Alzheimer's disease pathology with immunotherapy prevent dementia?. <i>Brain</i> , 2019, 142, 1853-1855.	3.7	3
501	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging's Alzheimer's Association Research Framework. <i>JAMA Neurology</i> , 2019, 76, 1174.	4.5	182
502	Current Concepts in the Pathogenesis of Neurodegenerative Diseases and Treatment Strategies. <i>Neuroscience and Behavioral Physiology</i> , 2019, 49, 399-405.	0.2	3
503	Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer's disease pathogenesis. <i>Nature Neuroscience</i> , 2019, 22, 1258-1268.	7.1	48

#	ARTICLE	IF	CITATIONS
504	Current and emerging avenues for Alzheimer's disease drug targets. <i>Journal of Internal Medicine</i> , 2019, 286, 398-437.	2.7	102
505	A Rationally Designed Humanized Antibody Selective for Amyloid Beta Oligomers in Alzheimer's Disease. <i>Scientific Reports</i> , 2019, 9, 9870.	1.6	35
506	Therapeutic vaccines for amyotrophic lateral sclerosis directed against disease specific epitopes of superoxide dismutase 1. <i>Vaccine</i> , 2019, 37, 4920-4927.	1.7	19
507	Anti-A β Antibodies and Cerebral Amyloid Angiopathy Complications. <i>Frontiers in Immunology</i> , 2019, 10, 1534.	2.2	25
508	A Snapshot on the Current Status of Alzheimer's Disease, Treatment Perspectives, &in-Vitro; and &in-Vivo; Research Studies and Future Opportunities. <i>Chemical and Pharmaceutical Bulletin</i> , 2019, 67, 1030-1041.	0.6	8
509	Intrinsically disordered proteins in various hypotheses on the pathogenesis of Alzheimer's and Parkinson's diseases. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 166, 145-223.	0.9	22
510	Ginsenoside Re Inhibits ROS/ASK-1 Dependent Mitochondrial Apoptosis Pathway and Activation of Nrf2-Antioxidant Response in Beta-Amyloid-Challenged SH-SY5Y Cells. <i>Molecules</i> , 2019, 24, 2687.	1.7	52
511	Slightly Symptomatic Cerebral Amyloid Angiopathy-Related Inflammation with Spontaneous Remission in Four Months. <i>Case Reports in Neurological Medicine</i> , 2019, 2019, 1-5.	0.3	4
512	A Near-Infrared-Controllable Artificial Metalloprotease Used for Degrading Amyloid β Monomers and Aggregates. <i>Chemistry - A European Journal</i> , 2019, 25, 11852-11858.	1.7	25
513	How many patients are eligible for disease-modifying treatment in Alzheimer's disease? A French national observational study over 5 years. <i>BMJ Open</i> , 2019, 9, e029663.	0.8	16
515	Early detection of Alzheimer's disease by peptides from phage display screening. <i>Brain Research</i> , 2019, 1721, 146306.	1.1	7
516	Challenges in the treatment of Alzheimer's disease: recent progress and treatment strategies of pharmaceuticals targeting notable pathological factors. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 623-652.	1.4	17
517	Applications of Neuroimaging Biomarkers in CNS Drug Development. <i>Handbook of Behavioral Neuroscience</i> , 2019, , 115-158.	0.7	0
518	Organoplatinum-Substituted Polyoxometalate Inhibits β -Amyloid Aggregation for Alzheimer's Therapy. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 18032-18039.	7.2	40
519	Biological, Diagnostic and Therapeutic Advances in Alzheimer's Disease. , 2019, , .		6
520	A Facile and Universal Method to Efficiently Fabricate Diverse Protein Capsules for Multiple Potential Applications. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 39209-39218.	4.0	22
523	Temporal dynamics of learning-promoted synaptic diversity in CA1 pyramidal neurons. <i>FASEB Journal</i> , 2019, 33, 14382-14393.	0.2	7
524	A Novel Model of Mixed Vascular Dementia Incorporating Hypertension in a Rat Model of Alzheimer's Disease. <i>Frontiers in Physiology</i> , 2019, 10, 1269.	1.3	22

#	ARTICLE	IF	CITATIONS
525	Organoplatinum-Substituted Polyoxometalate Inhibits β -Amyloid Aggregation for Alzheimer's Therapy. <i>Angewandte Chemie</i> , 2019, 131, 18200-18207.	1.6	12
526	Drugs for Targeted Therapies of Alzheimer's Disease. <i>Current Medicinal Chemistry</i> , 2019, 26, 335-359.	1.2	12
527	Cell size effects in the molecular dynamics of the intrinsically disordered A β peptide. <i>Journal of Chemical Physics</i> , 2019, 151, 085101.	1.2	17
528	Tau Based Therapeutics: Alternative Approaches in the War on Alzheimer's Disease. <i>Journal of prevention of Alzheimer's disease</i> , The, 2019, 6, 1-2.	1.5	3
529	Overview of Transgenic Mouse Models for Alzheimer's Disease. <i>Current Protocols in Neuroscience</i> , 2019, 89, e81.	2.6	78
530	Immunotherapy in Parkinson's disease: Current status and future directions. <i>Neurobiology of Disease</i> , 2019, 132, 104587.	2.1	41
531	AD molecular: PET amyloid imaging across the Alzheimer's disease spectrum: From disease mechanisms to prevention. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 165, 63-106.	0.9	10
532	The β -secretase of precision drug development for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 76.	3.0	148
533	Ageing as a risk factor for neurodegenerative disease. <i>Nature Reviews Neurology</i> , 2019, 15, 565-581.	4.9	1,578
534	Refining the understanding of typical Alzheimer disease. <i>Nature Reviews Neurology</i> , 2019, 15, 623-624.	4.9	3
535	Autoantibody-Based Diagnostic Biomarkers: Technological Approaches to Discovery and Validation. , O, , .		7
536	Encoding the Sequence of Specific Autoantibodies Against beta-Amyloid and alpha-Synuclein in Neurodegenerative Diseases. <i>Frontiers in Immunology</i> , 2019, 10, 2033.	2.2	7
537	Predictors for Favorable Cognitive Outcome Post-Stroke: A-Seven-Year Follow-Up Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019, 48, 45-55.	0.7	10
539	Affinity Maturation Enhances Antibody Specificity but Compromises Conformational Stability. <i>Cell Reports</i> , 2019, 28, 3300-3308.e4.	2.9	65
540	Risk Factors for Alzheimer's Disease: Focus on Stress. <i>Frontiers in Pharmacology</i> , 2019, 10, 976.	1.6	20
541	Alzheimer Disease: An Update on Pathobiology and Treatment Strategies. <i>Cell</i> , 2019, 179, 312-339.	13.5	1,675
542	Multidomain intervention and/or omega-3 in nondemented elderly subjects according to amyloid status. <i>Alzheimer's and Dementia</i> , 2019, 15, 1392-1401.	0.4	35
543	Current and Emerging Pharmacological Targets for the Treatment of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 72, S145-S176.	1.2	26

#	ARTICLE	IF	CITATIONS
544	Pre-Clinical Safety and Efficacy Evaluation of Amytrap, a Novel Therapeutic to Treat Alzheimer's Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2019, 3, 77-94.	1.2	4
545	Special topic section: linkages among cerebrovascular, cardiovascular, and cognitive disorders: Preventing dementia by preventing stroke: The Berlin Manifesto. <i>International Journal of Stroke</i> , 2019, , 174749301987191.	2.9	13
546	Probing the Aggregation and Immune Response of Human Islet Amyloid Polypeptides with Ligand-Stabilized Gold Nanoparticles. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 10462-10471.	4.0	37
547	Photoactive chlorin e6 is a multifunctional modulator of amyloid- β aggregation and toxicity via specific interactions with its histidine residues. <i>Chemical Science</i> , 2019, 10, 208-217.	3.7	25
548	Conformation-specific antibodies against multiple amyloid protofibril species from a single amyloid immunogen. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 2103-2114.	1.6	11
549	Indole Compound NC009-1 Augments APOE and TRKA in Alzheimer's Disease Cell and Mouse Models for Neuroprotection and Cognitive Improvement. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 737-756.	1.2	13
550	Drug Development for Alzheimer's Disease: Microglia Induced Neuroinflammation as a Target?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 558.	1.8	99
551	Inflammatory mechanisms in neurodegeneration. <i>Journal of Neurochemistry</i> , 2019, 149, 562-581.	2.1	85
552	Treatment Combinations for Alzheimer's Disease: Current and Future Pharmacotherapy Options. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 779-794.	1.2	336
553	Blood-brain and blood-cerebrospinal fluid passage of BRICHOS domains from two molecular chaperones in mice. <i>Journal of Biological Chemistry</i> , 2019, 294, 2606-5220.	1.6	15
554	^{18}F -Florbetaben PET/CT to Assess Alzheimer's Disease: A new Analysis Method for Regional Amyloid Quantification. <i>Journal of Neuroimaging</i> , 2019, 29, 383-393.	1.0	19
555	^{18}F -flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 13.	3.0	121
556	Optimized liposomes with transactivator of transcription peptide and anti-apoptotic drugs to target hippocampal neurons and prevent tau-hyperphosphorylated neurodegeneration. <i>Acta Biomaterialia</i> , 2019, 87, 207-222.	4.1	38
557	Chemical Kinetic Strategies for High-Throughput Screening of Protein Aggregation Modulators. <i>Chemistry - an Asian Journal</i> , 2019, 14, 500-508.	1.7	13
558	A short perspective on the long road to effective treatments for Alzheimer's disease. <i>British Journal of Pharmacology</i> , 2019, 176, 3636-3648.	2.7	17
559	Progress of Pharmacological Approaches in Parkinson's Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1106-1120.	2.3	34
560	Aging, lifestyle and dementia. <i>Neurobiology of Disease</i> , 2019, 130, 104481.	2.1	97
561	Inhibition of metal-induced amyloid β -peptide aggregation by a blood-brain barrier permeable silica-cyclen nanochelator. <i>RSC Advances</i> , 2019, 9, 14126-14131.	1.7	11

#	ARTICLE	IF	CITATIONS
562	Plant-based vaccines for Alzheimer's disease. Proceedings of the Japan Academy Series B: Physical and Biological Sciences, 2019, 95, 290-294.	1.6	8
563	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. JAMA - Journal of the American Medical Association, 2019, 321, 2316.	3.8	223
564	The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 216-227.	1.8	80
565	Upregulation of MIF as a defense mechanism and a biomarker of Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 54.	3.0	44
566	The Role of Antibodies and Their Receptors in Protection Against Ordered Protein Assembly in Neurodegeneration. Frontiers in Immunology, 2019, 10, 1139.	2.2	38
567	Perspectives on drug discovery strategies based on IDPs. , 2019, , 275-327.		9
568	Oral Immunization with Soybean Storage Protein Containing Amyloid- β 4 ² Prevents Spatial Learning Decline. Journal of Alzheimer's Disease, 2019, 70, 487-503.	1.2	4
569	Alzheimer's disease: future drug development and the blood-brain barrier. Expert Opinion on Investigational Drugs, 2019, 28, 569-572.	1.9	19
570	A good marker does not mean a good target for clinical trials in Alzheimer's disease: the amyloid hypothesis questioned. Neurodegenerative Disease Management, 2019, 9, 119-121.	1.2	17
571	Ultra-low-dose PET reconstruction using generative adversarial network with feature matching and task-specific perceptual loss. Medical Physics, 2019, 46, 3555-3564.	1.6	121
572	Diagnosis and treatment of cognitive impairment. Zeitschrift Fur Gerontologie Und Geriatrie, 2019, 52, 309-315.	0.8	14
573	Persistent neuropathological effects 14 years following amyloid- β immunization in Alzheimer's disease. Brain, 2019, 142, 2113-2126.	3.7	127
574	Alzheimer disease and aducanumab: adjusting our approach. Nature Reviews Neurology, 2019, 15, 365-366.	4.9	154
575	Target engagement in an alzheimer trial: Crenezumab lowers amyloid β oligomers in cerebrospinal fluid. Annals of Neurology, 2019, 86, 215-224.	2.8	70
576	β -secretase inhibitors for Alzheimer's disease: heading in the wrong direction?. Lancet Neurology, The, 2019, 18, 624-626.	4.9	17
577	Exploring the Pathogenesis of Alzheimer Disease in Basal Forebrain Cholinergic Neurons: Converging Insights From Alternative Hypotheses. Frontiers in Neuroscience, 2019, 13, 446.	1.4	122
578	Sequential Therapy Based on Evolvement of Patterns: A New Model for Treatment of Alzheimer's Disease. Chinese Journal of Integrative Medicine, 2019, 25, 565-573.	0.7	6
579	Texture descriptors and voxels for the early diagnosis of Alzheimer's disease. Artificial Intelligence in Medicine, 2019, 97, 19-26.	3.8	34

#	ARTICLE	IF	CITATIONS
580	Comparison of ¹⁸ F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL [®] approaches: Validation against histopathology. <i>Alzheimer's and Dementia</i> , 2019, 15, 807-816.	0.4	50
581	Clinical trials of prion disease therapeutics. <i>Current Opinion in Pharmacology</i> , 2019, 44, 53-60.	1.7	21
582	ApoA-I deficiency increases cortical amyloid deposition, cerebral amyloid angiopathy, cortical and hippocampal astrogliosis, and amyloid-associated astrocyte reactivity in APP/PS1 mice. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 44.	3.0	34
583	Vascular Dysfunction in Alzheimer's Disease: A Prelude to the Pathological Process or a Consequence of It?. <i>Journal of Clinical Medicine</i> , 2019, 8, 651.	1.0	131
585	A metabolic perspective of late onset Alzheimer's disease. <i>Pharmacological Research</i> , 2019, 145, 104255.	3.1	19
586	Detecting Non-cognitive Features of Prodromal Neurodegenerative Diseases. <i>Current Aging Science</i> , 2019, 11, 242-249.	0.4	6
587	Affibody-Mediated Sequestration of Amyloid β^2 Demonstrates Preventive Efficacy in a Transgenic Alzheimer's Disease Mouse Model. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 64.	1.7	16
588	Label-free distribution of anti-amyloid β AIP in <i>Drosophila melanogaster</i> : prevention of β^{42} -induced toxicity without side effects in transgenic flies. <i>Journal of Neurochemistry</i> , 2019, 150, 74-87.	2.1	7
589	Fluorescent 1,4-Naphthoquinones To Visualize Diffuse and Dense-Core Amyloid Plaques in APP/PS1 Transgenic Mouse Brains. <i>ACS Chemical Neuroscience</i> , 2019, 10, 3031-3044.	1.7	14
590	Toward personalized cognitive diagnostics of at-genetic-risk Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9285-9292.	3.3	118
591	Bassoon proteinopathy drives neurodegeneration in multiple sclerosis. <i>Nature Neuroscience</i> , 2019, 22, 887-896.	7.1	55
592	Identification of neurotoxic cross-linked amyloid- β^2 dimers in the Alzheimer's brain. <i>Brain</i> , 2019, 142, 1441-1457.	3.7	74
593	Distinct Binding Dynamics, Sites and Interactions of Fullerene and Fullerenols with Amyloid- β^2 Peptides Revealed by Molecular Dynamics Simulations. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2048.	1.8	28
594	Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. <i>Brain</i> , 2019, 142, 1503-1527.	3.7	873
595	Excitatory-inhibitory imbalance in Alzheimer's disease and therapeutic significance. <i>Neurobiology of Disease</i> , 2019, 127, 605-615.	2.1	79
596	Intravenous Immunoglobulin for Patients With Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2019, 34, 281-289.	0.9	10
597	Immune Signaling in Neurodegeneration. <i>Immunity</i> , 2019, 50, 955-974.	6.6	217
598	Disease Modification in Alzheimer's Disease: Current Thinking. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, , 216847901984189.	0.8	1

#	ARTICLE	IF	CITATIONS
599	Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 33.	3.0	30
600	Structure-Based Peptide Inhibitor Design of Amyloid- β^2 Aggregation. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 54.	1.4	58
601	Immunoglobulin G transport increases in an in vitro blood-brain barrier model with amyloid- β^2 and with neuroinflammatory cytokines. <i>Biotechnology and Bioengineering</i> , 2019, 116, 1752-1761.	1.7	16
602	Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders. <i>Neuron</i> , 2019, 101, 1003-1015.	3.8	29
603	A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward. <i>Neuron</i> , 2019, 101, 820-838.	3.8	338
604	A metabolomic approach to identifying biomarkers in blood of Alzheimer's disease. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 537-545.	1.7	37
605	Endosomal pH favors shedding of membrane-inserted amyloid- β^2 peptide. <i>Protein Science</i> , 2019, 28, 889-899.	3.1	3
606	Emergence of synaptic and cognitive impairment in a mature-onset APP mouse model of Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2019, 7, 25.	2.4	28
607	Magnetite/Ceria Nanoparticle Assemblies for Extracorporeal Cleansing of Amyloid- β^2 in Alzheimer's Disease. <i>Advanced Materials</i> , 2019, 31, e1807965.	11.1	87
608	Nature-inspired design and evolution of anti-amyloid antibodies. <i>Journal of Biological Chemistry</i> , 2019, 294, 8438-8451.	1.6	20
609	Why Amyloid Is Still a Target for Alzheimer Disease Clinical Trials. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 845-847.	1.3	4
610	Effects of concentration of amyloid β^2 ($A\beta^2$) on viability of cultured retinal pigment epithelial cells. <i>BMC Ophthalmology</i> , 2019, 19, 70.	0.6	20
611	Ca ²⁺ homeostasis dysregulation in Alzheimer's disease: a focus on plasma membrane and cell organelles. <i>FASEB Journal</i> , 2019, 33, 6697-6712.	0.2	62
612	A small molecule Nec-1 directly induces amyloid clearance in the brains of aged APP/PS1 mice. <i>Scientific Reports</i> , 2019, 9, 4183.	1.6	27
613	The Role of Mitochondrial Dysfunction in the Progression of Alzheimer's Disease. <i>Current Medicinal Chemistry</i> , 2019, 25, 5578-5587.	1.2	48
614	Microglial Progranulin: Involvement in Alzheimer's Disease and Neurodegenerative Diseases. <i>Cells</i> , 2019, 8, 230.	1.8	53
615	Reactive Amphiphilic Conjugated Polymers for Inhibiting Amyloid β^2 Assembly. <i>Angewandte Chemie</i> , 2019, 131, 6049-6054.	1.6	16
616	Reaction Kinetics-Mediated Control over Silver Nanogap Shells as Surface-Enhanced Raman Scattering Nanoprobes for Detection of Alzheimer's Disease Biomarkers. <i>Small</i> , 2019, 15, e1900613.	5.2	39

#	ARTICLE	IF	CITATIONS
617	Lowering of Amyloid-Beta by β -Secretase Inhibitors – Some Informative Failures. <i>New England Journal of Medicine</i> , 2019, 380, 1476-1478.	13.9	56
618	Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease. <i>New England Journal of Medicine</i> , 2019, 380, 1408-1420.	13.9	397
619	Informatics and Computational Methods in Natural Product Drug Discovery: A Review and Perspectives. <i>Frontiers in Genetics</i> , 2019, 10, 368.	1.1	95
620	Current and Future Treatments in Alzheimer's Disease. <i>Seminars in Neurology</i> , 2019, 39, 227-240.	0.5	161
621	Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1286.	3.8	391
622	Curcumin restores innate immune Alzheimer's disease risk gene expression to ameliorate Alzheimer pathogenesis. <i>Neurobiology of Disease</i> , 2019, 127, 432-448.	2.1	70
623	Fungal Metabolites as Promising New Drug Leads for the Treatment of Alzheimer's Disease. <i>Studies in Natural Products Chemistry</i> , 2019, , 1-39.	0.8	4
624	An automated microliter-scale high-throughput screening system (MSHTS) for real-time monitoring of protein aggregation using quantum-dot nanoprobe. <i>Scientific Reports</i> , 2019, 9, 2587.	1.6	17
625	Learning Promotes Subfield-Specific Synaptic Diversity in Hippocampal CA1 Neurons. <i>Cerebral Cortex</i> , 2019, 29, 2183-2195.	1.6	13
626	Alzheimer's –Prevention–vs. –Risk Reduction–: Transcending Semantics for Clinical Practice. <i>Frontiers in Neurology</i> , 2018, 9, 1179.	1.1	28
627	A phase 1 clinical trial of the sigma β 2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 20-26.	1.8	73
628	Novel Deoxyvasicinone –Donepezil Hybrids as Potential Multitarget Drug Candidates for Alzheimer’s Disease. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2397-2407.	1.7	32
629	The proteostasis network and its decline in ageing. <i>Nature Reviews Molecular Cell Biology</i> , 2019, 20, 421-435.	16.1	860
630	Vitamin D-binding protein-loaded PLGA nanoparticles suppress Alzheimer's disease-related pathology in 5XFAD mice. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2019, 17, 297-307.	1.7	76
631	FDA position statement –Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry–. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 13-19.	1.8	59
632	Reviews on Biomarker Studies in Psychiatric and Neurodegenerative Disorders. <i>Advances in Experimental Medicine and Biology</i> , 2019, , .	0.8	6
633	The Amazon rain forest plant <i>Uncaria tomentosa</i> (cat’s claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles. <i>Scientific Reports</i> , 2019, 9, 561.	1.6	42
634	Reactive Amphiphilic Conjugated Polymers for Inhibiting Amyloid β 2 Assembly. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 5988-5993.	7.2	60

#	ARTICLE	IF	CITATIONS
635	The Role of Biomarkers in Alzheimer's Disease Drug Development. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1118, 29-61.	0.8	84
636	Genetic Risk Factors for Alzheimer Disease: Emerging Roles of Microglia in Disease Pathomechanisms. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1118, 83-116.	0.8	34
637	The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation. <i>Laboratory Investigation</i> , 2019, 99, 958-970.	1.7	82
638	β -Secretase and its modulators: Twenty years and beyond. <i>Neuroscience Letters</i> , 2019, 701, 162-169.	1.0	46
639	Intranasal Delivery of Nanotherapeutics/ Nanobiotherapeutics for the Treatment of Alzheimer's Disease: A Proficient Approach. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2019, 36, 373-447.	1.2	12
640	Healthcare Models in Alzheimer's Disease. , 2019, , .		0
641	Emerging links between cerebrovascular and neurodegenerative diseases—a special role for pericytes. <i>EMBO Reports</i> , 2019, 20, e48070.	2.0	89
642	What's New on Alzheimer's Disease? Insights From AD Mouse Models. , 2019, , 431-431.		1
643	Alzheimer's disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 167, 231-255.	1.0	415
644	Amyloid Beta Oligomers Target to Extracellular and Intracellular Neuronal Synaptic Proteins in Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 1140.	1.1	46
645	The next steps in curing Alzheimer's disease. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 168, 219-221.	0.9	0
646	Oncostatin M, a muscle-secreted myokine, recovers high-glucose-induced impairment of Akt phosphorylation by Fos induction in hippocampal neuron cells. <i>NeuroReport</i> , 2019, 30, 765-770.	0.6	3
647	Benchmarking machine learning models for late-onset Alzheimer's disease prediction from genomic data. <i>BMC Bioinformatics</i> , 2019, 20, 709.	1.2	41
648	Caffeine destabilizes preformed $A\beta$ protofilaments: insights from all atom molecular dynamics simulations. <i>Physical Chemistry Chemical Physics</i> , 2019, 21, 22067-22080.	1.3	30
649	The Beta Amyloid Dysfunction (BAD) Hypothesis for Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 1154.	1.4	70
650	RANDOMIZED, PLACEBO CONTROLLED TRIAL OF NPT088, A PHAGE-DERIVED, AMYLOID-TARGETED TREATMENT FOR ALZHEIMER'S DISEASE. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2019, 6, 1-4.	1.5	8
651	Clinical Trials of the Anti-Amyloid Therapy, Aducanumab, Are Stopped After Disappointing Results. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2019, 19, 9-10.	0.0	0
652	The search for improved animal models of Alzheimer's disease and novel strategies for therapeutic intervention. <i>Future Medicinal Chemistry</i> , 2019, 11, 1853-1857.	1.1	7

#	ARTICLE	IF	CITATIONS
653	Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early-stage Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 111.	3.0	21
654	Characterization of lysosomal proteins Progranulin and Prosaposin and their interactions in Alzheimer's disease and aged brains: increased levels correlate with neuropathology. <i>Acta Neuropathologica Communications</i> , 2019, 7, 215.	2.4	29
655	C5aR agonist enhances phagocytosis of fibrillar and non-fibrillar A β amyloid and preserves memory in a mouse model of familial Alzheimer's disease. <i>PLoS ONE</i> , 2019, 14, e0225417.	1.1	14
656	Testing a MultiTEP-based combination vaccine to reduce A β and tau pathology in Tau22/5xFAD bigenic mice. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 107.	3.0	19
657	Friend, Foe or Both? Immune Activity in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 337.	1.7	63
658	Cognitive symptoms of Alzheimer's disease: clinical management and prevention. <i>BMJ, The</i> , 2019, 367, l6217.	3.0	162
659	Characterization of the selective in vitro and in vivo binding properties of crenezumab to oligomeric A β . <i>Alzheimer's Research and Therapy</i> , 2019, 11, 97.	3.0	22
660	Gantenerumab reduces amyloid- β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 101.	3.0	131
661	Future Treatment of Alzheimer Disease. , 0, , .		3
662	Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology. <i>Neurobiology of Aging</i> , 2019, 73, 61-67.	1.5	75
663	Single chain variable fragment antibodies directed against SOD1 ameliorate disease in mutant SOD1 transgenic mice. <i>Neurobiology of Disease</i> , 2019, 121, 131-137.	2.1	19
664	Task-enhanced arterial spin labeled perfusion MRI predicts longitudinal neurodegeneration in mild cognitive impairment. <i>Hippocampus</i> , 2019, 29, 26-36.	0.9	11
665	Amyloid Load: A More Sensitive Biomarker for Amyloid Imaging. <i>Journal of Nuclear Medicine</i> , 2019, 60, 536-540.	2.8	40
666	Identification of B cell epitopes enhanced by protein unfolding and aggregation. <i>Molecular Immunology</i> , 2019, 105, 181-189.	1.0	16
667	Selective reduction of APP-BACE1 activity improves memory via NMDA-NR2B receptor-mediated mechanisms in aged PDAPP mice. <i>Neurobiology of Aging</i> , 2019, 75, 136-149.	1.5	12
668	Early onset cerebral amyloid angiopathy following childhood exposure to cadaveric dura. <i>Annals of Neurology</i> , 2019, 85, 284-290.	2.8	54
669	Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention. <i>CNS Drugs</i> , 2019, 33, 99-106.	2.7	33
670	Brain β -Amyloid and Atrophy in Individuals at Increased Risk of Cognitive Decline. <i>American Journal of Neuroradiology</i> , 2019, 40, 80-85.	1.2	10

#	ARTICLE	IF	CITATIONS
671	Pivotal role of carnosine in the modulation of brain cells activity: Multimodal mechanism of action and therapeutic potential in neurodegenerative disorders. <i>Progress in Neurobiology</i> , 2019, 175, 35-53.	2.8	72
672	Comprehensive review of mechanisms of pathogenesis involved in Alzheimer's disease and potential therapeutic strategies. <i>Progress in Neurobiology</i> , 2019, 174, 53-89.	2.8	223
673	A critical appraisal of amyloid- β -targeting therapies for Alzheimer's disease. <i>Nature Reviews Neurology</i> , 2019, 15, 73-88.	4.9	666
674	Are antibodies directed against amyloid- β (A β) oligomers the last call for the A β hypothesis of Alzheimer's disease?. <i>Immunotherapy</i> , 2019, 11, 3-6.	1.0	50
675	Norepinephrine Inhibits Alzheimer's Amyloid- β Peptide Aggregation and Destabilizes Amyloid- β Protofibrils: A Molecular Dynamics Simulation Study. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1585-1594.	1.7	83
676	HMGB1 gene silencing inhibits neuroinflammation via down-regulation of NF- κ B signaling in primary hippocampal neurons induced by A β 25-35. <i>International Immunopharmacology</i> , 2019, 67, 294-301.	1.7	37
677	Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies. , 2019, 195, 186-198.		141
678	An Engineered Variant of the B1 Domain of Protein G Suppresses the Aggregation and Toxicity of Intra- and Extracellular A β 42. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1488-1496.	1.7	2
679	Treating Alzheimer's disease by targeting iron. <i>British Journal of Pharmacology</i> , 2019, 176, 3622-3635.	2.7	71
680	<scp>d</scp>-Enantiomeric RTHLVFFARK-NH₂: A Potent Multifunctional Decapeptide Inhibiting Cu²⁺-Mediated Amyloid β -Protein Aggregation and Remodeling Cu²⁺-Mediated Amyloid β Aggregates. <i>ACS Chemical Neuroscience</i> , 2019, 10, 1390-1401.	1.7	25
681	Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE. <i>Nature Neuroscience</i> , 2019, 22, 191-204.	7.1	358
682	Amyloid PET pattern with dementia and amyloid angiopathy in Taiwan familial AD with D678H APP mutation. <i>Journal of the Neurological Sciences</i> , 2019, 398, 107-116.	0.3	11
683	Bad news and good news in AD, and how to reconcile them. <i>Nature Reviews Neurology</i> , 2019, 15, 61-62.	4.9	35
684	Amyloid- β immunotherapy for alzheimer disease: Is it now a long shot?. <i>Annals of Neurology</i> , 2019, 85, 303-315.	2.8	126
685	A Combination of Tri-Leucine and Angiopep-2 Drives a Polyanionic Polymeric Acid Nanodrug Platform Across the Blood-Brain Barrier. <i>ACS Nano</i> , 2019, 13, 1253-1271.	7.3	51
686	Reassembly of native components with donepezil to execute dual-missions in Alzheimer's disease therapy. <i>Journal of Controlled Release</i> , 2019, 296, 14-28.	4.8	37
687	Unsupervised and real-time spike sorting chip for neural signal processing in hippocampal prosthesis. <i>Journal of Neuroscience Methods</i> , 2019, 311, 111-121.	1.3	23
688	Pharmacokinetics and Pharmacodynamics of the BACE 1 Inhibitor Verubecestat (MK -8931) in Healthy Japanese Adults: A Randomized, Placebo-Controlled Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 1234-1243.	2.3	15

#	ARTICLE	IF	CITATIONS
689	IgG Fc N-glycosylation: Alterations in neurologic diseases and potential therapeutic target?. Journal of Autoimmunity, 2019, 96, 14-23.	3.0	31
690	A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. Journal of Parkinson's Disease, 2019, 9, 31-61.	1.5	45
691	Activity-Induced Amyloid- β^2 Oligomers Drive Compensatory Synaptic Rearrangements in Brain Circuits Controlling Memory of Presymptomatic Alzheimer's Disease Mice. Biological Psychiatry, 2019, 86, 185-195.	0.7	15
692	Early-Phase Randomized Clinical Trials' Expectations vs Hard Reality. JAMA Neurology, 2019, 76, 15.	4.5	0
693	Development of an aggregate-selective, human-derived β -synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models. Neurobiology of Disease, 2019, 124, 276-288.	2.1	125
694	Elevated CSF GAP43 is Alzheimer's disease specific and associated with tau and amyloid pathology. Alzheimer's and Dementia, 2019, 15, 55-64.	0.4	97
695	Current viral-mediated gene transfer research for treatment of Alzheimer's disease. Biotechnology and Genetic Engineering Reviews, 2019, 35, 26-45.	2.4	14
696	Ultra-low-Dose 18 F-Florbetaben Amyloid PET Imaging Using Deep Learning with Multi-Contrast MRI Inputs. Radiology, 2019, 290, 649-656.	3.6	182
697	A vaccine against Alzheimer's disease: anything left but faith?. Expert Opinion on Biological Therapy, 2019, 19, 73-78.	1.4	27
698	The application of positron emission tomography (PET) imaging in CNS drug development. Brain Imaging and Behavior, 2019, 13, 354-365.	1.1	32
699	Connexins and pannexins in Alzheimer's disease. Neuroscience Letters, 2019, 695, 100-105.	1.0	28
700	Minimally symptomatic cerebral amyloid angiopathy-related inflammation: three descriptive case reports. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 113-115.	0.9	15
701	Delayed clearance of cerebrospinal fluid tracer from entorhinal cortex in idiopathic normal pressure hydrocephalus: A glymphatic magnetic resonance imaging study. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 1355-1368.	2.4	146
702	Targeted Gene Editing of Glia Maturation Factor in Microglia: a Novel Alzheimer's Disease Therapeutic Target. Molecular Neurobiology, 2019, 56, 378-393.	1.9	43
703	Canadian Stroke Best Practice Recommendations: Mood, Cognition and Fatigue following Stroke, 6th edition update 2019. International Journal of Stroke, 2020, 15, 668-688.	2.9	121
704	The Amyloid Phenomenon and Its Significance in Biology and Medicine. Cold Spring Harbor Perspectives in Biology, 2020, 12, a033878.	2.3	111
705	Mimicking Molecular Chaperones to Regulate Protein Folding. Advanced Materials, 2020, 32, e1805945.	11.1	61
706	Activation of PPARA-mediated autophagy reduces Alzheimer disease-like pathology and cognitive decline in a murine model. Autophagy, 2020, 16, 52-69.	4.3	193

#	ARTICLE	IF	CITATIONS
707	Protein aggregation in cell biology: An aggregomics perspective of health and disease. <i>Seminars in Cell and Developmental Biology</i> , 2020, 99, 40-54.	2.3	36
708	Rationale for the development of an Alzheimer's disease vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 645-653.	1.4	16
709	Setbacks and Opportunities in Disease-Modifying Therapies in Alzheimer Disease. <i>JAMA Psychiatry</i> , 2020, 77, 7.	6.0	5
710	Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer's disease from a ferroptosis perspective. <i>Progress in Neurobiology</i> , 2020, 184, 101716.	2.8	98
711	Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer's Disease. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 68-73.	1.6	25
712	Amyloid and tau pathology in the aging feline brain. <i>Journal of Comparative Neurology</i> , 2020, 528, 112-117.	0.9	17
713	BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease. <i>Medicinal Research Reviews</i> , 2020, 40, 339-384.	5.0	177
714	Effects of natural compounds on conformational properties and hairpin formation of amyloid- β_{42} monomer: docking and molecular dynamics simulation study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, 38, 3371-3383.	2.0	10
715	The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis. <i>Alzheimer's and Dementia</i> , 2020, 16, 1553-1560.	0.4	165
716	Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer's disease. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 148, 38-53.	2.0	64
717	Fear acquisition and extinction deficits in amnesic mild cognitive impairment and early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 87, 26-34.	1.5	23
718	Neuroimaging of Diseases Causing Dementia. <i>Neurologic Clinics</i> , 2020, 38, 65-94.	0.8	9
719	Active poly- β -galactosidase vaccination prevents microglia activation and motor deficits in a <i>C9orf72</i> mouse model. <i>EMBO Molecular Medicine</i> , 2020, 12, e10919.	3.3	39
720	Self-assembly hollow manganese Prussian white nanocapsules attenuate Tau-related neuropathology and cognitive decline. <i>Biomaterials</i> , 2020, 231, 119678.	5.7	37
721	Interactions between Curcumin Derivatives and Amyloid- β Fibrils: Insights from Molecular Dynamics Simulations. <i>Journal of Chemical Information and Modeling</i> , 2020, 60, 289-305.	2.5	44
722	Antibody Therapy Targeting RAN Proteins Rescues C9 ALS/FTD Phenotypes in <i>C9orf72</i> Mouse Model. <i>Neuron</i> , 2020, 105, 645-662.e11.	3.8	70
723	Spatially Distributed Amyloid- β Reduces Glucose Metabolism in Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 543-557.	1.2	22
724	Cerebral amyloid angiopathy and Alzheimer disease – one peptide, two pathways. <i>Nature Reviews Neurology</i> , 2020, 16, 30-42.	4.9	407

#	ARTICLE	IF	CITATIONS
725	An overview on recent in vivo biological application of cerium oxide nanoparticles. <i>Asian Journal of Pharmaceutical Sciences</i> , 2020, 15, 558-575.	4.3	55
726	Questions EMERGE as Biogen claims β -secretase inhibitor turnarounds. <i>Nature Reviews Neurology</i> , 2020, 16, 63-64.	4.9	98
727	Regional differences in Alzheimer's disease pathology confound behavioural rescue after amyloid- β attenuation. <i>Brain</i> , 2020, 143, 359-373.	3.7	41
728	Influence of Comorbidity of Cerebrovascular Disease and Amyloid- β on Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 897-907.	1.2	21
729	Developing Therapies for Neurodegenerative Disorders: Insights from Protein Aggregation and Cellular Stress Responses. <i>Annual Review of Cell and Developmental Biology</i> , 2020, 36, 165-189.	4.0	35
730	Peli1 impairs microglial β -phagocytosis through promoting C/EBP β degradation. <i>PLoS Biology</i> , 2020, 18, e3000837.	2.6	24
731	Sowing the Seeds of Discovery: Tau-Propagation Models of Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2020, 11, 3499-3509.	1.7	7
732	Alzheimer's disease: Recent treatment strategies. <i>European Journal of Pharmacology</i> , 2020, 887, 173554.	1.7	300
733	SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid- β antibody in a mouse model of Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2020, 9, 37.	3.6	32
734	Kinetic fingerprints differentiate the mechanisms of action of anti- β antibodies. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 1125-1133.	3.6	123
735	An Immunomodulatory Therapeutic Vaccine Targeting Oligomeric Amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1639-1653.	1.2	8
736	Neurofilaments in motor neuron disorders: towards promising diagnostic and prognostic biomarkers. <i>Molecular Neurodegeneration</i> , 2020, 15, 58.	4.4	68
737	Positron Emission Tomography (PET) and Neuroimaging in the Personalized Approach to Neurodegenerative Causes of Dementia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7481.	1.8	16
738	Emerging Microglia Biology Defines Novel Therapeutic Approaches for Alzheimer's Disease. <i>Neuron</i> , 2020, 108, 801-821.	3.8	132
739	Predicting future rates of tau accumulation on PET. <i>Brain</i> , 2020, 143, 3136-3150.	3.7	74
740	Tetavalent Bispecific Tandem Antibodies Improve Brain Exposure and Efficacy in an Amyloid Transgenic Mouse Model. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 19, 58-77.	1.8	13
741	Recent advances in clinical trial design considerations in Theranostics. <i>Contemporary Clinical Trials</i> , 2020, 96, 106100.	0.8	4
742	Design, synthesis, biological evaluation, and docking study of novel dual-acting thiazole-pyridiniums inhibiting acetylcholinesterase and β -amyloid aggregation for Alzheimer's disease. <i>Bioorganic Chemistry</i> , 2020, 103, 104186.	2.0	41

#	ARTICLE	IF	CITATIONS
743	Photostimulation of Extravasation of Beta-Amyloid through the Model of Blood-Brain Barrier. <i>Electronics (Switzerland)</i> , 2020, 9, 1056.	1.8	15
744	Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer's Disease. <i>Cell</i> , 2020, 182, 976-991.e19.	13.5	491
745	Evaluation of Amyloid β 242 Aggregation Inhibitory Activity of Commercial Dressings by a Microliter-Scale High-Throughput Screening System Using Quantum-Dot Nanoprobes. <i>Foods</i> , 2020, 9, 825.	1.9	8
746	From monomer to fibril: A β amyloid binding to Aducanumab antibody studied by molecular dynamics simulation. <i>Proteins: Structure, Function and Bioinformatics</i> , 2020, 88, 1592-1606.	1.5	12
747	Alzheimer's disease drug development pipeline: 2020. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12050.	1.8	353
748	Passive immunotherapies targeting A β 2 and tau in Alzheimer's disease. <i>Neurobiology of Disease</i> , 2020, 144, 105010.	2.1	81
749	Treatment of Alzheimer's Disease and Blood-Brain Barrier Drug Delivery. <i>Pharmaceuticals</i> , 2020, 13, 394.	1.7	92
750	Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life. <i>Nature Neuroscience</i> , 2020, 23, 1580-1588.	7.1	53
751	Therapeutic Strategies to Reduce the Toxicity of Misfolded Protein Oligomers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8651.	1.8	23
752	Therapeutic Strategies to Target Calcium Dysregulation in Alzheimer's Disease. <i>Cells</i> , 2020, 9, 2513.	1.8	22
753	Integrating music-based interventions with Gamma-frequency stimulation: Implications for healthy ageing. <i>European Journal of Neuroscience</i> , 2022, 55, 3303-3323.	1.2	10
754	CCCDTD5: Reducing the risk of later-life dementia. Evidence informing the Fifth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia (CCCDTD5). <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12083.	1.8	8
755	Antibody Fragments as Tools for Elucidating Structure-Toxicity Relationships and for Diagnostic/Therapeutic Targeting of Neurotoxic Amyloid Oligomers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8920.	1.8	8
756	Plasma p-tau217: from a new kid to most promising candidate for Alzheimer's disease blood test. <i>Brain</i> , 2020, 143, 3170-3172.	3.7	7
757	Alzheimer's disease: from basic science to precision medicine approach. <i>BMJ Neurology Open</i> , 2020, 2, e000079.	0.7	19
758	Molecular Level Insight Into the Benefit of Myricetin and Dihydromyricetin Uptake in Patients With Alzheimer's Diseases. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 601603.	1.7	29
759	Atomic Structures of Amyloid- β 2 Oligomers Illuminate a Neurotoxic Mechanism. <i>Trends in Neurosciences</i> , 2020, 43, 740-743.	4.2	10
760	Mathematical Model Shows How Sleep May Affect Amyloid- β 2 Fibrillization. <i>Biophysical Journal</i> , 2020, 119, 862-872.	0.2	10

#	ARTICLE	IF	CITATIONS
761	Direct measurement of lipid membrane disruption connects kinetics and toxicity of A β 242 aggregation. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 886-891.	3.6	38
762	Anti-amyloid- β 2 protein agents for the treatment of Alzheimer's disease: an update on emerging drugs. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 319-335.	1.0	57
763	Targeting nanoparticles to the brain by exploiting the blood-brain barrier impermeability to selectively label the brain endothelium. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 19141-19150.	3.3	82
764	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 772.	3.8	640
765	Dissolving microneedles for transdermal delivery of huperzine A for the treatment of Alzheimer's disease. <i>Drug Delivery</i> , 2020, 27, 1147-1155.	2.5	32
766	In vivo Retinal Fluorescence Imaging With Curcumin in an Alzheimer Mouse Model. <i>Frontiers in Neuroscience</i> , 2020, 14, 713.	1.4	34
767	A Biocompatible Second Near-Infrared Nanozyme for Spatiotemporal and Non-Invasive Attenuation of Amyloid Deposition through Scalp and Skull. <i>ACS Nano</i> , 2020, 14, 9894-9903.	7.3	78
768	Proteotoxicity and Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5646.	1.8	37
769	Design and Synthesis of Novel Hybrid 8-Hydroxy Quinoline-Indole Derivatives as Inhibitors of A β 2 Self-Aggregation and Metal Chelation-Induced A β 2 Aggregation. <i>Molecules</i> , 2020, 25, 3610.	1.7	15
770	Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 95.	3.0	218
771	Copper Toxicity Links to Pathogenesis of Alzheimer's Disease and Therapeutics Approaches. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7660.	1.8	64
772	Investigating the optimum size of nanoparticles for their delivery into the brain assisted by focused ultrasound-induced blood-brain barrier opening. <i>Scientific Reports</i> , 2020, 10, 18220.	1.6	105
773	Preformulation Studies of a Stable PTEN-PDZ Lipopeptide Able to Cross an In Vitro Blood-Brain-Barrier Model as a Potential Therapy for Alzheimer's Disease. <i>Pharmaceutical Research</i> , 2020, 37, 183.	1.7	5
774	A rationally designed bicyclic peptide remodels A β 242 aggregation in vitro and reduces its toxicity in a worm model of Alzheimer's disease. <i>Scientific Reports</i> , 2020, 10, 15280.	1.6	15
775	Pharmacological Inhibition of Amyloidogenic APP Processing and Knock-Down of APP in Primary Human Macrophages Impairs the Secretion of Cytokines. <i>Frontiers in Immunology</i> , 2020, 11, 1967.	2.2	13
776	Effects of optogenetic stimulation of basal forebrain parvalbumin neurons on Alzheimer's disease pathology. <i>Scientific Reports</i> , 2020, 10, 15456.	1.6	11
777	Limiting RyR2 Open Time Prevents Alzheimer's Disease-Related Neuronal Hyperactivity and Memory Loss but Not β -Amyloid Accumulation. <i>Cell Reports</i> , 2020, 32, 108169.	2.9	41
778	Rhizolutin, a Novel 7/10/6-Tricyclic Dilactone, Dissociates Misfolded Protein Aggregates and Reduces Apoptosis/Inflammation Associated with Alzheimer's Disease. <i>Angewandte Chemie</i> , 2020, 132, 23194-23198.	1.6	6

#	ARTICLE	IF	CITATIONS
779	Dietary Intake of Rosmarinic Acid Increases Serum Inhibitory Activity in Amyloid A Aggregation and Suppresses Deposition in the Organs of Mice. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6031.	1.8	9
780	Rhizolutin, a Novel 7/10/6-Tricyclic Dilactone, Dissociates Misfolded Protein Aggregates and Reduces Apoptosis/Inflammation Associated with Alzheimer's Disease. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 22994-22998.	7.2	15
781	Fe65 is the sole family member mediating transcription regulated by the amyloid precursor protein. <i>Journal of Cell Science</i> , 2020, 133, .	1.2	9
782	Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Sensitivity, Specificity and Potential for Clinical Use. <i>Journal of Personalized Medicine</i> , 2020, 10, 116.	1.1	26
783	Invasive and non-invasive therapies for Alzheimer's disease and other amyloidosis. <i>Biophysical Reviews</i> , 2020, 12, 1175-1186.	1.5	11
784	Aggregate-selective antibody attenuates seeded aggregation but not spontaneously evolving disease in SOD1 ALS model mice. <i>Acta Neuropathologica Communications</i> , 2020, 8, 161.	2.4	3
785	Anticoagulants for Treatment of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1373-1382.	1.2	15
786	Emodin inhibits aggregation of amyloid β peptide 1-42 and improves cognitive deficits in Alzheimer's disease transgenic mice. <i>Journal of Neurochemistry</i> , 2021, 157, 1992-2007.	2.1	17
787	Brain delivery of biologics using a cross-species reactive transferrin receptor 1 VNAR shuttle. <i>FASEB Journal</i> , 2020, 34, 13272-13283.	0.2	37
789	Assessment of the role of afucosylated glycoforms on the <i>in vitro</i> antibody-dependent phagocytosis activity of an antibody to A β aggregates. <i>MAbs</i> , 2020, 12, 1803645.	2.6	2
790	Label-free vibrational imaging of different A β plaque types in Alzheimer's disease reveals sequential events in plaque development. <i>Acta Neuropathologica Communications</i> , 2020, 8, 222.	2.4	40
791	Therapeutic Targeting Strategies for Early- to Late-Staged Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9591.	1.8	24
792	Vaccination against A β -Amyloid as a Strategy for the Prevention of Alzheimer's Disease. <i>Biology</i> , 2020, 9, 425.	1.3	26
793	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. <i>Nature Communications</i> , 2020, 11, 6252.	5.8	36
794	Tau and DNA Damage in Neurodegeneration. <i>Brain Sciences</i> , 2020, 10, 946.	1.1	22
795	Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9318.	1.8	54
796	Pre-Analytical Sampling and Storage Conditions of Amyloid β Peptides in Venous and Capillary Blood. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 529-535.	1.2	11
797	Novel deoxyvasicinone and tetrahydro-beta-carboline hybrids as inhibitors of acetylcholinesterase and amyloid beta aggregation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127659.	1.0	10

#	ARTICLE	IF	CITATIONS
798	Single domain antibody-based vectors in the delivery of biologics across the blood–brain barrier: a review. <i>Drug Delivery and Translational Research</i> , 2021, 11, 1818-1828.	3.0	9
799	Symptomatic amyloid-related imaging abnormalities in an APOE ϵ 4/ ϵ 4 patient treated with aducanumab. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12101.	1.2	41
800	Dual-Sensitive Nanomicelles Enhancing Systemic Delivery of Therapeutically Active Antibodies Specifically into the Brain. <i>ACS Nano</i> , 2020, 14, 6729-6742.	7.3	65
801	Profiles of Cognitive Change in Preclinical and Prodromal Alzheimer's Disease Using Change-Point Analysis. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 1169-1180.	1.2	21
802	Protective actions of exercise-related FNDC5/Irisin in memory and Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2020, 155, 602-611.	2.1	45
803	The current landscape in Alzheimer's disease research and drug discovery. <i>Drug Discovery Today</i> , 2020, 25, 943-945.	3.2	18
804	Targeting tau: Clinical trials and novel therapeutic approaches. <i>Neuroscience Letters</i> , 2020, 731, 134919.	1.0	63
805	Targeting Therapeutic Antibodies to the CNS: a Comparative Study of Intrathecal, Intravenous, and Subcutaneous Anti-Nogo A Antibody Treatment after Stroke in Rats. <i>Neurotherapeutics</i> , 2020, 17, 1153-1159.	2.1	14
806	Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation. <i>Acta Neuropathologica Communications</i> , 2020, 8, 74.	2.4	22
807	Mouse Bone Marrow-derived Microglia-like Cells Secrete Transforming Growth Factor- β 1 and Promote Microglial $A\beta$ Phagocytosis and Reduction of Brain $A\beta$. <i>Neuroscience</i> , 2020, 438, 217-228.	1.1	15
808	The biogenesis and biology of amyloid β oligomers in the brain. <i>Alzheimer's and Dementia</i> , 2020, 16, 1561-1567.	0.4	29
809	Training the next generation of radiopharmaceutical scientists. <i>Nuclear Medicine and Biology</i> , 2020, 88-89, 10-13.	0.3	7
810	Cellular polyamines condense hyperphosphorylated Tau, triggering Alzheimer's disease. <i>Scientific Reports</i> , 2020, 10, 10098.	1.6	12
811	Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions. <i>Life Sciences</i> , 2020, 256, 117996.	2.0	129
812	Pharmacogenetic studies in Alzheimer disease. <i>Neurologia (English Edition)</i> , 2022, 37, 287-303.	0.2	4
813	Biophysical studies of protein misfolding and aggregation in <i>in vivo</i> models of Alzheimer's and Parkinson's diseases. <i>Quarterly Reviews of Biophysics</i> , 2020, 53, e22.	2.4	13
814	Diagnostic Biomarkers for Alzheimer's Disease Using Non-Invasive Specimens. <i>Journal of Clinical Medicine</i> , 2020, 9, 1673.	1.0	32
815	Yeast β -glucan alleviates cognitive deficit by regulating gut microbiota and metabolites in $A\beta$ 1-42-induced AD-like mice. <i>International Journal of Biological Macromolecules</i> , 2020, 161, 258-270.	3.6	79

#	ARTICLE	IF	CITATIONS
816	Alzheimer's: Are we winning the fight? Not so sure. <i>Revue Neurologique</i> , 2020, 176, 299-300.	0.6	2
817	Hydrazides Are Potent Transition-State Analogues for Glutaminyl Cyclase Implicated in the Pathogenesis of Alzheimer's Disease. <i>Biochemistry</i> , 2020, 59, 2585-2591.	1.2	11
818	Translational Scoring of Candidate Treatments for Alzheimer's Disease: A Systematic Approach. <i>Dementia and Geriatric Cognitive Disorders</i> , 2020, 49, 22-37.	0.7	5
819	Microglia. , 2020, , 995-1020.		3
820	Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs. <i>Neuropharmacology</i> , 2020, 177, 108099.	2.0	22
821	Senescence as an Amyloid Cascade: The Amyloid Senescence Hypothesis. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 129.	1.8	35
822	AMBAR, an Encouraging Alzheimer's Trial That Raises Questions. <i>Frontiers in Neurology</i> , 2020, 11, 459.	1.1	11
823	Nanoliposomes as a Therapeutic Tool for Alzheimer's Disease. <i>Frontiers in Synaptic Neuroscience</i> , 2020, 12, 20.	1.3	24
824	Therapeutic potential of a TrkB agonistic antibody for Alzheimer's disease. <i>Theranostics</i> , 2020, 10, 6854-6874.	4.6	28
825	Enhancing protective microglial activities with a dual function <sc>TREM</sc> 2 antibody to the stalk region. <i>EMBO Molecular Medicine</i> , 2020, 12, e11227.	3.3	155
826	Select Atrophied Regions in Alzheimer disease (SARA): An improved volumetric model for identifying Alzheimer disease dementia. <i>NeuroImage: Clinical</i> , 2020, 26, 102248.	1.4	24
827	Stereospecific interactions between chiral inorganic nanomaterials and biological systems. <i>Chemical Society Reviews</i> , 2020, 49, 2481-2503.	18.7	138
828	A mechanistic hypothesis for the impairment of synaptic plasticity by soluble A β oligomers from Alzheimer's brain. <i>Journal of Neurochemistry</i> , 2020, 154, 583-597.	2.1	158
829	Real-Time 3D Imaging and Inhibition Analysis of Various Amyloid Aggregations Using Quantum Dots. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1978.	1.8	9
830	Immunotherapy against Prion Disease. <i>Pathogens</i> , 2020, 9, 216.	1.2	16
831	Prevention of dementia in an ageing world: Evidence and biological rationale. <i>Ageing Research Reviews</i> , 2020, 64, 101045.	5.0	107
832	Mammalian Sterile 20-Like Kinase (MST) 1/2: Crucial Players in Nervous and Immune System and Neurological Disorders. <i>Journal of Molecular Biology</i> , 2020, 432, 3177-3190.	2.0	7
833	Protein transmission in neurodegenerative disease. <i>Nature Reviews Neurology</i> , 2020, 16, 199-212.	4.9	330

#	ARTICLE	IF	CITATIONS
834	Early Diagnosis of Alzheimer's Disease in Blood Using a Disposable Electrochemical Microfluidic Platform. <i>ACS Sensors</i> , 2020, 5, 1010-1019.	4.0	40
835	Cerebrovascular amyloid Angiopathy in bioengineered vessels is reduced by high-density lipoprotein particles enriched in Apolipoprotein E. <i>Molecular Neurodegeneration</i> , 2020, 15, 23.	4.4	19
836	Current and Future Treatments in Alzheimer Disease: An Update. <i>Journal of Central Nervous System Disease</i> , 2020, 12, 117957352090739.	0.7	413
838	Topographical distribution of A β predicts progression to dementia in A β positive mild cognitive impairment. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12037.	1.2	7
839	Secretion of proteins and antibody fragments from transiently transfected endothelial progenitor cells. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 8772-8778.	1.6	9
840	The NMDA Receptor Antibody Paradox: A Possible Approach to Developing Immunotherapies Targeting the NMDA Receptor. <i>Frontiers in Neurology</i> , 2020, 11, 635.	1.1	8
841	ALS, a cellular whodunit on motor neuron degeneration. <i>Molecular and Cellular Neurosciences</i> , 2020, 107, 103524.	1.0	9
842	Yeast-Based A β 1-15 Vaccine Elicits Strong Immunogenicity and Attenuates Neuropathology and Cognitive Deficits in Alzheimer's Disease Transgenic Mice. <i>Vaccines</i> , 2020, 8, 351.	2.1	7
843	Invited Review "Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 623-640.	1.8	20
845	Rationally Designed Antibodies as Research Tools to Study the Structure-Toxicity Relationship of Amyloid- β Oligomers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4542.	1.8	12
846	Protofibrils of Amyloid- β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2020, 21, 952.	1.8	41
847	Super-Resolution Infrared Imaging of Polymorphic Amyloid Aggregates Directly in Neurons. <i>Advanced Science</i> , 2020, 7, 1903004.	5.6	71
848	Novel small molecule therapeutic agents for Alzheimer disease: Focusing on BACE1 and multi-target directed ligands. <i>Bioorganic Chemistry</i> , 2020, 97, 103649.	2.0	61
849	Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid- β had distinct effects on neuropathology and cognitive deficits in EAE/AD mice. <i>British Journal of Pharmacology</i> , 2020, 177, 2860-2871.	2.7	7
850	Development of the clinical candidate PBD-CO6, a humanized pGlu3-A β -specific antibody against Alzheimer's disease with reduced complement activation. <i>Scientific Reports</i> , 2020, 10, 3294.	1.6	17
851	Pathogenic A β generation in familial Alzheimer's disease: novel mechanistic insights and therapeutic implications. <i>Current Opinion in Neurobiology</i> , 2020, 61, 73-81.	2.0	22
852	Light-Induced Chiral Iron Copper Selenide Nanoparticles Prevent β -Amyloidopathy In Vivo. <i>Angewandte Chemie</i> , 2020, 132, 7197-7204.	1.6	11
853	Light-Induced Chiral Iron Copper Selenide Nanoparticles Prevent β -Amyloidopathy In Vivo. <i>Angewandte Chemie - International Edition</i> , 2020, 59, 7131-7138.	7.2	85

#	ARTICLE	IF	CITATIONS
854	Design, synthesis and evaluation of flurbiprofen-cloquinol hybrids as multitarget-directed ligands against Alzheimer's disease. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115374.	1.4	27
855	Therapeutic Plasmapheresis with Albumin Replacement in Alzheimer's Disease and Chronic Progressive Multiple Sclerosis: A Review. <i>Pharmaceuticals</i> , 2020, 13, 28.	1.7	6
856	Traitement de la maladie d'Alzheimer: une lueur au bout du tunnel?. <i>Pratique Neurologique - FMC</i> , 2020, 11, 46-48.	0.1	0
857	Uncertainty in Pharmacology. <i>Boston Studies in the Philosophy and History of Science</i> , 2020, , .	0.4	1
858	Functional connectivity between the entorhinal and posterior cingulate cortices underpins navigation discrepancies in at-risk Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 90, 110-118.	1.5	19
859	Peripheral Routes to Neurodegeneration: Passing Through the Blood-Brain Barrier. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 3.	1.7	18
860	Antibody transcytosis across brain endothelial-like cells occurs nonspecifically and independent of FcRn. <i>Scientific Reports</i> , 2020, 10, 3685.	1.6	38
862	Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials. <i>Neurobiology of Disease</i> , 2020, 139, 104823.	2.1	20
863	Genetic causes of PD: A pathway to disease modification. <i>Neuropharmacology</i> , 2020, 170, 108022.	2.0	24
864	Validation of a novel and accurate ApoE4 assay for automated chemistry analyzers. <i>Scientific Reports</i> , 2020, 10, 2138.	1.6	5
865	Aggregation Mechanism of Alzheimer's Amyloid β -Peptide Mediated by β -Strand/ β -Sheet Structure. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1094.	1.8	12
866	Clinical trials of new drugs for Alzheimer disease. <i>Journal of Biomedical Science</i> , 2020, 27, 18.	2.6	453
867	Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 796-805.	2.3	14
868	Disease Modification in Alzheimer's Disease: Current Thinking. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 396-403.	0.8	12
869	Amyloids in Site-Specific Autoimmune Reactions and Inflammatory Responses. <i>Frontiers in Immunology</i> , 2019, 10, 2980.	2.2	7
870	Interplay Between Mitochondrial Oxidative Disorders and Proteostasis in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2019, 13, 1444.	1.4	55
871	Effects of neural stem cell transplantation in Alzheimer's disease models. <i>Journal of Biomedical Science</i> , 2020, 27, 29.	2.6	54
872	Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 373.	1.7	220

#	ARTICLE	IF	CITATIONS
873	Role of Fluid Biomarkers and PET Imaging in Early Diagnosis and its Clinical Implication in the Management of Alzheimer's Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2020, 4, 21-37.	1.2	30
874	Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets. <i>Neurotherapeutics</i> , 2020, 17, 935-954.	2.1	40
875	An Affibody Molecule Is Actively Transported into the Cerebrospinal Fluid via Binding to the Transferrin Receptor. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2999.	1.8	12
876	Amyloid β -protein and beyond: the path forward in Alzheimer's disease. <i>Current Opinion in Neurobiology</i> , 2020, 61, 116-124.	2.0	87
877	Novel Anti-Alzheimer's Therapeutic Molecules Targeting Amyloid Precursor Protein Processing. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-19.	1.9	40
878	Dual functional liposomes carrying antioxidants against tau hyperphosphorylation and apoptosis of neurons. <i>Journal of Drug Targeting</i> , 2020, 28, 949-960.	2.1	9
879	Alzheimer's disease beyond amyloid: Can the repetitive failures of amyloid-targeted therapeutics inform future approaches to dementia drug discovery?. <i>Biochemical Pharmacology</i> , 2020, 177, 113945.	2.0	62
880	Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach. <i>Alzheimer's and Dementia</i> , 2020, 16, 862-872.	0.4	17
881	Significant combination of $A\beta$ aggregation inhibitory and neuroprotective properties in silico, in vitro and in vivo by bis(propyl)-cognitin, a multifunctional anti-Alzheimer's agent. <i>European Journal of Pharmacology</i> , 2020, 876, 173065.	1.7	7
882	Leveraging preclinical models for the development of Alzheimer disease therapeutics. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 447-462.	21.5	73
883	What works and what does not work in Alzheimer's disease? From interventions on risk factors to anti-amyloid trials. <i>Journal of Neurochemistry</i> , 2020, 155, 120-136.	2.1	26
884	Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2020, 17, 112-125.	0.7	40
885	The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer's Disease. <i>Frontiers in Immunology</i> , 2020, 11, 754.	2.2	100
886	Utility of spontaneous animal models of Alzheimer's disease in preclinical efficacy studies. <i>Cell and Tissue Research</i> , 2020, 380, 273-286.	1.5	10
887	Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2020, 8, 13.	2.4	61
888	Passive anti-amyloid immunotherapy for Alzheimer's disease. <i>Current Opinion in Psychiatry</i> , 2020, 33, 284-291.	3.1	40
889	Hippocampal Deficits in Amyloid- β -Related Rodent Models of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2020, 14, 266.	1.4	44
890	Utilization of a convolutional method for Alzheimer disease diagnosis. <i>Machine Vision and Applications</i> , 2020, 31, 1.	1.7	14

#	ARTICLE	IF	CITATIONS
891	Amyloid- β oligomers in cellular models of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2020, 155, 348-369.	2.1	50
892	Clinical Trials in Alzheimer's Disease: A Hurdle in the Path of Remedy. <i>International Journal of Alzheimer's Disease</i> , 2020, 2020, 1-13.	1.1	62
893	Alzheimer Drug Trials: Combination of Safe and Efficacious Biologicals to Break the Amyloidosis-Neuroinflammation Vicious Cycle. <i>ASN Neuro</i> , 2020, 12, 175909142091855.	1.5	2
894	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2020, 16, 750-758.	0.4	29
895	Investigation of the Dissociation Mechanism of Single-Walled Carbon Nanotube on Mature Amyloid- β Fibrils at Single Nanotube Level. <i>Journal of Physical Chemistry B</i> , 2020, 124, 3459-3468.	1.2	13
896	A Multifunctional Chemical Agent as an Attenuator of Amyloid Burden and Neuroinflammation in Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2020, 11, 1471-1481.	1.7	25
897	Multispecific drugs herald a new era of biopharmaceutical innovation. <i>Nature</i> , 2020, 580, 329-338.	13.7	166
898	Reparative Effects of Stem Cell Factor and Granulocyte Colony-Stimulating Factor in Aged APP/PS1 Mice. , 2020, 11, 1423.		9
899	Is Alzheimer's Disease a Liver Disease of the Brain?. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 1-14.	1.2	58
900	Pharmacotherapy of Alzheimer's Disease: Seeking Clarity in a Time of Uncertainty. <i>Frontiers in Pharmacology</i> , 2020, 11, 261.	1.6	48
901	Multi-angle development of therapeutic methods for Alzheimer's disease. <i>British Journal of Pharmacology</i> , 2021, 178, 770-783.	2.7	7
902	Effect of CTerm of human albumin on the aggregation propensity of A β ₁₋₄₂ peptide: a potential of mean force study. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, 39, 1334-1342.	2.0	1
903	Quercetin-3-O-Glucuronide Alleviates Cognitive Deficit and Toxicity in A β ₄₂ -Induced AD-Like Mice and SH-SY5Y Cells. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2000660.	1.5	33
904	Determining Amyloid- β Positivity Using ¹⁸ F-AZD4694 PET Imaging. <i>Journal of Nuclear Medicine</i> , 2021, 62, 247-252.	2.8	65
905	Alzheimer's protection effect of A673T mutation may be driven by lower A β oligomer binding affinity. <i>Journal of Neurochemistry</i> , 2021, 157, 1316-1330.	2.1	20
906	Tubulin modifying enzymes as target for the treatment of tau-related diseases. , 2021, 218, 107681.		6
907	Sigma ligands as potent inhibitors of A β and A β O _s in neurons and promising therapeutic agents of Alzheimer's disease. <i>Neuropharmacology</i> , 2021, 190, 108342.	2.0	8
908	A practical approach to the management of cerebral amyloid angiopathy. <i>International Journal of Stroke</i> , 2021, 16, 356-369.	2.9	38

#	ARTICLE	IF	CITATIONS
909	Anti-A β Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 249-265.	1.2	27
910	Green tea extract EGCG plays a dual role in A β 42 protofibril disruption and membrane protection: A molecular dynamic study. <i>Chemistry and Physics of Lipids</i> , 2021, 234, 105024.	1.5	19
911	Frontiers in Neuroscience Imaging. <i>PET Clinics</i> , 2021, 16, 137-146.	1.5	1
912	Maresin 1 attenuates pro-inflammatory activation induced by A β amyloid and stimulates its uptake. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 434-447.	1.6	16
913	Emerging role of AMPA receptor subunit GluA1 in synaptic plasticity: Implications for Alzheimer's disease. <i>Cell Proliferation</i> , 2021, 54, e12959.	2.4	38
914	Recognition and Removal of Amyloid A β by a Heteromultivalent Macrocyclic Coassembly: A Potential Strategy for the Treatment of Alzheimer's Disease. <i>Advanced Materials</i> , 2021, 33, e2006483.	11.1	39
915	Pulse-Chase Proteomics of the App Knockin Mouse Models of Alzheimer's Disease Reveals that Synaptic Dysfunction Originates in Presynaptic Terminals. <i>Cell Systems</i> , 2021, 12, 141-158.e9.	2.9	32
916	Future Imaging in Dementia. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 303-308.	2.5	5
917	Therapeutic considerations for APOE and TOMM40 in Alzheimers disease: A tribute to Allen Roses MD. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 39-44.	1.9	2
918	Orally Administered Benzofuran Derivative Disaggregated A β Plaques and Oligomers in the Brain of 5XFAD Alzheimer Transgenic Mouse. <i>ACS Chemical Neuroscience</i> , 2021, 12, 99-108.	1.7	5
919	Inhibition of miR-331-3p and miR-9-5p ameliorates Alzheimer's disease by enhancing autophagy. <i>Theranostics</i> , 2021, 11, 2395-2409.	4.6	72
920	Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2021, 33, 3-13.	0.9	17
921	Ligustilide alleviates neurotoxicity in SH-SY5Y cells induced by A β 25-35 via regulating endoplasmic reticulum stress and autophagy. <i>Phytotherapy Research</i> , 2021, 35, 1572-1584.	2.8	7
922	Critical thinking on amyloid-beta-targeted therapy: challenges and perspectives. <i>Science China Life Sciences</i> , 2021, 64, 926-937.	2.3	12
923	Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. <i>Alzheimer's and Dementia</i> , 2021, 17, 696-701.	0.4	330
924	Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019". <i>Alzheimer's and Dementia</i> , 2021, 17, 702-703.	0.4	28
925	Novel Targets for Alzheimer's Disease: A View Beyond Amyloid. <i>Annual Review of Medicine</i> , 2021, 72, 15-28.	5.0	22
926	Artificial Intelligence and Machine Learning in Nuclear Medicine: Future Perspectives. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 170-177.	2.5	55

#	ARTICLE	IF	CITATIONS
927	Unblinded by the light: amyloid- β -related imaging abnormalities in Alzheimer's clinical trials. <i>European Journal of Neurology</i> , 2021, 28, e1.	1.7	16
928	Physiology of cellular demise: Apoptosis, necrosis, and autophagy. , 2021, , 23-78.		0
929	Prediction of the progression from mild cognitive impairment to Alzheimer's disease using a radiomics-integrated model. <i>Therapeutic Advances in Neurological Disorders</i> , 2021, 14, 175628642110295.	1.5	16
930	Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2021, 8, 1-11.	1.5	24
931	Amyloid hypothesis through the lens of A β supersaturation. <i>Neural Regeneration Research</i> , 2021, 16, 1562.	1.6	7
932	Effect of aerobic exercise on amyloid accumulation in preclinical Alzheimer's: A 1-year randomized controlled trial. <i>PLoS ONE</i> , 2021, 16, e0244893.	1.1	42
933	Impact of Genetic Risk Factors for Alzheimer's Disease on Brain Glucose Metabolism. <i>Molecular Neurobiology</i> , 2021, 58, 2608-2619.	1.9	13
934	True ultra-low-dose amyloid PET/MRI enhanced with deep learning for clinical interpretation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2416-2425.	3.3	27
935	Aducanumab: Appropriate Use Recommendations. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2021, 8, 1-13.	1.5	115
936	The Pathogenesis Mechanism, Structure Properties, Potential Drugs and Therapeutic Nanoparticles against the Small Oligomers of Amyloid- β . <i>Current Topics in Medicinal Chemistry</i> , 2021, 21, 151-167.	1.0	5
937	Alzheimer's disease neuropathology is exacerbated following traumatic brain injury. Neuroprotection by co-administration of nanowired mesenchymal stem cells and cerebrolysin with monoclonal antibodies to amyloid beta peptide. <i>Progress in Brain Research</i> , 2021, 265, 1-97.	0.9	8
938	Neuroprotective Effects of 2-Substituted 1, 3-Selenazole Amide Derivatives on Amyloid-Beta-Induced Toxicity in a Transgenic <i>Caenorhabditis Elegans</i> Model of Alzheimer's Disease. <i>Neurotoxicity Research</i> , 2021, 39, 841-850.	1.3	3
939	Translational medicine of the glutamate AMPA receptor. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2021, 97, 1-21.	1.6	6
941	Translational Pharmacology and Clinical Trials. , 2021, , .		1
942	Positron emission tomography imaging agents for evaluating the pathologic features of Alzheimer's disease and drug development. , 2021, , 367-412.		0
943	Monoclonal Antibodies as Neurological Therapeutics. <i>Pharmaceuticals</i> , 2021, 14, 92.	1.7	35
944	Association of naturally occurring antibodies to β -amyloid with cognitive decline and cerebral amyloidosis in Alzheimer's disease. <i>Science Advances</i> , 2021, 7, .	4.7	26
945	Early β -Amyloid Accumulation in the Brain Is Associated With Blood T and B Cell Alterations. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
946	Microvascular Alterations in Alzheimer's Disease. <i>Frontiers in Cellular Neuroscience</i> , 2020, 14, 618986.	1.8	41
947	Rational affinity maturation of anti-amyloid antibodies with high conformational and sequence specificity. <i>Journal of Biological Chemistry</i> , 2021, 296, 100508.	1.6	19
948	PET and SPECT Imaging of Neurodegenerative Diseases. , 2021, , 1309-1334.		0
949	Strategies for Engineered Negligible Senescence. , 2021, , 1-6.		0
950	Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer's disease and supporting differential diagnosis. <i>Annals of Nuclear Medicine</i> , 2021, 35, 139-147.	1.2	3
951	Anti-dementia Medication. , 2021, , 73-104.		0
952	Pseudopeptide Amyloid Aggregation Inhibitors: In Silico, Single Molecule and Cell Viability Studies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1051.	1.8	12
953	Immunotherapy for Alzheimer's Disease: Current Scenario and Future Perspectives. <i>Journal of prevention of Alzheimer's disease, The</i> , 2021, 8, 1-18.	1.5	10
954	Role of Adaptive Immune and Impacts of Risk Factors on Adaptive Immune in Alzheimer's Disease: Are Immunotherapies Effective or Off-Target?. <i>Neuroscientist</i> , 2022, 28, 254-270.	2.6	9
955	Rationally Designed Bicyclic Peptides Prevent the Conversion of A β 242 Assemblies Into Fibrillar Structures. <i>Frontiers in Neuroscience</i> , 2021, 15, 623097.	1.4	6
956	Quantifying misfolded protein oligomers as drug targets and biomarkers in Alzheimer and Parkinson diseases. <i>Nature Reviews Chemistry</i> , 2021, 5, 277-294.	13.8	56
957	Interaction of NF- κ B and Wnt/ β -catenin Signaling Pathways in Alzheimer's Disease and Potential Active Drug Treatments. <i>Neurochemical Research</i> , 2021, 46, 711-731.	1.6	16
958	Serotonin and Melatonin Show Different Modes of Action on A β 42 Protofibril Destabilization. <i>ACS Chemical Neuroscience</i> , 2021, 12, 799-809.	1.7	24
959	Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. <i>BMJ, The</i> , 2021, 372, n156.	3.0	113
960	Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis. <i>Chemical Reviews</i> , 2021, 121, 2545-2647.	23.0	406
961	Role of Retinal Amyloid- β in Neurodegenerative Diseases: Overlapping Mechanisms and Emerging Clinical Applications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2360.	1.8	26
962	APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	76
963	Automated detection of cerebral microbleeds on T2*-weighted MRI. <i>Scientific Reports</i> , 2021, 11, 4004.	1.6	24

#	ARTICLE	IF	CITATIONS
964	A Decade of FDA-Approved Drugs (2010â€“2019): Trends and Future Directions. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 2312-2338.	2.9	145
965	Insights Into the Mechanism of Tyrosine Nitration in Preventing β -Amyloid Aggregation in Alzheimerâ€™s Disease. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 619836.	1.4	4
967	Alzheimer's disease research: past approaches and future directions. <i>British Journal of Neuroscience Nursing</i> , 2021, 17, 34-39.	0.1	0
969	Deep learning based Alzheimer's disease early diagnosis using T2w segmented gray matter <scp>MRI</scp>. <i>International Journal of Imaging Systems and Technology</i> , 2021, 31, 1692-1710.	2.7	16
970	Nanomaterial-based Optical and Electrochemical Biosensors for Amyloid beta and Tau: Potential for early diagnosis of Alzheimerâ€™s Disease. <i>Expert Review of Molecular Diagnostics</i> , 2021, 21, 175-193.	1.5	18
971	Molecular Factors Mediating Neural Cell Plasticity Changes in Dementia Brain Diseases. <i>Neural Plasticity</i> , 2021, 2021, 1-20.	1.0	13
972	Association of <i>APOE</i> Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease. <i>Neurology</i> , 2021, 96, e2414-e2428.	1.5	34
973	Alzheimer Disease Clinical Trials Targeting Amyloid. <i>Neurologist</i> , 2021, 26, 52-61.	0.4	19
974	Quantification of N-terminal amyloid- β isoforms reveals isomers are the most abundant form of the amyloid- β peptide in sporadic Alzheimerâ€™s disease. <i>Brain Communications</i> , 2021, 3, fcab028.	1.5	25
975	Molecular Imaging Approaches in Dementia. <i>Radiology</i> , 2021, 298, 517-530.	3.6	27
976	On the role of Brain Imaging in drug development for psychiatry. <i>Current Clinical Pharmacology</i> , 2021, 16, 46-71.	0.2	0
977	Machine learning methods to predict amyloid positivity using domain scores from cognitive tests. <i>Scientific Reports</i> , 2021, 11, 4822.	1.6	11
978	Bispecific Tau Antibodies with Additional Binding to C1q or Alpha-Synuclein. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 813-829.	1.2	2
979	Catalytic photooxygenation degrades brain $A\beta$ in vivo. <i>Science Advances</i> , 2021, 7, .	4.7	42
980	Donepezil Combined with DL-3-n-Butylphthalide Delays Cognitive Decline in Patients with Mild to Moderate Alzheimerâ€™s Disease: A Multicenter, Prospective Cohort Study. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 673-681.	1.2	7
981	Alzheimerâ€™s Dementia: The Emerging Role of Positron Emission Tomography. <i>Neuroscientist</i> , 2022, 28, 507-519.	2.6	8
982	Modeling the Inhibition Kinetics of Curcumin, Orange G, and Resveratrol with Amyloid- β Peptide. <i>ACS Omega</i> , 2021, 6, 8680-8686.	1.6	7
983	The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models. <i>Molecular Therapy</i> , 2021, 29, 949-972.	3.7	10

#	ARTICLE	IF	CITATIONS
985	Preclinical validation of a potent β -secretase modulator for Alzheimer's disease prevention. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	39
986	Enhancing GABAergic signaling ameliorates aberrant gamma oscillations of olfactory bulb in AD mouse models. <i>Molecular Neurodegeneration</i> , 2021, 16, 14.	4.4	34
987	Inhibitory mechanism of an antifungal drug, caspofungin against amyloid β peptide aggregation: Repurposing via neuroinformatics and an experimental approach. <i>Molecular and Cellular Neurosciences</i> , 2021, 112, 103612.	1.0	3
988	The Protective A673T Mutation of Amyloid Precursor Protein (APP) in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2021, 58, 4038-4050.	1.9	16
989	Alzheimer's disease diagnosis based on the visual attention model and equal-distance ring shape context features. <i>IET Image Processing</i> , 2021, 15, 2351-2362.	1.4	3
990	The Use, Standardization, and Interpretation of Brain Imaging Data in Clinical Trials of Neurodegenerative Disorders. <i>Neurotherapeutics</i> , 2021, 18, 686-708.	2.1	19
991	Alzheimer's Disease's Rationales for Potential Treatment with the Thrombin Inhibitor Dabigatran. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4805.	1.8	13
992	Meningeal lymphatics affect microglia responses and anti- $A\beta$ immunotherapy. <i>Nature</i> , 2021, 593, 255-260.	13.7	179
993	Intracellular amyloid hypothesis for ultra-early phase pathology of Alzheimer's disease. <i>Neuropathology</i> , 2021, 41, 93-98.	0.7	21
994	Photo-oxygenation by a biocompatible catalyst reduces amyloid- β levels in Alzheimer's disease mice. <i>Brain</i> , 2021, 144, 1884-1897.	3.7	28
995	A comparative study of the effects of Aducanumab and scanning ultrasound on amyloid plaques and behavior in the APP23 mouse model of Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 76.	3.0	53
996	Alternative Targets to Fight Alzheimer's Disease: Focus on Astrocytes. <i>Biomolecules</i> , 2021, 11, 600.	1.8	16
997	Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 82.	3.0	14
999	Bridging Scales in Alzheimer's Disease: Biological Framework for Brain Simulation With The Virtual Brain. <i>Frontiers in Neuroinformatics</i> , 2021, 15, 630172.	1.3	20
1000	Alzheimer's Disease: New Concepts on the Role of Autoimmunity and NLRP3 Inflammasome in the Pathogenesis of the Disease. <i>Current Neuropharmacology</i> , 2021, 19, 498-512.	1.4	16
1001	Alzheimer's disease. <i>Lancet</i> , The, 2021, 397, 1577-1590.	6.3	1,530
1002	Increasing the confidence of ^{18}F -Florbetaben PET interpretations: Machine learning quantitative approximation. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2022, 41, 153-163.	0.1	1
1003	Alzheimer's Disease: Related Targets, Synthesis of Available Drugs, Bioactive Compounds Under Development and Promising Results Obtained from Multi-target Approaches. <i>Current Drug Targets</i> , 2021, 22, 505-538.	1.0	7

#	ARTICLE	IF	CITATIONS
1004	Current Quest in Natural Bioactive Compounds for Alzheimer's Disease: Multi-Targeted-Designed-Ligand Based Approach with Preclinical and Clinical Based Evidence. <i>Current Drug Targets</i> , 2021, 22, 685-720.	1.0	11
1005	From Small Molecules to Synthesized Polymers: Potential Role in Combating Amyloidogenic Disorders. <i>ACS Chemical Neuroscience</i> , 2021, 12, 1737-1748.	1.7	24
1006	Modulating innate immune activation states impacts the efficacy of specific A β 2 immunotherapy. <i>Molecular Neurodegeneration</i> , 2021, 16, 32.	4.4	4
1008	Screening for Early-Stage Alzheimer's Disease Using Optimized Feature Sets and Machine Learning. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 355-366.	1.2	21
1009	Fluid Biomarkers in Clinical Trials for Alzheimer's Disease: Current and Future Application. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 19-32.	1.2	3
1010	The role of Bcl-2 proteins in modulating neuronal Ca ²⁺ signaling in health and in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021, 1868, 118997.	1.9	31
1011	Systematic in silico analysis of clinically tested drugs for reducing amyloid β plaque accumulation in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1487-1498.	0.4	22
1012	Bacille Calmette-Guérin attenuates vascular amyloid pathology and maximizes synaptic preservation in APP/PS1 mice following active amyloid- β immunotherapy. <i>Neurobiology of Aging</i> , 2021, 101, 94-108.	1.5	8
1013	Monoclonal antibody therapy efficacy can be boosted by combinations with other treatments: Predictions using an integrated Alzheimer's Disease Platform. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 543-550.	1.3	4
1014	Donanemab in Early Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2021, 384, 1691-1704.	13.9	633
1015	Immunotherapies for Parkinson's disease: Progression of Clinical Development. <i>CNS and Neurological Disorders - Drug Targets</i> , 2021, 20, 802-813.	0.8	5
1016	Mesenchymal Stem Cell-Derived Exosomes Ameliorate Alzheimer's Disease Pathology and Improve Cognitive Deficits. <i>Biomedicines</i> , 2021, 9, 594.	1.4	55
1017	Polyphenol-Peptide Interactions in Mitigation of Alzheimer's Disease: Role of Biosurface-Induced Aggregation. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 33-55.	1.2	4
1018	Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney. <i>Alzheimer's and Dementia</i> , 2022, 18, 178-190.	0.4	5
1019	Effect of anti-amyloid- β 2 drugs on Alzheimer's disease: study protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2021, 11, e048453.	0.8	0
1020	Enhancing Anti-A β 2 Properties of Recombinant Autoantibodies. <i>Neuroscience</i> , 2021, 463, 354.	1.1	0
1021	Alzheimer's Disease: Innovative Therapeutic Approaches Based on Peptides and Nanoparticles. <i>Neuroscientist</i> , 2023, 29, 78-96.	2.6	7
1022	A β 243 aggregates exhibit enhanced prion-like seeding activity in mice. <i>Acta Neuropathologica Communications</i> , 2021, 9, 83.	2.4	14

#	ARTICLE	IF	CITATIONS
1023	Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	50
1024	Feasibility of short imaging protocols for [18F]PI-2620 tau-PET in progressive supranuclear palsy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3872-3885.	3.3	22
1025	A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 106.	3.0	37
1026	Glitter in the Darkness? Nonfibrillar β -Amyloid Plaque Components Significantly Impact the β -Amyloid PET Signal in Mouse Models of Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2022, 63, 117-124.	2.8	14
1027	Evaluation of Aducanumab for Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1717.	3.8	152
1028	Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis. <i>Alzheimer's and Dementia</i> , 2022, 18, 10-28.	0.4	93
1029	Advances in Brain Amyloid Imaging. <i>Seminars in Nuclear Medicine</i> , 2021, 51, 241-252.	2.5	30
1030	Effects of a Multimerized Recombinant Autoantibody Against Amyloid- β . <i>Neuroscience</i> , 2021, 463, 355-369.	1.1	3
1031	A human antibody selective for transthyretin amyloid removes cardiac amyloid through phagocytic immune cells. <i>Nature Communications</i> , 2021, 12, 3142.	5.8	42
1032	Alzheimer's Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5549.	1.8	20
1033	Autoantibodies in neurological disease. <i>Nature Reviews Immunology</i> , 2021, 21, 798-813.	10.6	147
1034	Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 98.	3.0	152
1036	Aducanumab for Alzheimer's disease: An update. <i>Neuroscience Research Notes</i> , 2021, 4, 17-20.	0.5	3
1037	Properties and molecular mechanisms underlying geniposide-mediated therapeutic effects in chronic inflammatory diseases. <i>Journal of Ethnopharmacology</i> , 2021, 273, 113958.	2.0	31
1038	Small, Seeding-Competent Huntingtin Fibrils Are Prominent Aggregate Species in Brains of zQ175 Huntingtin's Disease Knock-in Mice. <i>Frontiers in Neuroscience</i> , 2021, 15, 682172.	1.4	7
1039	Aducanumab: The first targeted Alzheimer's therapy. <i>Drug Discoveries and Therapeutics</i> , 2021, 15, 166-168.	0.6	40
1040	MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response. <i>Brain</i> , 2021, 144, 2361-2374.	3.7	29
1041	The neural economics of brain aging. <i>Scientific Reports</i> , 2021, 11, 12167.	1.6	0

#	ARTICLE	IF	CITATIONS
1042	The Conspicuous Link between Ear, Brain and Heart—Could Neurotrophin-Treatment of Age-Related Hearing Loss Help Prevent Alzheimer’s Disease and Associated Amyloid Cardiomyopathy?. <i>Biomolecules</i> , 2021, 11, 900.	1.8	10
1043	Group 1 Metabotropic Glutamate Receptors in Neurological and Psychiatric Diseases: Mechanisms and Prospective. <i>Neuroscientist</i> , 2022, 28, 453-468.	2.6	19
1044	Critical Appraisal of Amyloid Lowering Agents in AD. <i>Current Neurology and Neuroscience Reports</i> , 2021, 21, 39.	2.0	57
1045	Immunotherapies for Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2021, 12, 654739.	1.1	31
1046	A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease. <i>Pharmacological Reports</i> , 2021, 73, 1565-1581.	1.5	23
1047	A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease. <i>Nature Medicine</i> , 2021, 27, 1187-1196.	15.2	182
1048	The informed road map to prevention of Alzheimer Disease: A call to arms. <i>Molecular Neurodegeneration</i> , 2021, 16, 49.	4.4	43
1049	A cross-sectional study in healthy elderly subjects aimed at development of an algorithm to increase identification of Alzheimer pathology for the purpose of clinical trial participation. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 132.	3.0	4
1050	Leveraging hallmark Alzheimer’s molecular targets using phytoconstituents: Current perspective and emerging trends. <i>Biomedicine and Pharmacotherapy</i> , 2021, 139, 111634.	2.5	6
1051	A review on advances of treatment modalities for Alzheimer's disease. <i>Life Sciences</i> , 2021, 276, 119129.	2.0	85
1052	Synthesis and Biological Assessment of 4,1-Benzothiazepines with Neuroprotective Activity on the Ca ²⁺ Overload for the Treatment of Neurodegenerative Diseases and Stroke. <i>Molecules</i> , 2021, 26, 4473.	1.7	9
1053	Passive immunotherapy with a novel antibody against 3pE-modified A β demonstrates potential for enhanced efficacy and favorable safety in combination with BACE inhibitor treatment in plaque-depositing mice. <i>Neurobiology of Disease</i> , 2021, 154, 105365.	2.1	5
1054	The complexity of Alzheimer’s disease: an evolving puzzle. <i>Physiological Reviews</i> , 2021, 101, 1047-1081.	13.1	110
1055	The Geriatrician, the Primary Care Physician, Aducanumab and the FDA Decision: From Frustration to New Hope. <i>Journal of Nutrition, Health and Aging</i> , 2021, 25, 821-823.	1.5	8
1056	A Picture Is Worth a Thousand Words: The Power of Neuroimaging. <i>ACS Chemical Neuroscience</i> , 2021, 12, 2553-2554.	1.7	1
1057	Alzheimer’s disease: the controversial approval of Aducanumab. <i>Neurological Sciences</i> , 2021, 42, 3069-3070.	0.9	20
1058	Aducanumab for Alzheimer’s disease?. <i>BMJ, The</i> , 2021, 374, n1682.	3.0	107
1059	Tetrahydrocurcumin ameliorates Alzheimer's pathological phenotypes by inhibition of microglial cell cycle arrest and apoptosis via Ras/ERK signaling. <i>Biomedicine and Pharmacotherapy</i> , 2021, 139, 111651.	2.5	22

#	ARTICLE	IF	CITATIONS
1060	Amyloid- β : A double agent in Alzheimer's disease?. <i>Biomedicine and Pharmacotherapy</i> , 2021, 139, 111575.	2.5	32
1061	Therapeutic Ultrasound as a Treatment Modality for Physiological and Pathological Ageing Including Alzheimer's Disease. <i>Pharmaceutics</i> , 2021, 13, 1002.	2.0	4
1062	Chiral LVFFARK enantioselectively inhibits amyloid- β protein fibrillogenesis. <i>Chinese Journal of Chemical Engineering</i> , 2022, 48, 227-235.	1.7	2
1063	Therapy for Alzheimer's disease: Missing targets and functional markers?. <i>Ageing Research Reviews</i> , 2021, 68, 101318.	5.0	34
1064	El anticuerpo aducanumab en la enfermedad de Alzheimer. <i>Neurologia Argentina</i> , 2021, 13, 197-198.	0.1	0
1065	Aducanumab: First Approval. <i>Drugs</i> , 2021, 81, 1437-1443.	4.9	118
1066	First-level Neurocognitive Screening Tests and Their Application. <i>Journal of Regenerative Biology and Medicine</i> , 0, , .	0.0	0
1067	Mutual Interactions between Brain States and Alzheimer's Disease Pathology: A Focus on Gamma and Slow Oscillations. <i>Biology</i> , 2021, 10, 707.	1.3	16
1068	Biomarkers for the Clinical Diagnosis of Alzheimer's Disease: Metabolomics Analysis of Brain Tissue and Blood. <i>Frontiers in Pharmacology</i> , 2021, 12, 700587.	1.6	11
1070	Preclinical <i>in vivo</i> longitudinal assessment of KG207-M as a disease-modifying Alzheimer's disease therapeutic. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 788-801.	2.4	8
1071	Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment. <i>Molecules</i> , 2021, 26, 5091.	1.7	23
1072	Controversy and Progress in Alzheimer's Disease – FDA Approval of Aducanumab. <i>New England Journal of Medicine</i> , 2021, 385, 771-774.	13.9	101
1073	Long Noncoding RNAs in Neurodegenerative Diseases: Pathogenesis and Potential Implications as Clinical Biomarkers. <i>Frontiers in Molecular Neuroscience</i> , 2021, 14, 685143.	1.4	27
1074	Protective Effects of <i>Dendrobium nobile</i> Lindl. Alkaloids on Alzheimer's Disease-like Symptoms Induced by High-methionine Diet. <i>Current Neuropharmacology</i> , 2022, 20, 983-997.	1.4	12
1075	Casein Kinase 2 dependent phosphorylation of eIF4B regulates BACE1 expression in Alzheimer's disease. <i>Cell Death and Disease</i> , 2021, 12, 769.	2.7	8
1076	Segmented Linear Mixed Model Analysis Reveals Association of the APOE ϵ 4 Allele with Faster Rate of Alzheimer's Disease Dementia Progression. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 921-937.	1.2	13
1077	Oxorhenium(V) and Oxotechnetium(V) Complexes of N ₃ S Tetradentate Ligands with a Styrylpyridyl Functional Group: Toward Imaging Agents to Assist in the Diagnosis of Alzheimer's Disease. <i>Inorganic Chemistry</i> , 2021, 60, 13669-13680.	1.9	5
1078	Limiting RyR2 open time prevents Alzheimer's disease-related deficits in the 3xTCAD mouse model. <i>Journal of Neuroscience Research</i> , 2021, 99, 2906-2921.	1.3	18

#	ARTICLE	IF	CITATIONS
1079	The Ageing Brain: Molecular and Cellular Basis of Neurodegeneration. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 683459.	1.8	94
1080	Amyloid-Targeting Drugs for the Treatment of Alzheimer Disease. <i>Journal of the Korean Neurological Association</i> , 2021, 39, 134-140.	0.0	2
1081	Are Parkinsonâ€™s Disease Patients the Ideal Preclinical Population for Alzheimerâ€™s Disease Therapeutics?. <i>Journal of Personalized Medicine</i> , 2021, 11, 834.	1.1	3
1082	Nanosilver-embedded silicon nanowires as a SERS-active substrate for the ultrasensitive detection of monoamine neurotransmitters. <i>Surfaces and Interfaces</i> , 2021, 25, 101181.	1.5	7
1084	Toward deep MRI segmentation for Alzheimerâ€™s disease detection. <i>Neural Computing and Applications</i> , 2022, 34, 1047-1063.	3.2	24
1085	A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1537-1552.	1.2	38
1086	Advances in Genetic and Molecular Understanding of Alzheimerâ€™s Disease. <i>Genes</i> , 2021, 12, 1247.	1.0	9
1087	Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimerâ€™s Disease. <i>Neurology and Therapy</i> , 2021, 10, 919-940.	1.4	25
1088	Unveiling the inhibitory mechanism of peptidomimetic inhibitor against A β ²⁴² aggregation and protofibril disaggregation by molecular dynamics. <i>Journal of Molecular Liquids</i> , 2021, 335, 116474.	2.3	5
1089	Curcumin improves memory deficits by inhibiting HMGB1â€“RAGE/TLR4â€“NFâ€“ κ B signalling pathway in APP ^{swe} /PS1 ^{dE9} transgenic mice hippocampus. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 8947-8956.	1.6	21
1090	Basic Concepts in Immunobiology. , 2021, , 1-24.		0
1091	Integrating inÂ–vitro disease models of the neurovascular unit into discovery and development of neurotherapeutics. <i>Current Opinion in Biomedical Engineering</i> , 2021, 20, 100341.	1.8	2
1093	Should Canadian patients look forward to aducanumab for Alzheimer disease?. <i>Cmaj</i> , 2021, 193, E1430-E1431.	0.9	3
1094	Ophthalmic Biomarkers for Alzheimerâ€™s Disease: A Review. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 720167.	1.7	15
1095	Understanding the Modulatory Effects of Cannabidiol on Alzheimerâ€™s Disease. <i>Brain Sciences</i> , 2021, 11, 1211.	1.1	23
1096	Can we learn lessons from the FDAâ€™s approval of aducanumab?. <i>Nature Reviews Neurology</i> , 2021, 17, 715-722.	4.9	66
1097	Diagnosis and Treatment of Alzheimerâ€™s Disease:. <i>Delaware Journal of Public Health</i> , 2021, 7, 74-85.	0.2	8
1098	Immunotherapeutics for AD: A Work in Progress. <i>CNS and Neurological Disorders - Drug Targets</i> , 2021, 20, .	0.8	2

#	ARTICLE	IF	CITATIONS
1099	Progression along data-driven disease timelines is predictive of Alzheimer's disease in a population-based cohort. <i>NeuroImage</i> , 2021, 238, 118233.	2.1	5
1100	Lipid-Based Drug Delivery Systems in Regenerative Medicine. <i>Materials</i> , 2021, 14, 5371.	1.3	16
1101	GLP-1 and Underlying Beneficial Actions in Alzheimer's Disease, Hypertension, and NASH. <i>Frontiers in Endocrinology</i> , 2021, 12, 721198.	1.5	15
1102	The Development of Pharmacological Therapies for Alzheimer's Disease. <i>Neurology and Therapy</i> , 2021, 10, 609-626.	1.4	10
1103	The Problem of Aducanumab for the Treatment of Alzheimer Disease. <i>Annals of Internal Medicine</i> , 2021, 174, 1303-1304.	2.0	35
1104	Overexpression of wild-type human amyloid precursor protein alters GABAergic transmission. <i>Scientific Reports</i> , 2021, 11, 17600.	1.6	11
1105	Should We Open Fire on Microglia? Depletion Models as Tools to Elucidate Microglial Role in Health and Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9734.	1.8	9
1106	Circular RNA Cwc27 contributes to Alzheimer's disease pathogenesis by repressing Pur-1 activity. <i>Cell Death and Differentiation</i> , 2022, 29, 393-406.	5.0	48
1108	Phytotherapeutics against Alzheimer's Disease: Mechanism, Molecular Targets and Challenges for Drug Development. <i>CNS and Neurological Disorders - Drug Targets</i> , 2022, 21, 409-426.	0.8	5
1109	Effects of Shear Rate and Protein Concentration on Amyloidogenesis via Interfacial Shear. <i>Journal of Physical Chemistry B</i> , 2021, 125, 10355-10363.	1.2	6
1110	Oral Administration of Resveratrol-Selenium-Peptide Nanocomposites Alleviates Alzheimer's Disease-like Pathogenesis by Inhibiting A β Aggregation and Regulating Gut Microbiota. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 46406-46420.	4.0	69
1111	Lipid Profiling of Alzheimer's Disease Brain Highlights Enrichment in Glycerol(phospho)lipid, and Sphingolipid Metabolism. <i>Cells</i> , 2021, 10, 2591.	1.8	38
1112	The Rhesus Macaque as a Translational Model for Neurodegeneration and Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 734173.	1.7	15
1113	Longitudinal assessment of amyloid-beta deposition in initially amyloid-negative non-demented individuals with [11C]-PIB PET imaging. <i>Medicine (United States)</i> , 2021, 100, e27055.	0.4	4
1114	Glutamate Metabolism in Mitochondria is Closely Related to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 557-578.	1.2	8
1115	Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta. <i>Translational Neurodegeneration</i> , 2021, 10, 38.	3.6	17
1116	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in the Era of Disease-Modifying Treatments. <i>Brain Sciences</i> , 2021, 11, 1258.	1.1	3
1117	Immune modulations and immunotherapies for Alzheimer's disease: a comprehensive review. <i>Reviews in the Neurosciences</i> , 2022, 33, 365-381.	1.4	5

#	ARTICLE	IF	CITATIONS
1118	Ergosta-7,9(11),22-trien-3 β -ol Rescues AD Deficits by Modulating Microglia Activation but Not Oxidative Stress. <i>Molecules</i> , 2021, 26, 5338.	1.7	2
1119	Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease. <i>JAMA Network Open</i> , 2021, 4, e2124124.	2.8	30
1120	Aducanumab Fails to Produce Efficacy Results Yet Obtains US Food and Drug Administration Approval. <i>Population Health Management</i> , 2021, 24, 638-639.	0.8	2
1121	Aducanumab and the "post-amyloid" era of Alzheimer research?. <i>Neuron</i> , 2021, 109, 3045-3047.	3.8	11
1122	Citrullination of Amyloid- β Peptides in Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2021, 12, 3719-3732.	1.7	10
1123	The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. <i>Nature Reviews Neurology</i> , 2021, 17, 703-714.	4.9	65
1124	Prion protein and prion disease at a glance. <i>Journal of Cell Science</i> , 2021, 134, .	1.2	8
1125	Amyloid- β and α -Synuclein Immunotherapy: From Experimental Studies to Clinical Trials. <i>Frontiers in Neuroscience</i> , 2021, 15, 733857.	1.4	25
1127	Inflammatory Pathways Are Impaired in Alzheimer Disease and Differentially Associated With Apolipoprotein E Status. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 922-932.	0.9	12
1128	Roles of microglia in Alzheimer's disease and impact of new findings on microglial heterogeneity as a target for therapeutic intervention. <i>Biochemical Pharmacology</i> , 2021, 192, 114754.	2.0	24
1129	In vivo imaging of synaptic density with [11C]UCB-J PET in two mouse models of neurodegenerative disease. <i>NeuroImage</i> , 2021, 239, 118302.	2.1	19
1130	3D shearlet-based descriptors combined with deep features for the classification of Alzheimer's disease based on MRI data. <i>Computers in Biology and Medicine</i> , 2021, 138, 104879.	3.9	37
1131	Mechanistic insights into procyanidins as therapies for Alzheimer's disease: A review. <i>Journal of Functional Foods</i> , 2021, 86, 104683.	1.6	11
1132	Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [18F]-AV-1451 PET data. <i>NeuroImage</i> , 2021, 243, 118553.	2.1	23
1133	Abnormal amyloid beta metabolism in systemic abnormalities and Alzheimer's pathology: Insights and therapeutic approaches from periphery. <i>Ageing Research Reviews</i> , 2021, 71, 101451.	5.0	20
1134	Mechanistic role of boswellic acids in Alzheimer's disease: Emphasis on anti-inflammatory properties. <i>Biomedicine and Pharmacotherapy</i> , 2021, 144, 112250.	2.5	23
1135	Microglial Turnover in Ageing-Related Neurodegeneration: Therapeutic Avenue to Intervene in Disease Progression. <i>Cells</i> , 2021, 10, 150.	1.8	23
1136	Aging, Dementia, and Alzheimer Disease. , 2021, , 81-107.		0

#	ARTICLE	IF	CITATIONS
1137	Natural stereoisomeric flavonoids exhibit different disruptive effects and the mechanism of action on A β ₄₂ protofibril. Chemical Communications, 2021, 57, 4267-4270.	2.2	24
1138	The Ups and Downs of Amyloid in Alzheimer's. journal of prevention of Alzheimer's disease, The, 2022, 9, 1-4.	1.5	2
1139	Amyloid binding and beyond: a new approach for Alzheimer's disease drug discovery targeting A β C-terminal binding and downstream pathways. Chemical Science, 2021, 12, 3768-3785.	3.7	6
1140	CADASIL from Bench to Bedside: Disease Models and Novel Therapeutic Approaches. Molecular Neurobiology, 2021, 58, 2558-2573.	1.9	25
1141	VStore: A Novel Virtual Reality Assessment of Functional Cognition. SSRN Electronic Journal, 0, , .	0.4	0
1142	Parkinson's disease: Genetic-driven therapeutic approaches. , 2021, , 135-159.		0
1143	Alzheimer's Disease Pharmacology. , 2021, , .		1
1144	Molecular mechanisms of resveratrol and EGCG in the inhibition of A β ₄₂ aggregation and disruption of A β ₄₂ protofibril: similarities and differences. Physical Chemistry Chemical Physics, 2021, 23, 18843-18854.	1.3	31
1145	Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer's Disease. journal of prevention of Alzheimer's disease, The, 2021, 8, 1-9.	1.5	25
1146	Positron Emission Tomography in Drug Development. , 2021, , 165-181.		1
1148	SMPL Synaptic Membranes: Nanodisc-Mediated Synaptic Membrane Mimetics Expand the Toolkit for Drug Discovery and the Molecular Cell Biology of Synapses. Neuromethods, 2018, , 227-250.	0.2	1
1149	PET Neuroimaging in Dementia Conditions. , 2021, , 211-282.		7
1150	Prevention of Alzheimer's Disease and Alzheimer's Dementia. Mental Health and Illness Worldwide, 2016, , 1-26.	0.1	1
1151	Removal of Blood Amyloid As a Therapeutic Strategy for Alzheimer's Disease: The Influence of Smoking and Nicotine. , 2018, , 173-191.		2
1152	Unraveling Alzheimer's Disease Using Drosophila. , 2019, , 251-277.		10
1153	Advances in Drug Therapy for Alzheimer's Disease. Current Medical Science, 2020, 40, 999-1008.	0.7	18
1154	Progressive supranuclear palsy: Advances in diagnosis and management. Parkinsonism and Related Disorders, 2020, 73, 105-116.	1.1	55
1155	The Molecularised Me. , 0, , 245-260.		3

#	ARTICLE	IF	CITATIONS
1156	Green Tea Extracts EGCG and EGC Display Distinct Mechanisms in Disrupting A β ₄₂ Protofibril. ACS Chemical Neuroscience, 2020, 11, 1841-1851.	1.7	73
1157	Recent developments in antibody therapeutics against prion disease. Emerging Topics in Life Sciences, 2020, 4, 169-173.	1.1	10
1158	From Reproducibility to Translation in Neurodegenerative Disease. ILAR Journal, 2017, 58, 106-114.	1.8	11
1162	Transcranial optical imaging reveals a pathway for optimizing the delivery of immunotherapeutics to the brain. JCI Insight, 2018, 3, .	2.3	64
1163	Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. Journal of Clinical Investigation, 2018, 128, 2144-2155.	3.9	105
1164	Effector function of anti-pyroglutamate-3 A β antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like mice. Alzheimer's Research and Therapy, 2020, 12, 12.	3.0	26
1165	Beta-amyloid imaging in dementia. Yeungnam University Journal of Medicine, 2018, 35, 1-6.	0.7	9
1166	New treatment modalities in Alzheimer's disease. World Journal of Clinical Cases, 2019, 7, 1764-1774.	0.3	12
1167	A simulation study on the impact of the blood flow-dependent component in [18F]AV45 SUVR in Alzheimer's disease. PLoS ONE, 2017, 12, e0189155.	1.1	14
1168	THE FUTURE OF ANTI-AMYLOID TRIALS. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-6.	1.5	34
1169	Functional Amyloids and their Possible Influence on Alzheimer Disease. Discoveries, 2017, 5, e79.	1.5	9
1170	Large Soluble Oligomers of Amyloid β -Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate. Journal of Neuroscience, 2017, 37, 152-163.	1.7	19
1171	The diphenylpyrazole compound anle138b blocks A β channels and rescues disease phenotypes in a mouse model for amyloid pathology. EMBO Molecular Medicine, 2018, 10, 32-47.	3.3	63
1172	Alzheimer's disease: amyloid-based pathogenesis and potential therapies. Cell Stress, 2018, 2, 150-161.	1.4	27
1173	Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges. Revista Brasileira De Psiquiatria, 2020, 42, 431-441.	0.9	42
1175	A β Plaques. Free Neuropathology, 2020, 1, .	2.4	21
1176	Down syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein. Aging, 2020, 12, 1011-1033.	1.4	48
1177	The antigen-binding fragment of human gamma immunoglobulin prevents amyloid β -peptide folding into β -sheet to form oligomers. Oncotarget, 2017, 8, 41154-41165.	0.8	7

#	ARTICLE	IF	CITATIONS
1178	APOE genotype and Alzheimer's immunotherapy. <i>Oncotarget</i> , 2017, 8, 39941-39942.	0.8	7
1179	Anticoagulants inhibit proteolytic clearance of plasma amyloid beta. <i>Oncotarget</i> , 2018, 9, 5614-5626.	0.8	10
1180	<p>Chlorogenic Acid Alleviates A β ₂₅₋₃₅ -Induced Autophagy and Cognitive Impairment via the mTOR/TFEB Signaling Pathway</p>. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 1705-1716.	2.0	64
1181	Current Limitations in the Treatment of Parkinson's and Alzheimer's Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers. <i>Current Medicinal Chemistry</i> , 2019, 25, 5755-5771.	1.2	31
1182	Neuropharmacological Properties of the Essential Oil of Bergamot for the Clinical Management of Pain-Related BPSDs. <i>Current Medicinal Chemistry</i> , 2019, 26, 3764-3774.	1.2	31
1183	A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease. <i>Current Pharmaceutical Design</i> , 2020, 26, 1286-1299.	0.9	12
1184	Amyloid Beta Hypothesis in Alzheimer's Disease: Major Culprits and Recent Therapeutic Strategies. <i>Current Drug Targets</i> , 2020, 21, 148-166.	1.0	14
1185	Therapeutic Strategies Targeting Amyloid- β in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2019, 16, 418-452.	0.7	88
1186	Alzheimer's Disease and Retinal Degeneration: A Glimpse at Essential Trace Metals in Ocular Fluids and Tissues. <i>Current Alzheimer Research</i> , 2020, 16, 1073-1083.	0.7	8
1187	Genetic Variants and Oxidative Stress in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2020, 17, 208-223.	0.7	23
1188	Mechanistic Modeling of Soluble A β Dynamics and Target Engagement in the Brain by Anti-A β mAbs in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2020, 17, 393-406.	0.7	6
1189	Emerging Promise of Immunotherapy for Alzheimer's Disease: A New Hope for the Development of Alzheimer's Vaccine. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 1214-1234.	1.0	22
1190	The Amyloid Cascade Hypothesis in Alzheimer's Disease: It's Time to Change Our Mind. <i>Current Neuropharmacology</i> , 2017, 15, 926-935.	1.4	253
1191	Current Status of Drug Targets and Emerging Therapeutic Strategies in the Management of Alzheimer's Disease. <i>Current Neuropharmacology</i> , 2020, 18, 883-903.	1.4	17
1192	Multiple Targets for the Management of Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2016, 15, 1279-1289.	0.8	29
1193	Oxidative Stress in the Pathogenesis of Alzheimer's Disease and Cerebrovascular Disease with Therapeutic Implications. <i>CNS and Neurological Disorders - Drug Targets</i> , 2020, 19, 94-108.	0.8	20
1194	What are we trying to prevent in Alzheimer disease?. <i>Dialogues in Clinical Neuroscience</i> , 2019, 21, 27-34.	1.8	6
1195	Brain Delivery of Nanomedicines: Trojan Horse Liposomes for Plasmid DNA Gene Therapy of the Brain. <i>Frontiers in Medical Technology</i> , 2020, 2, 602236.	1.3	20

#	ARTICLE	IF	CITATIONS
1196	Promising Results from Alzheimer's Disease Passive Immunotherapy Support the Development of a Preventive Vaccine. <i>Research</i> , 2019, 2019, 5341375.	2.8	18
1197	Research of new drugs for Alzheimer's disease. <i>Psychiatrie Pro Praxi</i> , 2017, 18, 7-10.	0.0	2
1198	Targeting amyloid precursor protein shuttling and processing - long before amyloid beta formation. <i>Neural Regeneration Research</i> , 2017, 12, 207.	1.6	6
1199	Synaptic dysfunction in Alzheimer's disease: the effects of amyloid beta on synaptic vesicle dynamics as a novel target for therapeutic intervention. <i>Neural Regeneration Research</i> , 2018, 13, 616.	1.6	106
1200	Knowledge domain and emerging trends in Alzheimer's disease: a scientometric review based on CiteSpace analysis. <i>Neural Regeneration Research</i> , 2019, 14, 1643.	1.6	102
1201	Uncertainty and health literacy in dementia care. <i>Tzu Chi Medical Journal</i> , 2020, 32, 14.	0.4	12
1202	Towards the design of anti-amyloid short peptide helices. <i>Bioinformatics</i> , 2018, 14, 001-007.	0.2	10
1203	Atomic structures of fibrillar segments of hIAPP suggest tightly mated β -sheets are important for cytotoxicity. <i>ELife</i> , 2017, 6, .	2.8	95
1204	Fibrillar $A\beta$ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models. <i>ELife</i> , 2020, 9, .	2.8	80
1205	Chemical catalyst-promoted photooxygenation of amyloid proteins. <i>Organic and Biomolecular Chemistry</i> , 2021, 19, 10017-10029.	1.5	8
1206	A Novel Virtual Reality Assessment of Functional Cognition: Validation Study. <i>Journal of Medical Internet Research</i> , 2022, 24, e27641.	2.1	14
1207	Past, present and future of therapeutic strategies against amyloid- β peptides in Alzheimer's disease: a systematic review. <i>Ageing Research Reviews</i> , 2021, 72, 101496.	5.0	131
1208	Tau fibril with membrane lipids: Insight from computational modeling and simulations. <i>PLoS ONE</i> , 2021, 16, e0258692.	1.1	2
1209	Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque-removing agent, in patients with Alzheimer's disease. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 7-19.	1.3	10
1210	An Overview of Several Inhibitors for Alzheimer's Disease: Characterization and Failure. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10798.	1.8	12
1211	Systematic phenotyping and characterization of the 5xFAD mouse model of Alzheimer's disease. <i>Scientific Data</i> , 2021, 8, 270.	2.4	138
1212	Targeted protein degradation using intracellular antibodies and its application to neurodegenerative disease. <i>Seminars in Cell and Developmental Biology</i> , 2022, 126, 138-149.	2.3	12
1213	Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	21

#	ARTICLE	IF	CITATIONS
1214	Alzheimer's disease clinical trial update 2019-2021. Journal of Neurology, 2022, 269, 1038-1051.	1.8	39
1215	Mesenchymal Stem Cell-Derived Extracellular Vesicle-Based Therapy for Alzheimer's Disease: Progress and Opportunity. Membranes, 2021, 11, 796.	1.4	11
1216	Restoration of Calmodulin-Like Skin Protein as Treatment for Alzheimer's Disease. Frontiers in Neurology, 2021, 12, 771856.	1.1	0
1217	Human serum albumin fusion protein as therapeutics for targeting amyloid beta in Alzheimer's diseases. Neuroscience Letters, 2022, 767, 136298.	1.0	3
1218	Direct Delivery of ANA-TA9, a Peptide Capable of A β Hydrolysis, to the Brain by Intranasal Administration. Pharmaceutics, 2021, 13, 1673.	2.0	2
1219	Aducanumab (Marketed as Aduhelm) Approval Is Likely Based on Misinterpretation of PET Imaging Data. Journal of Alzheimer's Disease, 2021, , 1-4.	1.2	17
1220	Novel API Coated Catheter Removes Amyloid- β from Plasma of Patients with Alzheimer's Disease. Alzheimer's & Neurodegenerative Diseases, 2021, 7, 1-7.	0.1	0
1221	Small Molecule Improvement of Trafficking Defects in Models of Neurodegeneration. ACS Chemical Neuroscience, 2021, 12, 3972-3984.	1.7	0
1222	The Swedish dilemma - the almost exclusive use of APP ^{sw} -based mouse models impedes adequate evaluation of alternative β -secretases. Biochimica Et Biophysica Acta - Molecular Cell Research, 2021, , 119164.	1.9	13
1223	NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load. ELife, 2021, 10, .	2.8	12
1224	d-Amino Acids and pLG72 in Alzheimer's Disease and Schizophrenia. International Journal of Molecular Sciences, 2021, 22, 10917.	1.8	14
1225	A geroscience motivated approach to treat Alzheimer's disease: Senolytics move to clinical trials. Mechanisms of Ageing and Development, 2021, 200, 111589.	2.2	15
1226	Alzheimer's treatment appears to alleviate memory loss in small trial. Nature, 0, , .	13.7	0
1227	RETA A TU MENTE, DESAFÃA A TU CEREBRO: COMPLEJIDAD AMBIENTAL Y SALUD CEREBRAL. International Journal of Developmental and Educational Psychology Revista INFAD De PsicologÃa, 2016, 1, 201.	0.0	0
1229	Can we switch production of toxic A β oligomers to neuroprotective A β monomers to allow synapse regeneration?. Neural Regeneration Research, 2017, 12, 1437.	1.6	1
1230	Prevention of Alzheimer's Disease and Alzheimer's Dementia. Mental Health and Illness Worldwide, 2017, , 549-574.	0.1	0
1233	13. Disease Modifying Therapies and Care of Alzheimer's Disease. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1991-1995.	0.0	0
1234	Prion-Like Propagation in Neurodegenerative Diseases. , 2018, , 189-242.		0

#	ARTICLE	IF	CITATIONS
1235	Clinical Meaningfulness of Biomarker Endpoints in Alzheimer's Disease Research. <i>Neuromethods</i> , 2018, , 235-248.	0.2	0
1236	The Beneficial Effect of Enriched Environment on Pathogenesis of Alzheimer's Disease. <i>Yangtze Medicine</i> , 2018, 02, 225-243.	0.1	3
1239	Personalised Medicine, Individual Choice and the Common Good. , 2018, , .		3
1240	Strategies for Engineered Negligible Senescence. , 2019, , 1-6.		0
1241	New strategies for diagnosis and treatment of Alzheimer's disease: monoclonal antibodies to beta-amyloid. <i>Medical Alphabet</i> , 2019, 1, 35-42.	0.0	4
1242	Immunotherapy in Alzheimer's Disease. , 2019, , 271-293.		0
1243	Literaturverzeichnis zu Voderholzer/Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 14. Auflage. , 2019, , 1-119.		0
1245	Development of Artificial Catalysts that Selectively Photooxygenate Pathogenic Amyloid. <i>Yuki Gosei Kagaku Kyokaishi/Journal of Synthetic Organic Chemistry</i> , 2019, 77, 246-253.	0.0	0
1248	Progression of Treating Alzheimer's Disease with Stem Cell-based Therapies. <i>International Annals of Science</i> , 2019, 8, 38-46.	0.4	1
1249	Spectrum of Pharmacological Activity of Monoclonal Antibodies. <i>Ukrainian Journal of Medicine and Sports</i> , 2019, 4, 17-32.	0.0	0
1251	Alteration in the Expression of Alzheimer's-Related Genes in Rat Hippocampus by Exercise and Morphine Treatments. <i>The Neuroscience Journal of Shefaye Khatam</i> , 2019, 7, 23-29.	0.4	0
1253	Limitations of amyloid imaging in Alzheimer's disease. , 2020, , 491-506.		0
1254	GANDALF: Generative Adversarial Networks with Discriminator-Adaptive Loss Fine-Tuning for Alzheimer's Disease Diagnosis from MRI. <i>Lecture Notes in Computer Science</i> , 2020, , 688-697.	1.0	7
1258	Dissecting the Crosstalk between Endothelial Mitochondrial Damage, Vascular Inflammation, and Neurodegeneration in Cerebral Amyloid Angiopathy and Alzheimer's Disease. <i>Cells</i> , 2021, 10, 2903.	1.8	36
1259	Genomics of Alzheimer's disease implicates the innate and adaptive immune systems. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 7397-7426.	2.4	32
1260	Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain A β Pathology in Transgenic Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11791.	1.8	10
1261	Molecular and Therapeutic Targets for Amyloid-beta Plaques in Alzheimer's Disease: A Review Study. <i>Basic and Clinical Neuroscience</i> , 2024, 15, 1-26.	0.3	1
1262	Removal of blood amyloid- β as an effective and safe therapeutic strategy for Alzheimer's disease. , 2020, , 647-662.		0

#	ARTICLE	IF	CITATIONS
1263	Alzheimer's disease: clinical management errors. Meditsinskiy Sovet, 2020, , 23-28.	0.1	4
1264	Immunotherapy Targeting Amyloid- β Peptides in Alzheimer's Disease. , 0, , 23-49.		3
1265	The Application Prospect of PET/CT in the Diagnosis and Evaluation of Glaucoma. Hans Journal of Ophthalmology, 2020, 09, 274-279.	0.0	0
1266	THE ROLE OF CLINICAL TRIALS IN PRECLINICAL ALZHEIMER'S DISEASE DRUG DEVELOPMENT PROGRAMS. journal of prevention of Alzheimer's disease, The, 2020, 7, 1-3.	1.5	1
1267	Cerebral Amyloid Angiopathy: Emerging Evidence for Novel Pathophysiology and Pathogenesis. Stroke Revisited, 2020, , 81-94.	0.2	0
1268	Whole-brain three-dimensional imaging for quantification of drug targets and treatment effects in mouse models of neurodegenerative diseases. Neural Regeneration Research, 2020, 15, 2255.	1.6	3
1269	Robust Biomarkers: Methodologically Tracking Causal Processes in Alzheimer's Measurement. Boston Studies in the Philosophy and History of Science, 2020, , 289-318.	0.4	2
1270	Genomics of Alzheimer's disease. , 2020, , 3-18.		0
1271	Wireless Soft Microfluidics for Chronic In Vivo Neuropharmacology. , 2020, , 321-336.		0
1273	Comparative functional genomic analysis of Alzheimer's affected and naturally aging brains. PeerJ, 2020, 8, e8682.	0.9	3
1274	Acetylcholinesterase Inhibitory Activity and Anti-amyloidogenic Effect of Cercis chinensis Bunge Seed Ethanol Extract. Korean Journal of Medicinal Crop Science, 2021, 29, 337-344.	0.1	0
1275	Extensive frontal focused ultrasound mediated blood-brain barrier opening for the treatment of Alzheimer's disease: a proof-of-concept study. Translational Neurodegeneration, 2021, 10, 44.	3.6	46
1276	Neuropathology of Alzheimer's Disease. Neurotherapeutics, 2022, 19, 173-185.	2.1	83
1277	Talking points for physicians, patients and caregivers considering Aduhelm [®] infusion and the accelerated pathway for its approval by the FDA. Molecular Neurodegeneration, 2021, 16, 74.	4.4	10
1278	Peptide-Based Vaccines for Neurodegenerative Diseases: Recent Endeavors and Future Perspectives. Vaccines, 2021, 9, 1278.	2.1	13
1280	Focused Ultrasound Mediated Opening of the Blood-Brain Barrier for Neurodegenerative Diseases. Frontiers in Neurology, 2021, 12, 749047.	1.1	14
1281	A Novel Method to Stimulate Lymphatic Clearance of Beta-Amyloid from Mouse Brain Using Noninvasive Music-Induced Opening of the Blood-Brain Barrier with EEG Markers. Applied Sciences (Switzerland), 2021, 11, 10287.	1.3	3
1283	Development and evaluation of an automated quantification tool for amyloid PET images. EJNMMI Physics, 2020, 7, 59.	1.3	5

#	ARTICLE	IF	CITATIONS
1284	AÎ² Imaging in Aging, Alzheimerâ€™s Disease, and Other Neurodegenerative Conditions. , 2021, , 283-343.		0
1286	Antibody DDS therapeutics against cancer, inflammatory autoimmune and infectious disease. Drug Delivery System, 2020, 35, 356-366.	0.0	0
1288	A Cationic Gallium Phthalocyanine Inhibits Amyloid Î² Peptide Fibril Formation. Current Alzheimer Research, 2020, 17, 589-600.	0.7	1
1289	Combating the Trade in Organs. , 0, , 77-112.		1
1291	Amyloid-beta immunotherapy: the hope for Alzheimer disease?. Colombia Medica, 2016, 47, 203-212.	0.7	21
1292	Alzheimer's Toxic Amyloid Beta Oligomers: Unwelcome Visitors to the Na/K ATPase alpha3 Docking Station. Yale Journal of Biology and Medicine, 2017, 90, 45-61.	0.2	23
1293	New Drug Research and Development for Alzheimer's Pathology: Present and Prospect. Shanghai Archives of Psychiatry, 2017, 29, 237-239.	0.7	3
1294	Abnormal Homocysteine Metabolism: An Insight of Alzheimer's Disease from DNA Methylation. Behavioural Neurology, 2020, 2020, 8438602.	1.1	3
1296	Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid Î² and Tau Protein. Medical Science Monitor, 2021, 27, e934077.	0.5	1
1297	Innate Immunity and Cell Death in Alzheimer's Disease. ASN Neuro, 2021, 13, 17590914211051908.	1.5	1
1298	Immunopharmacology of Alzheimerâ€™s disease. , 2022, , 277-298.		0
1299	Dual-targeted carbon-dot-drugs nanoassemblies for modulating Alzheimer's related amyloid-Î² aggregation and inhibiting fungal infection. Materials Today Bio, 2021, 12, 100167.	2.6	10
1301	Is Aducanumab for LMICs? Promises and Challenges. Brain Sciences, 2021, 11, 1547.	1.1	5
1302	Significance of GABAA Receptor for Cognitive Function and Hippocampal Pathology. International Journal of Molecular Sciences, 2021, 22, 12456.	1.8	23
1304	Antibody-Based Therapeutic Interventions for Amyotrophic Lateral Sclerosis: A Systematic Literature Review. Frontiers in Neuroscience, 2021, 15, 790114.	1.4	9
1305	Boosting the diagnostic power of amyloid-Î² PET using a data-driven spatially informed classifier for decision support. Alzheimer's Research and Therapy, 2021, 13, 185.	3.0	1
1306	Amyloid Î² 42 fibril structure based on small-angle scattering. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	23
1307	Aumento de la confianza en la interpretaciÃ³n del PET con 18F-Florbetaben: â€œmachine learningâ€ basado en la aproximaciÃ³n cuantitativa. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2022, 41, 153-163.	0.0	1

#	ARTICLE	IF	CITATIONS
1308	Presenilin/β-Secretase Activity Is Located in Acidic Compartments of Live Neurons. <i>Journal of Neuroscience</i> , 2022, 42, 145-154.	1.7	19
1309	Structural biology of cell surface receptors implicated in Alzheimer's disease. <i>Biophysical Reviews</i> , 2022, 14, 233-255.	1.5	5
1310	4-(2-Hydroxyethyl)1-piperazine ethane sulfonic acid repositioning: Amyloid disaggregating agent and its sustained-release system. <i>Bulletin of the Korean Chemical Society</i> , 2022, 43, 78-82.	1.0	6
1311	Secondary Prevention of Dementia: Combining Risk Factors and Scalable Screening Technology. <i>Frontiers in Neurology</i> , 2021, 12, 772836.	1.1	9
1312	The Hybrid Compounds as Multi-target Ligands for the Treatment of Alzheimer's Disease: Considerations on Donepezil. <i>Current Topics in Medicinal Chemistry</i> , 2022, 22, 395-407.	1.0	6
1313	Deer antler extracts reduce amyloid-beta toxicity in a <i>Caenorhabditis elegans</i> model of Alzheimer's disease. <i>Journal of Ethnopharmacology</i> , 2022, 285, 114850.	2.0	12
1314	The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. <i>Nature Reviews Neuroscience</i> , 2022, 23, 53-66.	4.9	203
1315	NMR Studies of Tau Protein in Tauopathies. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 761227.	1.6	9
1316	Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer's Disease. <i>Review of Reviews. Biomedicines</i> , 2021, 9, 1689.	1.4	31
1317	Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 13.	4.5	244
1319	Microglia-Based Sex-Biased Neuropathology in Early-Stage Alzheimer's Disease Model Mice and the Potential Pharmacologic Efficacy of Dioscin. <i>Cells</i> , 2021, 10, 3261.	1.8	5
1320	Qu'apporte l'imagerie hybride TEP-IRM dans l'étude des pathologies neuro-dégénératives? <i>Bulletin De L'Academie Nationale De Medecine</i> , 2021, 206, 28-28.	0.0	0
1321	miRNAs as Therapeutic Tools in Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13012.	1.8	22
1322	A Survey of the Clinical Pipeline in Neuroscience. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2021, 56, 128482.	1.0	0
1323	Essential Oils from Spices Inhibit Cholinesterase Activity and Improve Behavioral Disorder in Aβ ₁₋₄₂ Induced Dementia. <i>Chemistry and Biodiversity</i> , 2021, , e2100443.	1.0	10
1324	Integrating Bio-metabolism and Structural Changes for the Diagnosis of Dementia. , 2022, , 169-172.		0
1325	Complement as a powerful influencer in the brain during development, adulthood and neurological disorders. <i>Advances in Immunology</i> , 2021, 152, 157-222.	1.1	11
1326	Innate Immunity and Cell Death in Alzheimer's Disease. <i>ASN Neuro</i> , 2021, 13, 175909142110519.	1.5	19

#	ARTICLE	IF	CITATIONS
1327	Strategies for Engineered Negligible Senescence. , 2021, , 4768-4773.		0
1328	Knowledge of Dementia Treatment : Prospects for Disease-modifying Therapy in Alzheimer's Disease. Japanese Journal of Neurosurgery, 2021, 30, 840-844.	0.0	0
1329	Can exercise training teach us how to treat Alzheimerâ€™s disease?. Ageing Research Reviews, 2022, 75, 101559.	5.0	23
1330	Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab. Stroke, 2022, 53, 298-302.	1.0	16
1331	Identification and analysis of a selective DYRK1A inhibitor. Biomedicine and Pharmacotherapy, 2022, 146, 112580.	2.5	8
1332	Abnormal Homocysteine Metabolism: An Insight of Alzheimerâ€™s Disease from DNA Methylation. Behavioural Neurology, 2020, 2020, 1-11.	1.1	29
1333	Photo-Oxygenation: An Innovative New Therapeutic Approach Against Amyloidoses. Advances in Experimental Medicine and Biology, 2021, 1339, 415-422.	0.8	2
1334	Psychedelics as Novel Therapeutics in Alzheimerâ€™s Disease: Rationale and Potential Mechanisms. Current Topics in Behavioral Neurosciences, 2021, , 287-317.	0.8	11
1335	Comparative Analysis of Aducanumab, Zagotenemab and Pioglitazone as Targeted Treatment Strategies for Alzheimerâ€™s Disease. , 2021, 12, 1964.		35
1336	Aluminium co-localises with Biondi ring tangles in Parkinsonâ€™s disease and epilepsy. Scientific Reports, 2022, 12, 1465.	1.6	3
1337	Plasma p τ 231, p τ 181, <sc>PET</sc> Biomarkers, and Cognitive Change in Older Adults. Annals of Neurology, 2022, 91, 548-560.	2.8	42
1338	Plasma Phosphorylated Tau181 is a Biomarker of Alzheimer's Disease Pathology and Associated with Cognitive and Functional Decline. SSRN Electronic Journal, 0, , .	0.4	6
1339	Histopathological correlates of haemorrhagic lesions on <i>ex vivo</i> magnetic resonance imaging in immunized Alzheimerâ€™s disease cases. Brain Communications, 2022, 4, fcac021.	1.5	7
1340	Amyloid-beta peptide and tau protein crosstalk in Alzheimerâ€™s disease. Neural Regeneration Research, 2022, 17, 1666.	1.6	87
1341	Specificity of Adaptive Immune Responses in Central Nervous System Health, Aging and Diseases. Frontiers in Neuroscience, 2021, 15, 806260.	1.4	11
1342	Public Policy Should Foster Alzheimerâ€™s Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (Aduhelm TM) to Patients Participating in Clinical Trials. journal of prevention of Alzheimer's disease, The, 2022, 9, 241-246.	1.5	0
1343	Reactive astrogliosis: A friend or foe in the pathogenesis of Alzheimerâ€™s disease. Journal of Neurochemistry, 2023, 164, 309-324.	2.1	43
1344	Emerging Roles of Microfluidics in Brain Research: From Cerebral Fluids Manipulation to Brain-on-a-Chip and Neuroelectronic Devices Engineering. Chemical Reviews, 2022, 122, 7142-7181.	23.0	21

#	ARTICLE	IF	CITATIONS
1345	Detoxification of amyloid β fibrils by curcumin derivatives and their verification in a Drosophila Alzheimer's model. <i>Chemical Communications</i> , 2022, , .	2.2	10
1346	The amyloid- β 42-oligomer interacting peptide D-AIP possesses favorable biostability, pharmacokinetics, and brain region distribution. <i>Journal of Biological Chemistry</i> , 2022, 298, 101483.	1.6	1
1347	Sodium-calcium exchanger isoform-3 targeted <i>Withania somnifera</i> (L.) Dunal therapeutic intervention ameliorates cognition in the 5xFAD mouse model of Alzheimer's disease. <i>Scientific Reports</i> , 2022, 12, 1537.	1.6	4
1348	Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy. <i>Journal of prevention of Alzheimer's disease</i> , The, 2022, 9, 211-220.	1.5	25
1349	Turning the tide on Alzheimer's disease: modulation of β -secretase. <i>Cell and Bioscience</i> , 2022, 12, 2.	2.1	22
1350	Kinetic Modulation of Amyloid- β (1-42) Aggregation and Toxicity by Structure-Based Rational Design. <i>Journal of the American Chemical Society</i> , 2022, 144, 1603-1611.	6.6	10
1351	Therapeutic effects of anti-amyloid β antibody after intravenous injection and efficient nose-to-brain delivery in Alzheimer's disease mouse model. <i>Drug Delivery and Translational Research</i> , 2022, , 1.	3.0	2
1352	The Road to Personalized Medicine in Alzheimer's Disease: The Use of Artificial Intelligence. <i>Biomedicines</i> , 2022, 10, 315.	1.4	15
1353	Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer's Disease: A Comprehensive Review. <i>Health Psychology Research</i> , 2022, 10, .	0.6	16
1354	Wnt Signaling Rescues Amyloid Beta-Induced Gut Stem Cell Loss. <i>Cells</i> , 2022, 11, 281.	1.8	6
1355	Sodium tanshinone IIA sulfonate improves cognitive impairment via regulating $A\beta$ transportation in AD transgenic mouse model. <i>Metabolic Brain Disease</i> , 2022, 37, 989-1001.	1.4	3
1356	Targeting the immune system towards novel therapeutic avenues to fight brain aging and neurodegeneration. <i>European Journal of Neuroscience</i> , 2022, 56, 5413-5427.	1.2	2
1357	Machine Learning-Assisted Pattern Recognition of Amyloid Beta Aggregates with Fluorescent Conjugated Polymers and Graphite Oxide Electrostatic Complexes. <i>Analytical Chemistry</i> , 2022, 94, 2757-2763.	3.2	12
1358	Blood-brain barrier leakage in Alzheimer's disease: From discovery to clinical relevance. , 2022, 234, 108119.		38
1359	Amyloid-Related Imaging Abnormalities and β -Amyloid-Targeting Antibodies. <i>JAMA Neurology</i> , 2022, 79, 291.	4.5	43
1360	Recent Developments in Positron Emission Tomography Tracers for Proteinopathies Imaging in Dementia. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 751897.	1.7	12
1361	Age and Anterior Basal Forebrain Volume Predict the Cholinergic Deficit in Patients with Mild Cognitive Impairment due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-16.	1.2	3
1362	Advances in prodrug design for Alzheimer's disease: the state of the art. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 325-341.	2.5	2

#	ARTICLE	IF	CITATIONS
1364	Naturally Occurring Antioxidant Therapy in Alzheimer's Disease. <i>Antioxidants</i> , 2022, 11, 213.	2.2	38
1365	A hybrid approach unveils drug repurposing candidates targeting an Alzheimer pathophysiology mechanism. <i>Patterns</i> , 2022, 3, 100433.	3.1	13
1366	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. <i>Brain Communications</i> , 2022, 4, fcac017.	1.5	12
1367	The Current Evidence for the Therapeutic Role of Curcumin in Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2023, 22, 318-320.	0.8	2
1368	Anti-Dementia Medications and Anti-Alzheimer's Disease Drugs: Side Effects, Contraindications, and Interactions. , 2022, , 1-10.		3
1369	Disease Modeling and Model-Based Meta-Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer's Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 857-866.	2.3	7
1370	Quantitative systems pharmacology model for Alzheimer's disease to predict the effect of aducanumab on brain amyloid. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 362-372.	1.3	9
1371	Chemical-Driven Outflow of Dissociated Amyloid Burden from Brain to Blood. <i>Advanced Science</i> , 2022, 9, e2104542.	5.6	3
1372	Challenges and hopes for Alzheimer's disease. <i>Drug Discovery Today</i> , 2022, 27, 1027-1043.	3.2	87
1373	New therapeutic opportunities for Alzheimer disease. , 2022, 1, 15-21.		0
1374	Amyloid fishing: β -Amyloid adsorption using tailor-made coated titania nanoparticles. <i>Colloids and Surfaces B: Biointerfaces</i> , 2022, 212, 112374.	2.5	1
1375	Deep learning-based identification of genetic variants: application to Alzheimer's disease classification. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	26
1376	Amyloid- β peptide 37, 38 and 40 individually and cooperatively inhibit amyloid- β 42 aggregation. <i>Chemical Science</i> , 2022, 13, 2423-2439.	3.7	20
1377	Quelles perspectives de traitements curatifs À court et À long terme pour la Maladie d'Alzheimer?. <i>La Presse Médicale Formation</i> , 2022, , .	0.1	0
1378	What have we learnt from past failures in Alzheimer's disease drug discovery?. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 309-323.	2.5	9
1379	Hydrogel-Coated Gate Field-Effect Transistor for Real-Time and Label-Free Monitoring of β -Amyloid Aggregation and Its Inhibition. <i>Analytical Chemistry</i> , 2022, , .	3.2	2
1380	Considerations regarding a diagnosis of Alzheimer's disease before dementia: a systematic review. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 31.	3.0	25
1381	The accuracy and robustness of plasma biomarker models for amyloid PET positivity. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 26.	3.0	49

#	ARTICLE	IF	CITATIONS
1382	Alcohol-Induced Neuroinflammatory Response and Mitochondrial Dysfunction on Aging and Alzheimer's Disease. <i>Frontiers in Behavioral Neuroscience</i> , 2021, 15, 778456.	1.0	10
1383	Serum levels of 4-hydroxynonenal adducts and responding autoantibodies correlate with the pathogenesis from hyperglycemia to Alzheimer's disease. <i>Clinical Biochemistry</i> , 2022, 101, 26-34.	0.8	7
1384	Targeting MicroRNA-485-3p Blocks Alzheimer's Disease Progression. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13136.	1.8	20
1385	Physiological clearance of A β by spleen and splenectomy aggravates Alzheimer's type pathogenesis. <i>Aging Cell</i> , 2022, 21, e13533.	3.0	14
1386	Immunotherapy: An Approach to Treat Alzheimer's Disease and Autism Spectrum Disorder. , 2021, , 191-214.		1
1387	Neurotrophic fragments as therapeutic alternatives to ameliorate brain aging. <i>Neural Regeneration Research</i> , 2022, Publish Ahead of Print, 2215-2217.	1.6	3
1388	Application of predictive models in boosting power of Alzheimer's disease clinical trials: A post hoc analysis of phase 3 solanezumab trials. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, e12223.	1.8	3
1389	Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2022, 9, 197-210.	1.5	201
1390	Hope or hype? Aducanumab as a magic bullet for Alzheimer's disease. <i>BIO Integration</i> , 2022, 3, .	0.9	3
1391	Insights into the Mechanisms of Oligomerization/Fibrilization of Amyloid β Peptide from Nuclear Magnetic Resonance. <i>Seibutsu Butsuri</i> , 2022, 62, 39-42.	0.0	0
1392	DNA vaccines targeting amyloid- β oligomer ameliorate cognitive deficits of aged APP/PS1/tau triple-transgenic mouse models of Alzheimer's disease. <i>Neural Regeneration Research</i> , 2022, 17, 2305.	1.6	6
1393	Anodal transcranial direct current stimulation alleviates cognitive impairment in an APP/PS1 model of Alzheimer's disease in the preclinical stage. <i>Neural Regeneration Research</i> , 2022, 17, 2278.	1.6	5
1395	Principles of Pharmacology in Dementia. , 2022, , 15-29.		0
1396	New Perspectives for Treatment in Alzheimer's Disease. , 2022, , 199-225.		0
1398	Function and therapeutic value of astrocytes in neurological diseases. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 339-358.	21.5	160
1399	Emerging Electroencephalographic Biomarkers to Improve Preclinical to Clinical Translation in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 805063.	1.7	2
1400	Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2011.	1.8	22
1401	Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus. <i>Neurology</i> , 2022, 98, 619-631.	1.5	24

#	ARTICLE	IF	CITATIONS
1404	Efficacy of probucol on cognitive function in Alzheimer's disease: study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA study). <i>BMJ Open</i> , 2022, 12, e058826.	0.8	8
1405	Optogenetics: implications for Alzheimer's disease research and therapy. <i>Molecular Brain</i> , 2022, 15, 20.	1.3	14
1406	Physiological Considerations for Modeling in vivo Antibody-Target Interactions. <i>Frontiers in Pharmacology</i> , 2022, 13, 856961.	1.6	11
1407	A Machine Learning-Based Holistic Approach to Predict the Clinical Course of Patients within the Alzheimer's Disease Spectrum. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1639-1655.	1.2	7
1409	The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 306-318.	21.5	273
1410	Slowing Parkinson's Disease Progression with Vaccination and Other Immunotherapies. <i>CNS Drugs</i> , 2022, 36, 327-343.	2.7	6
1411	Knockdown of Amyloid Precursor Protein: Biological Consequences and Clinical Opportunities. <i>Frontiers in Neuroscience</i> , 2022, 16, 835645.	1.4	10
1412	Low-Dose Delta-9-Tetrahydrocannabinol as Beneficial Treatment for Aged APP/PS1 Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2757.	1.8	10
1413	Financing Alzheimer's Disease Drug Development. , 2022, , 465-479.		1
1414	Europium-Doped Cerium Oxide Nanoparticles for Microglial Amyloid Beta Clearance and Homeostasis. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1232-1244.	1.7	16
1415	Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer's disease with an implantable ultrasound device. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 40.	3.0	30
1416	Challenges and Approaches of Drugs Such as Memantine, Donepezil, Rivastigmine, and Aducanumab in the Treatment, Control and Management of Alzheimer's Disease. <i>Recent Patents on Biotechnology</i> , 2022, 16, 102-121.	0.4	13
1417	Mechanisms of Acupuncture in Improving Alzheimer's Disease Caused by Mitochondrial Damage. <i>Chinese Journal of Integrative Medicine</i> , 2022, 28, 272-280.	0.7	4
1418	Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease. <i>Therapeutic Innovation and Regulatory Science</i> , 2022, 56, 501-516.	0.8	11
1419	Aducanumab Therapy to Treat Alzheimer's Disease: A Narrative Review. <i>International Journal of Alzheimer's Disease</i> , 2022, 2022, 1-10.	1.1	25
1420	Translating pharmacology models effectively to predict therapeutic benefit. <i>Drug Discovery Today</i> , 2022, 27, 1604-1621.	3.2	2
1421	Alzheimer's Disease Drug Development: A Research and Development Ecosystem. , 2022, , 1-24.		2
1422	Iron Dysregulation in Mitochondrial Dysfunction and Alzheimer's Disease. <i>Antioxidants</i> , 2022, 11, 692.	2.2	30

#	ARTICLE	IF	CITATIONS
1424	The Importance of Phase 2 in Drug Development for Alzheimer's Disease. , 2022, , 150-161.		0
1425	Evidence for Enhanced Efficacy of Passive Immunotherapy against Beta-Amyloid in CD33-Negative 5xFAD Mice. <i>Biomolecules</i> , 2022, 12, 399.	1.8	1
1426	Current Status, Issues and Future Prospects of Personalized Medicine for Each Disease. <i>Journal of Personalized Medicine</i> , 2022, 12, 444.	1.1	21
1427	Reply to A Letter Concerning "Aducanumab: What About the Patient?", <i>Annals of Neurology</i> , 2022, 91, 733-734.	2.8	0
1428	Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 101-129.	1.2	31
1429	Peripheral Immune Cells and Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Pathology in Cognitively Intact Older Adults: The CABLE Study. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 721-730.	1.2	2
1430	Neurotechnological Approaches to the Diagnosis and Treatment of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2022, 16, 854992.	1.4	12
1431	The Role of M1- and M2-Type Macrophages in Neurological and Infectious Diseases. , 0, , .		1
1432	Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2022, 13, 862369.	1.1	43
1433	USP25 inhibition ameliorates Alzheimer's pathology through the regulation of APP processing and A β generation. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	21
1434	Drug Development for Alzheimer's Disease: An Historical Perspective. , 2022, , 25-33.		0
1436	From synapses to circuits and back: Bridging levels of understanding in animal models of Alzheimer's disease. <i>European Journal of Neuroscience</i> , 2022, 56, 5564-5586.	1.2	2
1437	Multiadducts of C60 Modulate Amyloid- β Fibrillation with Dual Acetylcholinesterase Inhibition and Antioxidant Properties: In Vitro and In Silico Studies. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 741-759.	1.2	1
1438	Personalized Management and Treatment of Alzheimer's Disease. <i>Life</i> , 2022, 12, 460.	1.1	4
1439	Brain Imaging for Alzheimer's Disease Clinical Trials. , 2022, , 375-394.		0
1440	β -Synuclein Radiotracer Development and <i>In Vivo</i> Imaging: Recent Advancements and New Perspectives. <i>Movement Disorders</i> , 2022, 37, 936-948.	2.2	24
1441	Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes. <i>Nature Reviews Neurology</i> , 2022, 18, 323-332.	4.9	29
1442	Valley of Death and the Role of Venture Philanthropy in Alzheimer's Disease Drug Development. , 2022, , 480-485.		0

#	ARTICLE	IF	CITATIONS
1443	Low Subicular Volume as an Indicator of Dementia-Risk Susceptibility in Old Age. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 811146.	1.7	5
1444	Accelerated decline in white matter microstructure in subsequently impaired older adults and its relationship with cognitive decline. <i>Brain Communications</i> , 2022, 4, fcac051.	1.5	16
1445	Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer's model. <i>ELife</i> , 2022, 11, .	2.8	6
1446	Role of Pharmacogenomics in Individualizing Treatment for Alzheimer's Disease. <i>CNS Drugs</i> , 2022, 36, 365-376.	2.7	6
1447	Phase 1 Trials in Alzheimer's Disease Drug Development. , 2022, , 135-149.		0
1449	CRISPR-Cas9 treatment partially restores amyloid- β 42/40 in human fibroblasts with the Alzheimer's disease PSEN1 M146L mutation. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 28, 450-461.	2.3	13
1450	Solving neurodegeneration: common mechanisms and strategies for new treatments. <i>Molecular Neurodegeneration</i> , 2022, 17, 23.	4.4	83
1452	Aducanumab na Doença de Alzheimer: Percurso e Perspetiva. , 2022, 8, 21-23.	0.1	0
1453	Immunotherapy for Alzheimer's disease: targeting β -amyloid and beyond. <i>Translational Neurodegeneration</i> , 2022, 11, 18.	3.6	75
1454	Preclinical Longitudinal In Vivo Biomarker Platform for Alzheimer's Disease Drug Discovery. , 2022, , 106-122.		0
1455	Development of Fluid Biomarkers for Alzheimer's Disease. , 2022, , 361-374.		0
1456	Use of Induced Pluripotent Stem Cell-Derived Neuronal Disease Models from Patients with Familial Early-Onset Alzheimer's Disease in Drug Discovery. , 2022, , 95-105.		0
1457	“Aducanumab” making a comeback in Alzheimer's disease: An old wine in a new bottle. <i>Biomedicine and Pharmacotherapy</i> , 2022, 148, 112746.	2.5	20
1458	β -Secretase in Alzheimer's disease. <i>Experimental and Molecular Medicine</i> , 2022, 54, 433-446.	3.2	67
1460	Comprehensive proteomic profiling of plasma and serum phosphatidylserine-positive extracellular vesicles reveals tissue-specific proteins. <i>IScience</i> , 2022, 25, 104012.	1.9	24
1461	Targeted protein degraders march towards the clinic for neurodegenerative diseases. <i>Ageing Research Reviews</i> , 2022, 78, 101616.	5.0	19
1462	Lights and Shadows of Cerebrospinal Fluid Biomarkers in the Current Alzheimer's Disease Framework. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1061-1072.	1.2	1
1463	Quantification of amyloid PET for future clinical use: a state-of-the-art review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3508-3528.	3.3	34

#	ARTICLE	IF	CITATIONS
1464	On the relationships between epilepsy, sleep, and Alzheimer's disease: A narrative review. <i>Epilepsy and Behavior</i> , 2022, 129, 108609.	0.9	8
1465	Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2022, 236, 114354.	2.6	10
1466	Targeting the M1 muscarinic acetylcholine receptor in Alzheimer's disease. <i>Neuronal Signaling</i> , 2022, 6, NS20210004.	1.7	14
1467	Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis. <i>Heart Failure Reviews</i> , 2022, 27, 2187-2200.	1.7	11
1468	The Role of Osteopontin in Microglia Biology: Current Concepts and Future Perspectives. <i>Biomedicines</i> , 2022, 10, 840.	1.4	30
1469	A Time-Event Exposure-Response Model for Amyloid-Related Imaging Abnormalities Following Administration of Aducanumab to Subjects With Early Alzheimer Disease. <i>Journal of Clinical Pharmacology</i> , 2022, , .	1.0	3
1470	Genetic obstacles to developing and tolerizing human B cells. <i>WIREs Mechanisms of Disease</i> , 2022, 14, e1554.	1.5	1
1471	Microglial Endocannabinoid Signalling in AD. <i>Cells</i> , 2022, 11, 1237.	1.8	8
1472	Sleep apnea and the risk of dementia: A systematic review and meta-analysis. <i>Journal of Sleep Research</i> , 2022, 31, e13589.	1.7	16
1473	Theranostic F-SLOH mitigates Alzheimer's disease pathology involving TFEB and ameliorates cognitive functions in Alzheimer's disease models. <i>Redox Biology</i> , 2022, 51, 102280.	3.9	41
1474	Blood-brain barrier delivery for lysosomal storage disorders with IgG-lysosomal enzyme fusion proteins. <i>Advanced Drug Delivery Reviews</i> , 2022, 184, 114234.	6.6	21
1475	Antroquinonol administration in animal preclinical studies for Alzheimer's disease (AD): A new avenue for modifying progression of AD pathophysiology. <i>Brain, Behavior, & Immunity - Health</i> , 2022, 21, 100435.	1.3	3
1476	Immunotherapeutic Approaches for the Treatment of Neurodegenerative Diseases: Challenges and Outcomes. <i>CNS and Neurological Disorders - Drug Targets</i> , 2021, 21, .	0.8	0
1477	Associations of TFEB Gene Polymorphisms With Cognitive Function in Rural Chinese Population. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 757992.	1.7	2
1478	China Registry Study on Cognitive Impairment in the Elderly: Protocol of a Prospective Cohort Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 797704.	1.7	2
1479	A Case of Possible Chronic Traumatic Encephalopathy and Alzheimer's Disease in an Ex-Football Player. <i>Neurologist</i> , 2021, Publish Ahead of Print, .	0.4	1
1480	Apolipoprotein E Polymorphism, Cardiac Remodeling, and Heart Failure in the ARIC Study. <i>Journal of Cardiac Failure</i> , 2022, 28, 1128-1136.	0.7	2
1481	Perspectives on the <i>Pseudomonas aeruginosa</i> Type III Secretion System Effector ExoU and Its Subversion of the Host Innate Immune Response to Infection. <i>Toxins</i> , 2021, 13, 880.	1.5	10

#	ARTICLE	IF	CITATIONS
1482	Next-generation antibody-based therapies in neurology. <i>Brain</i> , 2022, 145, 1229-1241.	3.7	11
1483	Tieguanyin Oolong Tea Extracts Alleviate Behavioral Abnormalities by Modulating Neuroinflammation in APP/PS1 Mouse Model of Alzheimer's Disease. <i>Foods</i> , 2022, 11, 81.	1.9	7
1484	Potential Roles of β -amylase in Alzheimer's Disease: Biomarker and Drug Target. <i>Current Neuropharmacology</i> , 2022, 20, 1554-1563.	1.4	3
1485	What have we learned from past failures of investigational drugs for Alzheimer's disease?. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 1175-1182.	1.9	13
1487	Research Strategy of Anti-Transferrin Receptor Antibody Targeting Intracerebral Drug Delivery. <i>Pharmacy Information</i> , 2022, 11, 137-145.	0.1	0
1488	White matter hyperintensities and longitudinal cognitive decline in cognitively normal populations and across diagnostic categories: A meta-analysis, systematic review, and recommendations for future study harmonization. <i>Alzheimer's and Dementia</i> , 2023, 19, 194-207.	0.4	22
1489	Transcriptomic mapping of the human cerebrovasculature. <i>Nature Reviews Neurology</i> , 2022, 18, 319-320.	4.9	3
1490	AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System. <i>Frontiers in Neurology</i> , 2022, 13, 870799.	1.1	4
1491	Lipid-Based Nanocarriers for Neurological Disorders: A Review of the State-of-the-Art and Therapeutic Success to Date. <i>Pharmaceutics</i> , 2022, 14, 836.	2.0	18
1492	Recent Advances in the Treatment of Alzheimer's Disease Using Nanoparticle-Based Drug Delivery Systems. <i>Pharmaceutics</i> , 2022, 14, 835.	2.0	30
1493	Therapeutic effects of thymoquinone on Alzheimer's disease through modulating amyloid beta neurotoxicity and neuro-inflammatory cytokine levels. <i>CNS and Neurological Disorders - Drug Targets</i> , 2022, 21, .	0.8	3
1494	Impact of Anti-amyloid- β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 870517.	1.7	91
1496	Gut Microbiota as a Hidden Player in the Pathogenesis of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 86, 1501-1526.	1.2	9
1497	Neuroprotective Effects of PARP Inhibitors in Drosophila Models of Alzheimer's Disease. <i>Cells</i> , 2022, 11, 1284.	1.8	9
1517	Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers. <i>Neurotherapeutics</i> , 2022, 19, 209-227.	2.1	36
1518	FDA's dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps. <i>BMJ Evidence-Based Medicine</i> , 2023, 28, 78-82.	1.7	2
1520	Glucose Metabolism is a Better Marker for Predicting Clinical Alzheimer's Disease than Amyloid or Tau.. <i>Journal of Cellular Immunology</i> , 2022, 4, 15-18.	0.8	0
1521	The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report. <i>Journal of prevention of Alzheimer's disease</i> , The, 0, , .	1.5	7

#	ARTICLE	IF	CITATIONS
1523	Cognitive and physical benefits of a game-like dual-task exercise among the oldest nursing home residents in Japan. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, e12276.	1.8	2
1524	PET Imaging of Amyloid and Tau in Alzheimer's Disease. , 2022, , 307-323.		2
1525	Executive Summary of the 2021 International Conference of Korean Dementia Association: A Report From the Academic Committee of the Korean Dementia Association. <i>Dementia and Neurocognitive Disorders</i> , 2022, 21, 45.	0.4	0
1526	Polymer Features in Crystallization. <i>Chinese Journal of Polymer Science (English Edition)</i> , 2022, 40, 545-555.	2.0	28
1527	Commentary: Diagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 895398.	1.7	0
1528	Correlation Between Brain Structure Atrophy and Plasma Amyloid- β^2 and Phosphorylated Tau in Patients With Alzheimer's Disease and Amnesic Mild Cognitive Impairment Explored by Surface-Based Morphometry. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 816043.	1.7	10
1529	Therapeutic news in Alzheimer's disease: Soon a disease-modifying therapy?. <i>Revue Neurologique</i> , 2022, 178, 437-440.	0.6	8
1530	Functional Imaging for Neurodegenerative Diseases. <i>Presse Medicale</i> , 2022, 51, 104121.	0.8	3
1531	Spinal Cord Injury Causes Prominent Tau Pathology Associated with Brain Post-Injury Sequela. <i>Molecular Neurobiology</i> , 2022, 59, 4197-4208.	1.9	2
1532	ACU193: An Immunotherapeutic Poised to Test the Amyloid β^2 Oligomer Hypothesis of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2022, 16, 848215.	1.4	17
1533	Sepsis-associated brain injury: underlying mechanisms and potential therapeutic strategies for acute and long-term cognitive impairments. <i>Journal of Neuroinflammation</i> , 2022, 19, 101.	3.1	31
1534	Amyloid-beta targeted therapeutic approaches for Alzheimer's disease: long road ahead. <i>Current Drug Targets</i> , 2022, 23, .	1.0	6
1535	The Influence of Selected Antipsychotic Drugs on Biochemical Aspects of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4621.	1.8	1
1536	PET Imaging in Preclinical Anti-A β^2 Drug Development. <i>Pharmaceutical Research</i> , 2022, 39, 1481-1496.	1.7	7
1537	Transferrin Receptor Binding BBB-Shuttle Facilitates Brain Delivery of Anti-A β^2 -Affibodies. <i>Pharmaceutical Research</i> , 2022, , 1.	1.7	1
1538	Structure-based discovery and development of novel O-GlcNAcase inhibitors for the treatment of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114444.	2.6	8
1539	Investigating the Association Between Polygenic Risk Scores for Alzheimer's Disease With Cognitive Performance and Intrinsic Functional Connectivity in Healthy Adults. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, .	1.7	0
1540	Impact of cerebral blood flow and amyloid load on SUVR bias. <i>EJNMMI Research</i> , 2022, 12, 29.	1.1	6

#	ARTICLE	IF	CITATIONS
1541	Conditioned medium from amniotic fluid mesenchymal stem cells could modulate Alzheimer's disease-like changes in human neuroblastoma cell line SY-SY5Y in a paracrine manner. <i>Tissue and Cell</i> , 2022, 76, 101808.	1.0	2
1542	New A β (1-42) ligands from anti-amyloid antibodies: Design, synthesis, and structural interaction. <i>European Journal of Medicinal Chemistry</i> , 2022, 237, 114400.	2.6	7
1543	Food for Memory: A Review of the Effects of Diet on Alzheimer's Disease Progression. <i>Journal of Student Research</i> , 2021, 10, .	0.0	0
1544	Amyloid- β Oligomers: Multiple Moving Targets. <i>Biophysica</i> , 2022, 2, 91-110.	0.6	17
1545	Natural medicine HLXL targets multiple pathways of amyloid-mediated neuroinflammation and immune response in treating alzheimer's disease. <i>Phytomedicine</i> , 2022, 104, 154158.	2.3	2
1546	Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 67.	3.0	18
1547	Alzheimer disease neuropathology in a patient previously treated with aducanumab. <i>Acta Neuropathologica</i> , 2022, 144, 143-153.	3.9	18
1548	An aggregation inhibitor specific to oligomeric intermediates of A β 42 derived from phage display libraries of stable, small proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2121966119.	3.3	5
1549	Aptamer-Induced-Dimerization Strategy Attenuates A β O Toxicity through Modulating the Trophic Activity of PrP ^C Signaling. <i>Journal of the American Chemical Society</i> , 2022, 144, 9264-9270.	6.6	11
1554	Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities. <i>Clinical Interventions in Aging</i> , 0, Volume 17, 797-810.	1.3	59
1556	Shared pathophysiology: Understanding stroke and Alzheimer's disease. <i>Clinical Neurology and Neurosurgery</i> , 2022, 218, 107306.	0.6	9
1557	Neuroprotective, Neurite Enhancing and Cholinesterase Inhibitory Effects of Lamiaceae Family Essential Oils in Alzheimer's Disease Model. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1558	Unfolded p53 in non-neuronal cells supports bacterial etiology of Alzheimer's disease. <i>Neural Regeneration Research</i> , 2022, 17, 2619.	1.6	2
1559	Identifying candidate genes and drug targets for Alzheimer's disease by an integrative network approach using genetic and brain region-specific proteomic data. <i>Human Molecular Genetics</i> , 2022, 31, 3341-3354.	1.4	3
1560	Increasing Brain Gamma Activity Improves Episodic Memory and Restores Cholinergic Dysfunction in Alzheimer's Disease. <i>Annals of Neurology</i> , 2022, 92, 322-334.	2.8	38
1561	Influence of Cortisol on the Fibril Formation Kinetics of A β 42 Peptide: A Multi-Technical Approach. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6007.	1.8	0
1562	Anti-Amyloid- β Immunotherapy: A Leading Novel Avenue for Alzheimer's Disease. <i>Mini-Reviews in Medicinal Chemistry</i> , 2022, 22, .	1.1	0
1563	Functional and Phenotypic Diversity of Microglia: Implication for Microglia-Based Therapies for Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	15

#	ARTICLE	IF	CITATIONS
1564	Therapeutic Approach to Alzheimer's Disease: Current Treatments and New Perspectives. <i>Pharmaceutics</i> , 2022, 14, 1117.	2.0	62
1565	Effects of Interventions on Cerebral Perfusion in the Alzheimer's Disease Spectrum: A Systematic Review. <i>Ageing Research Reviews</i> , 2022, , 101661.	5.0	5
1566	A comparison of advanced semi-quantitative amyloid PET analysis methods. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4097-4108.	3.3	4
1567	Casein Kinase 1 and Human Disease: Insights From the Circadian Phosphoswitch. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, .	1.6	3
1568	The role and therapeutic implication of protein tyrosine phosphatases in Alzheimer's disease. <i>Biomedicine and Pharmacotherapy</i> , 2022, 151, 113188.	2.5	6
1569	In silico exploration of amyloid-related imaging abnormalities in the gantenerumab open-label extension trials using a semi-mechanistic model. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2022, 8, .	1.8	5
1570	Physiological Roles of Monomeric Amyloid- β and Implications for Alzheimer's Disease Therapeutics. <i>Experimental Neurobiology</i> , 2022, 31, 65-88.	0.7	21
1571	Neuroimmune contributions to Alzheimer's disease: a focus on human data. <i>Molecular Psychiatry</i> , 2022, 27, 3164-3181.	4.1	20
1572	Multimodal deep learning for Alzheimer's disease dementia assessment. <i>Nature Communications</i> , 2022, 13, .	5.8	65
1573	HSP10 as a Chaperone for Neurodegenerative Amyloid Fibrils. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	2
1574	Photo-Oxygenation as a New Therapeutic Strategy for Neurodegenerative Proteinopathies by Enhancing the Clearance of Amyloid Proteins. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	4
1575	p38 MAPK Is a Major Regulator of Amyloid Beta-Induced IL-6 Expression in Human Microglia. <i>Molecular Neurobiology</i> , 2022, 59, 5284-5298.	1.9	7
1576	Therapeutic potential for amyloid surface inhibitor: only amyloid- β oligomers formed by secondary nucleation disrupt lipid membrane integrity. <i>FEBS Journal</i> , 2022, 289, 6767-6781.	2.2	7
1577	Alzheimer Disease. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2022, 28, 648-675.	0.4	6
1578	Is Aducanumab a Miracle Drug?. <i>Journal of Student Research</i> , 2021, 10, .	0.0	0
1579	Current peptide vaccine and immunotherapy approaches against Alzheimer's disease. <i>Peptide Science</i> , 2023, 115, .	1.0	8
1580	Brain Cell Type-Specific Nuclear Proteomics Is Imperative to Resolve Neurodegenerative Disease Mechanisms. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	4
1581	A Historical Review of Brain Drug Delivery. <i>Pharmaceutics</i> , 2022, 14, 1283.	2.0	65

#	ARTICLE	IF	CITATIONS
1582	Ganglioside Nanocluster-Targeting Peptidyl Inhibitor Prevents Amyloid β Fibril Formation on the Neuronal Membrane. <i>ACS Chemical Neuroscience</i> , 2022, 13, 1868-1876.	1.7	5
1583	In silico design of a TLR4-mediated multi-epitope chimeric vaccine against amyotrophic lateral sclerosis via advanced immunoinformatics. <i>Journal of Leukocyte Biology</i> , 0, , .	1.5	11
1584	SNMMI Clinical Trials Network Research Series for Technologists: Clinical Research Primer—Use of Imaging Agents in Therapeutic Drug Development and Approval. <i>Journal of Nuclear Medicine Technology</i> , 2022, 50, 291-300.	0.4	2
1585	Mouse Models of Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 0, 15, .	1.4	50
1586	Identification of sulfonamide-based butyrylcholinesterase inhibitors using machine learning. <i>Future Medicinal Chemistry</i> , 2022, 14, 1049-1070.	1.1	2
1587	Staging of Alzheimer's disease: past, present, and future perspectives. <i>Trends in Molecular Medicine</i> , 2022, 28, 726-741.	3.5	36
1588	Preventive pharmacological treatment in subjects at risk for fatal familial insomnia: science and public engagement. <i>Prion</i> , 2022, 16, 66-77.	0.9	3
1590	The dense-core plaques of Alzheimer's disease are granulomas. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	15
1591	A Novel Explainability Approach for Technology-Driven Translational Research on Brain Aging. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-11.	1.2	2
1592	Overview of therapeutic targets in management of dementia. <i>Biomedicine and Pharmacotherapy</i> , 2022, 152, 113168.	2.5	15
1593	Molecular insights into the very early steps of $A\beta$ 1-42 pentameric protofibril disassembly by PGG: A molecular dynamics simulation study. <i>Journal of Molecular Liquids</i> , 2022, 361, 119638.	2.3	5
1594	Promising Blood Biomarkers for Clinical Use in Alzheimer's Disease: A Focused Update. <i>Journal of</i>		

#	ARTICLE	IF	CITATIONS
1602	Aducanumab: A new hope in Alzheimer's disease. <i>Health Sciences Review</i> , 2022, 4, 100039.	0.6	7
1603	Insights for Alzheimer's disease pharmacotherapy and current clinical trials. <i>Neurochemistry International</i> , 2022, 159, 105401.	1.9	5
1604	Multiscale optical and optoacoustic imaging of amyloid- β^2 deposits in mice. <i>Nature Biomedical Engineering</i> , 2022, 6, 1031-1044.	11.6	39
1607	Reducing fibrosis progression of biliary atresia by continuous administration of aducanumab at low dose: A potential treatment. <i>Medical Hypotheses</i> , 2022, 165, 110901.	0.8	0
1608	Dynamic observations of various oligomers in amyloid β^2 isoforms using laboratory diffracted X-ray blinking. <i>Biochemistry and Biophysics Reports</i> , 2022, 31, 101298.	0.7	2
1609	Targeting gut microbiota to alleviate neuroinflammation in Alzheimer's disease. <i>Advanced Drug Delivery Reviews</i> , 2022, 188, 114418.	6.6	16
1610	Mathematical model of Alzheimer's disease with prion proteins interactions and treatment. <i>Applied Mathematics and Computation</i> , 2022, 433, 127377.	1.4	4
1611	Genetic inhibition of PDK1 robustly reduces plaque deposition and ameliorates gliosis in the 5 β -FAD mouse model of Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	2
1612	If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?. <i>PLoS Biology</i> , 2022, 20, e3001694.	2.6	67
1613	Non-Invasive Nasal Discharge Fluid and Other Body Fluid Biomarkers in Alzheimer's Disease. <i>Pharmaceutics</i> , 2022, 14, 1532.	2.0	3
1614	Photodynamic Alzheimer's disease therapy: From molecular catalysis to photo-nanomedicine. <i>Coordination Chemistry Reviews</i> , 2022, 470, 214726.	9.5	12
1615	Capillary Dysfunction Correlates with Cortical Amyloid Load in Early Alzheimer's Disease. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1616	Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment. <i>JAMA Neurology</i> , 2022, 79, 975.	4.5	36
1617	Effects of Aducanumab on treating Alzheimer's disease: targets and clinical trials. , 0, 6, 292-301.		0
1618	Oxidative Stress: Glutathione and Its Potential to Protect Methionine-35 of A β^2 Peptide from Oxidation. <i>ACS Omega</i> , 2022, 7, 27052-27061.	1.6	19
1619	Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer's Disease: A comprehensive review. <i>Health Psychology Research</i> , 2022, 10, .	0.6	4
1620	Alzheimer's and Parkinson's disease therapies in the clinic. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	37
1621	Moxifloxacin Disrupts and Attenuates A β^2 Fibril and Oligomer Formation: Plausibly Repositioning an Antibiotic as Therapeutic against Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2022, 13, 2529-2539.	1.7	5

#	ARTICLE	IF	CITATIONS
1622	<i>N</i> -Benzyl Benzamide Derivatives as Selective Sub-Nanomolar Butyrylcholinesterase Inhibitors for Possible Treatment in Advanced Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 11365-11387.	2.9	14
1623	Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer's disease: Current trends and future perspectives. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	16
1624	Farnesyltransferase inhibitor LNK-754 attenuates axonal dystrophy and reduces amyloid pathology in mice. <i>Molecular Neurodegeneration</i> , 2022, 17, .	4.4	5
1625	Direct Oral Anticoagulants (DOACs) for Therapeutic Targeting of Thrombin, a Key Mediator of Cerebrovascular and Neuronal Dysfunction in Alzheimer's Disease. <i>Biomedicines</i> , 2022, 10, 1890.	1.4	9
1626	Multi-task longitudinal forecasting with missing values on Alzheimer's disease. <i>Computer Methods and Programs in Biomedicine</i> , 2022, 226, 107056.	2.6	2
1627	Anti-inflammatory clearance of amyloid- β by a chimeric Gas6 fusion protein. <i>Nature Medicine</i> , 2022, 28, 1802-1812.	15.2	26
1628	Using Alzheimer's disease blood tests to accelerate clinical trial enrollment. <i>Alzheimer's and Dementia</i> , 2023, 19, 1175-1183.	0.4	7
1629	Elevated Levels of Naturally-Occurring Autoantibodies Against the Extracellular Domain of p75NTR Aggravate the Pathology of Alzheimer's Disease. <i>Neuroscience Bulletin</i> , 0, , .	1.5	1
1630	Amyloid-Related Imaging Abnormalities with Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for Clinical Practice. <i>American Journal of Neuroradiology</i> , 2022, 43, E19-E35.	1.2	31
1632	Discovery and engineering of an anti-TREM2 antibody to promote amyloid plaque clearance by microglia in 5XFAD mice. <i>MAbs</i> , 2022, 14, .	2.6	5
1633	Historical efforts to develop ^{99m}Tc -based amyloid plaque targeting radiotracers. <i>Frontiers in Nuclear Medicine</i> , 0, 2, .	0.7	1
1634	Modulation of ligand-gated glycine receptors via functional monoclonal antibodies. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 0, , JPET-AR-2021-001026.	1.3	0
1635	Association of Microglial Activation With Spontaneous ARIA-E and CSF Levels of Anti- $\text{A}\beta$ Autoantibodies. <i>Neurology</i> , 2022, 99, .	1.5	17
1636	Temporal and Sex-Linked Protein Expression Dynamics in a Familial Model of Alzheimer's Disease. <i>Molecular and Cellular Proteomics</i> , 2022, 21, 100280.	2.5	8
1637	Chiral Nanoparticles Force Neural Stem Cell Differentiation to Alleviate Alzheimer's Disease. <i>Advanced Science</i> , 2022, 9, .	5.6	26
1638	Kinetic and structural studies on the inhibition of acetylcholinesterase and butyrylcholinesterase by a series of multitarget-directed galantamine-peptide derivatives. <i>Chemico-Biological Interactions</i> , 2022, 365, 110092.	1.7	6
1639	Update on new trend and progress of the mechanism of polysaccharides in the intervention of Alzheimer's disease, based on the new understanding of relevant theories: A review. <i>International Journal of Biological Macromolecules</i> , 2022, 218, 720-738.	3.6	9
1640	Alzheimer's disease failed clinical trials. <i>Life Sciences</i> , 2022, 306, 120861.	2.0	42

#	ARTICLE	IF	CITATIONS
1641	Comparative efficacy of lithium and aducanumab for cognitive decline in patients with mild cognitive impairment or Alzheimer's disease: A systematic review and network meta-analysis. <i>Ageing Research Reviews</i> , 2022, 81, 101709.	5.0	17
1642	Design, synthesis and structure-activity relationship studies of 3-phenylpyrazino[1,2-a]indol-1(2H)-ones as amyloid aggregation and cholinesterase inhibitors with antioxidant activity. <i>European Journal of Medicinal Chemistry Reports</i> , 2022, 6, 100075.	0.6	1
1643	Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases. <i>Journal of Neuroinflammation</i> , 2022, 19, .	3.1	32
1646	Ultrasound-mediated blood-brain barrier opening: An effective drug delivery system for theranostics of brain diseases. <i>Advanced Drug Delivery Reviews</i> , 2022, 190, 114539.	6.6	34
1647	Recent advance on pleiotropic cholinesterase inhibitors bearing amyloid modulation efficacy. <i>European Journal of Medicinal Chemistry</i> , 2022, 242, 114695.	2.6	8
1648	Active immunotherapy against pathogenic Cis pT231-tau suppresses neurodegeneration in traumatic brain injury mouse models. <i>Neuropeptides</i> , 2022, 96, 102285.	0.9	3
1649	Effects of dose change on the success of clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2022, 30, 100988.	0.5	4
1650	Impact of aging on the central nervous system: Approaches for antiaging. , 2023, , 403-412.		0
1651	Promotion in the Clearance of Aggregated A β In Vivo Using Amyloid Selective Photo-Oxygenation Technology. <i>Neuroscience Insights</i> , 2022, 17, 263310552211261.	0.9	1
1652	A sporadic Alzheimer's blood-brain barrier model for developing ultrasound-mediated delivery of Aducanumab and anti-Tau antibodies. <i>Theranostics</i> , 2022, 12, 6826-6847.	4.6	18
1653	Therapeutic nanosweepers promote β -amyloid removal from the brain for Alzheimer's disease treatment. <i>Biomaterials Science</i> , 2022, 10, 6525-6534.	2.6	4
1654	Pharmacogenomics of Alzheimer's Disease: Novel Strategies for Drug Utilization and Development. <i>Methods in Molecular Biology</i> , 2022, , 275-387.	0.4	4
1655	Polypharmacology in Clinical Applications: Neurological Polypharmacology. , 2022, , 231-269.		0
1656	Free-standing vertically aligned tin disulfide nanosheets for ultrasensitive aptasensor design toward Alzheimer's diagnosis applications. <i>Chemical Engineering Journal</i> , 2023, 452, 139394.	6.6	10
1657	A Novel C-Type Lectin Receptor-Targeted β -Synuclein-Based Parkinson Vaccine Induces Potent Immune Responses and Therapeutic Efficacy in Mice. <i>Vaccines</i> , 2022, 10, 1432.	2.1	2
1659	The emerging neuroprotective roles of exerkines in Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	11
1660	Effect of reduction in brain amyloid levels on change in cognitive and functional decline in randomized clinical trials: An instrumental variable meta-analysis. <i>Alzheimer's and Dementia</i> , 2023, 19, 1292-1299.	0.4	5
1661	High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects. <i>Revue Neurologique</i> , 2022, 178, 1011-1030.	0.6	40

#	ARTICLE	IF	CITATIONS
1662	Toward inflammation-free therapeutics in Alzheimer's disease. <i>Nature Medicine</i> , 2022, 28, 1765-1766.	15.2	1
1663	Safety and efficacy of plasma transfusion from exercise-trained donors in patients with early Alzheimer's disease: protocol for the ExPlas study. <i>BMJ Open</i> , 2022, 12, e056964.	0.8	2
1664	The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification. <i>Journal of Nuclear Medicine</i> , 0, , jnumed.122.264031.	2.8	4
1665	Recent Advances in Psychopharmacology. <i>Advances in Psychiatry and Behavioral Health</i> , 2022, 2, 253-266.	0.4	0
1666	Immunotherapies for Alzheimer's Disease—A Review. <i>Vaccines</i> , 2022, 10, 1527.	2.1	12
1667	CX3CL1 Derived from Bone Marrow Mesenchymal Stem Cells Inhibits A β 1-42-Induced SH-SY5Y Cell Pathological Damage through TXNIP/NLRP3 Signaling Pathway. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-12.	0.7	2
1669	Protein condensation diseases: therapeutic opportunities. <i>Nature Communications</i> , 2022, 13, .	5.8	38
1670	A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer's disease. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	33
1671	The Immune System as a Therapeutic Target for Alzheimer's Disease. <i>Life</i> , 2022, 12, 1440.	1.1	6
1672	The Therapeutic Potential of Restoring Gamma Oscillations in Alzheimer's Disease. <i>Advances in Psychiatry and Behavioral Health</i> , 2022, 2, 47-55.	0.4	2
1673	Clinical relevance of biomarkers, new therapeutic approaches, and role of post-translational modifications in the pathogenesis of Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	4
1674	Optimal anti-amyloid-beta therapy for Alzheimer's disease via a personalized mathematical model. <i>PLoS Computational Biology</i> , 2022, 18, e1010481.	1.5	8
1675	Aducanumab: a review of the first approved amyloid-targeting antibody for Alzheimer's disease. <i>Drugs and Therapy Perspectives</i> , 2022, 38, 443-454.	0.3	2
1676	Amyloid-Related Imaging Abnormalities in the <sc>DIAN</sc> Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease. <i>Annals of Neurology</i> , 2022, 92, 729-744.	2.8	8
1677	Interactions of Curcumin Degradation Products with the A β ₄₂ Dimer: A Computational Study. <i>Journal of Physical Chemistry B</i> , 2022, 126, 7627-7637.	1.2	4
1678	Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective. <i>Neurotherapeutics</i> , 2022, 19, 1489-1502.	2.1	12
1679	Communicating and Using Dementia Risk Evidence. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 933-944.	1.2	2
1681	Correlative Chemical Imaging Identifies Amyloid Peptide Signatures of Neuritic Plaques and Dystrophy in Human Sporadic Alzheimer's Disease. <i>Brain Connectivity</i> , 0, , .	0.8	3

#	ARTICLE	IF	CITATIONS
1683	Proteinopathies: Deciphering Physiology and Mechanisms to Develop Effective Therapies for Neurodegenerative Diseases. <i>Molecular Neurobiology</i> , 2022, 59, 7513-7540.	1.9	5
1684	Inhibition of Amyloid- β^2 Aggregation by p-Terphenyls from the Mushroom <i>Polyozellus multiplex</i> and Their Neuroprotective Effects. <i>Heterocycles</i> , 2022, 104, 2025.	0.4	1
1685	Big dynorphin is a neuroprotector scaffold against amyloid β^2 -peptide aggregation and cell toxicity. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 5672-5679.	1.9	7
1686	Seeding, maturation and propagation of amyloid β^2 -peptide aggregates in Alzheimer's disease. <i>Brain</i> , 2022, 145, 3558-3570.	3.7	6
1687	Early Memory Impairment is Accompanied by Changes in GluA1/ p-GluA1 in APP/PS1 Mice. <i>Current Alzheimer Research</i> , 2022, 19, 667-673.	0.7	1
1688	Implications of Microorganisms in Alzheimer's Disease. <i>Current Issues in Molecular Biology</i> , 2022, 44, 4584-4615.	1.0	11
1689	The role of the adaptive immune system and T cell dysfunction in neurodegenerative diseases. <i>Journal of Neuroinflammation</i> , 2022, 19, .	3.1	29
1690	White Blood Cell and Platelet Counts Are Not Suitable as Biomarkers in the Differential Diagnostics of Dementia. <i>Brain Sciences</i> , 2022, 12, 1424.	1.1	5
1691	Advances in the roles and mechanisms of lignans against Alzheimer's disease. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
1692	Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 62-73.	1.3	7
1693	Monte Carlo cross-validation for a study with binary outcome and limited sample size. <i>BMC Medical Informatics and Decision Making</i> , 2022, 22, .	1.5	10
1694	Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis. <i>Med</i> , 2022, 3, 860-882.e15.	2.2	21
1695	Pyrazoline Containing Compounds as Therapeutic Targets for Neurodegenerative Disorders. <i>ACS Omega</i> , 2022, 7, 38207-38245.	1.6	16
1696	N-terminal Domain of Amyloid- β^2 Impacts Fibrillation and Neurotoxicity. <i>ACS Omega</i> , 2022, 7, 38847-38855.	1.6	3
1697	Review of Advanced Drug Trials Focusing on the Reduction of Brain Beta-Amyloid to Prevent and Treat Dementia. <i>Journal of Experimental Pharmacology</i> , 0, Volume 14, 331-352.	1.5	8
1698	Lecanemab, Aducanumab, and Gantenerumab's Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease. <i>Neurotherapeutics</i> , 2023, 20, 195-206.	2.1	104
1699	Rational design of photoactivatable metal complexes to target and modulate amyloid- β^2 peptides. <i>Journal of Inorganic Biochemistry</i> , 2023, 238, 112053.	1.5	2
1700	Amyloid PET: A Questionable Single Primary Surrogate Efficacy Measure on Alzheimer Immunotherapy Trials. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 1395-1399.	1.2	7

#	ARTICLE	IF	CITATIONS
1701	Gossypetin ameliorates 5xFAD spatial learning and memory through enhanced phagocytosis against A β . <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	3
1702	Vascular Considerations for Amyloid Immunotherapy. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 709-719.	2.0	3
1703	The industrial genomic revolution: A new era in neuroimmunology. <i>Neuron</i> , 2022, 110, 3429-3443.	3.8	2
1704	Fast and Accurate Amyloid Brain PET Quantification Without MRI Using Deep Neural Networks. <i>Journal of Nuclear Medicine</i> , 2023, 64, 659-666.	2.8	1
1705	Unravelling the relationship between amyloid accumulation and brain network function in normal aging and very mild cognitive decline: a longitudinal analysis. <i>Brain Communications</i> , 2022, 4, .	1.5	3
1706	A Therapeutic Nanovaccine that Generates Anti-Amyloid Antibodies and Amyloid-specific Regulatory T Cells for Alzheimer's Disease. <i>Advanced Materials</i> , 2023, 35, .	11.1	17
1707	Guanidine-based β amyloid precursor protein cleavage enzyme 1 (BACE-1) inhibitors for the Alzheimer's disease (AD): A review. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 74, 117047.	1.4	11
1708	Suppression of amyloid- β fibril growth by drug-engineered polymorph transformation. <i>Journal of Biological Chemistry</i> , 2022, 298, 102662.	1.6	1
1709	VStore: Feasibility and acceptability of a novel virtual reality functional cognition task. <i>Frontiers in Virtual Reality</i> , 0, 3, .	2.5	0
1710	Amyloid-Related Imaging Abnormalities: An Update. <i>American Journal of Roentgenology</i> , 2023, 220, 562-574.	1.0	16
1711	Electrochemiluminescence monitoring the interaction between human serum albumin and amyloid- β peptide. <i>Bioelectrochemistry</i> , 2023, 149, 108315.	2.4	3
1712	Biologics for the management of dementia. , 2023, , 193-234.		0
1713	New Possibilities in the Therapeutic Approach to Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8902.	1.8	14
1714	Anti-dementia Medications and Anti-Alzheimer's Disease Drugs: Side Effects, Contraindications, and Interactions. , 2022, , 2779-2788.		0
1715	Anti-dementia Medications: Classification, Indications, and Differential Indications. , 2022, , 2637-2647.		0
1716	Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report. <i>Radiology Case Reports</i> , 2023, 18, 275-279.	0.2	3
1717	My Experimental Life. , 2023, , 83-90.		0
1718	Polyunsaturated Fatty Acids Mend Macrophage Transcriptome, Glycome, and Phenotype in the Patients with Neurodegenerative Diseases, Including Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2023, 91, 245-261.	1.2	1

#	ARTICLE	IF	CITATIONS
1719	Toward the end of a controversy on the effect of reduction in brain amyloid levels on change in cognitive and functional decline in Alzheimer's disease—Reply to a letter. <i>Alzheimer's and Dementia</i> , 0, , .	0.4	0
1720	AAV-mediated neuronal expression of an scFv antibody selective for A β oligomers protects synapses and rescues memory in Alzheimer models. <i>Molecular Therapy</i> , 2023, 31, 409-419.	3.7	3
1721	Protein conformation characterization via a silicon resonator-based optical sensor based on the combination of wavelength interrogation and dual polarization detection. <i>Optics Express</i> , 2022, 30, 44472.	1.7	1
1722	Amyloid- β and the Risk of Heart Failure. <i>JACC: Heart Failure</i> , 2023, 11, 103-105.	1.9	2
1724	Novel Uracil-Based Inhibitors of Acetylcholinesterase with Potency for Treating Memory Impairment in an Animal Model of Alzheimer's Disease. <i>Molecules</i> , 2022, 27, 7855.	1.7	2
1725	ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. <i>Molecular Neurodegeneration</i> , 2022, 17, .	4.4	97
1726	Whole-brain microscopy reveals distinct temporal and spatial efficacy of anti-A β therapies. <i>EMBO Molecular Medicine</i> , 0, , .	3.3	4
1727	Multiple Actions of H ₂ S-Releasing Peptides in Human β -Amyloid Expressing <i>C. elegans</i> . <i>ACS Chemical Neuroscience</i> , 2022, 13, 3378-3388.	1.7	6
1728	Therapeutic Potential of Targeting Mitochondria for Alzheimer's Disease Treatment. <i>Journal of Clinical Medicine</i> , 2022, 11, 6742.	1.0	5
1730	Engineering antibody and protein therapeutics to cross the blood-brain barrier. <i>Antibody Therapeutics</i> , 2022, 5, 311-331.	1.2	4
1731	Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome. <i>Annals of Neurology</i> , 2023, 93, 604-614.	2.8	27
1733	Current understanding of metal-dependent amyloid- β aggregation and toxicity. <i>RSC Chemical Biology</i> , 2023, 4, 121-131.	2.0	7
1734	Combinatorial screening for therapeutics in ATTRv amyloidosis identifies naphthoquinone analogues as TTR-selective amyloid disruptors. <i>Journal of Pharmacological Sciences</i> , 2023, 151, 54-62.	1.1	0
1735	Current mouse models of Alzheimer's disease for investigating therapeutic agents. , 2023, , 31-41.		0
1736	Borneol-driven meningeal lymphatic drainage clears amyloid- β peptide to attenuate Alzheimer-like phenotype in mice. <i>Theranostics</i> , 2023, 13, 106-124.	4.6	9
1737	Postulating the possible cellular signalling mechanisms of antibody drug conjugates in Alzheimer's disease. <i>Cellular Signalling</i> , 2023, 102, 110539.	1.7	5
1738	Proteomic alterations in the cerebellum and hippocampus in an Alzheimer's disease mouse model: Alleviating effect of palmatine. <i>Biomedicine and Pharmacotherapy</i> , 2023, 158, 114111.	2.5	9
1739	The metal ion hypothesis of Alzheimer's disease and the anti-neuroinflammatory effect of metal chelators. <i>Bioorganic Chemistry</i> , 2023, 131, 106301.	2.0	35

#	ARTICLE	IF	CITATIONS
1740	Current Themes and Controversies in the Alzheimer's Disease Field: Looking Ahead to the ctad Meeting in San Francisco, November 29-December 2 2022. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 0, , .	1.5	0
1741	A Review of CRISPR Cas9 for Alzheimer's Disease: Treatment Strategies and Could target APOE e4, APP, and PSEN-1 Gene using CRISPR cas9 Prevent the Patient from Alzheimer's Disease?. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2022, 10, 745-757.	0.1	1
1742	A Review of the Recent Advances in Alzheimer's Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics. <i>Diagnostics</i> , 2022, 12, 2975.	1.3	5
1743	Neuroprotective Effect of Stearidonic Acid on Amyloid β^2 -Induced Neurotoxicity in Rat Hippocampal Cells. <i>Antioxidants</i> , 2022, 11, 2357.	2.2	1
1744	Gantenerumab: an anti-amyloid monoclonal antibody with potential disease-modifying effects in early Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	32
1745	Structure-Activity Relationship of 5-mer Catalytides, GSGYR and RYGSG. <i>Biomolecules</i> , 2022, 12, 1766.	1.8	1
1746	Linking Cerebrovascular Dysfunction to Age-Related Hearing Loss and Alzheimer's Disease Are Systemic Approaches for Diagnosis and Therapy Required?. <i>Biomolecules</i> , 2022, 12, 1717.	1.8	2
1748	Alternative Pharmacological Strategies for the Treatment of Alzheimer's Disease: Focus on Neuromodulator Function. <i>Biomedicines</i> , 2022, 10, 3064.	1.4	1
1749	Connectivity between default mode and frontoparietal networks mediates the association between global amyloid β^2 and episodic memory. <i>Human Brain Mapping</i> , 2023, 44, 1147-1157.	1.9	4
1750	Grabody B, an IGF1 receptor-based shuttle, mediates efficient delivery of biologics across the blood-brain barrier. <i>Cell Reports Methods</i> , 2022, 2, 100338.	1.4	11
1752	Cerebral Superficial Siderosis. <i>Clinical Neuroradiology</i> , 2023, 33, 293-306.	1.0	6
1753	Aryloxypropanolamine targets amyloid aggregates and reverses Alzheimer-like phenotypes in Alzheimer mouse models. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	4
1754	Development of Alkaline Phosphatase-Fused Mouse Prion Protein and Its Application in Toxic $A\beta^2$ Oligomer Detection. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14588.	1.8	1
1755	R-carvedilol, a potential new therapy for Alzheimer's disease. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	0
1756	Swollen axons impair neuronal circuits in Alzheimer's disease. <i>Nature</i> , 2022, 612, 218-220.	13.7	0
1757	Early diagnosis and treatment of Alzheimer's disease by targeting toxic soluble $A\beta^2$ oligomers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	18
1758	Plasma phosphorylated tau181 predicts cognitive and functional decline. <i>Annals of Clinical and Translational Neurology</i> , 2023, 10, 18-31.	1.7	7
1759	Comprehensive evaluation of human-derived anti-poly-GA antibodies in cellular and animal models of <i>C9orf72</i> disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	3

#	ARTICLE	IF	CITATIONS
1760	MRI Monitoring of Anti-Alzheimer Therapy Amyloid-Related Imaging Abnormalities: Due Diligence or Overkill?. American Journal of Neuroradiology, 0, , .	1.2	0
1761	Gut Microbiota and Immunotherapy for Alzheimer's Disease. International Journal of Molecular Sciences, 2022, 23, 15230.	1.8	5
1762	Hierarchical Two-Stage Cost-Sensitive Clinical Decision Support System for Screening Prodromal Alzheimer's Disease and Related Dementias. Journal of Alzheimer's Disease, 2023, 91, 895-909.	1.2	3
1763	Insights into the Pathophysiology of Alzheimer's Disease and Potential Therapeutic Targets: A Current Perspective. Journal of Alzheimer's Disease, 2023, 91, 507-530.	1.2	8
1764	Molecular Mechanism of Cyanidin-3-O-Glucoside Disassembling A β Fibril In Silico. Nutrients, 2023, 15, 109.	1.7	0
1765	Evaluation of a dementia prevention program to improve health and social care and promote human rights among older adults. International Journal of Human Rights in Healthcare, 2022, ahead-of-print, .	0.6	0
1766	Recent advancement in drugs of Alzheimer's disease. International Journal of Basic and Clinical Pharmacology, 2022, 12, 125.	0.0	0
1767	Active immunotherapy reduces γ -secretase 1 deposition in brain capillaries in a C57BL/6J mouse model. EMBO Molecular Medicine, 2023, 15, .	3.3	5
1768	Editorial: The relationship of neuroinflammation with aging and neurodegenerative diseases. Frontiers in Aging Neuroscience, 0, 14, .	1.7	2
1769	Longitudinal Analysis of the Microbiome and Metabolome in the 5xAD Mouse Model of Alzheimer's Disease. MBio, 2022, 13, .	1.8	12
1770	Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	150
1771	Identification of RNA markers associated with Parkinson's disease using multiplex gene expression analysis. Annals of Clinical and Experimental Neurology, 2022, 16, 38-43.	0.1	0
1773	Role of Tau in Various Tauopathies, Treatment Approaches, and Emerging Role of Nanotechnology in Neurodegenerative Disorders. Molecular Neurobiology, 2023, 60, 1690-1720.	1.9	11
1774	Emerging therapeutics agents and recent advances in drug repurposing for Alzheimer's disease. Ageing Research Reviews, 2023, 85, 101815.	5.0	6
1775	Beyond the classical amyloid hypothesis in Alzheimer's disease: Molecular insights into current concepts of pathogenesis, therapeutic targets, and study models. WIREs Mechanisms of Disease, 2023, 15, .	1.5	3
1776	Brain borders at the central stage of neuroimmunology. Nature, 2022, 612, 417-429.	13.7	53
1777	Therapeutic anti-amyloid β antibodies cause neuronal disturbances. Alzheimer's and Dementia, 2023, 19, 2479-2496.	0.4	8
1778	Effects of Melissa officinalis Extract Containing Rosmarinic Acid on Cognition in Older Adults Without Dementia: A Randomized Controlled Trial. Journal of Alzheimer's Disease, 2023, 91, 805-814.	1.2	4

#	ARTICLE	IF	CITATIONS
1779	Brain pharmacokinetics of mono- and bispecific amyloid- β^2 antibodies in wild-type and Alzheimer's disease mice measured by high cut-off microdialysis. <i>Fluids and Barriers of the CNS</i> , 2022, 19, .	2.4	0
1780	Multimodality imaging of neurodegenerative disorders with a focus on multiparametric magnetic resonance and molecular imaging. <i>Insights Into Imaging</i> , 2023, 14, .	1.6	5
1781	A review of harmonization strategies for quantitative PET. <i>Annals of Nuclear Medicine</i> , 2023, 37, 71-88.	1.2	4
1782	Pre-targeting amyloid- β^2 with antibodies for potential molecular imaging of Alzheimer's disease. <i>Chemical Communications</i> , 2023, 59, 2243-2246.	2.2	3
1783	A novel cascade machine learning pipeline for Alzheimer's disease identification and prediction. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	3
1784	Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 0, , .	1.5	1
1785	Iron Oxide Nanoparticle-Incorporated Mesenchymal Stem Cells for Alzheimer's Disease Treatment. <i>Nano Letters</i> , 2023, 23, 476-490.	4.5	7
1786	Microglial autophagy in Alzheimer's disease and Parkinson's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	6
1787	Intranasal delivery of full-length anti-Nogo-A antibody: A potential alternative route for therapeutic antibodies to central nervous system targets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	11
1788	A Review of Scientific Ethics Issues Associated with the Recently Approved Drugs for Alzheimer's Disease. <i>Science and Engineering Ethics</i> , 2023, 29, .	1.7	9
1789	Application of ^{89}Zr -DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid- β^2 monoclonal antibody. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 1306-1317.	3.3	2
1790	Methods for analyzing the coordination and aggregation of metal-amyloid- β^2 . <i>Metallomics</i> , 2023, 15, .	1.0	4
1791	Seeing Neurodegeneration in a New Light Using Genetically Encoded Fluorescent Biosensors and iPSCs. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1766.	1.8	0
1792	Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2023, 50, 45-62.	0.8	1
1793	Potential Alzheimer's disease therapeutic nano-platform: Discovery of amyloid-beta plaque disaggregating agent and brain-targeted delivery system using porous silicon nanoparticles. <i>Bioactive Materials</i> , 2023, 24, 497-506.	8.6	9
1794	Beneficial Effect of ACI-24 Vaccination on $\text{A}\beta^2$ Plaque Pathology and Microglial Phenotypes in an Amyloidosis Mouse Model. <i>Cells</i> , 2023, 12, 79.	1.8	2
1795	A low-dimensional cognitive-network space in Alzheimer's disease and frontotemporal dementia. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	8
1796	Enhanced delivery of a low dose of aducanumab via FUS in 5Å -FAD mice, an AD model. <i>Translational Neurodegeneration</i> , 2022, 11, .	3.6	11

#	ARTICLE	IF	CITATIONS
1797	Drug Discovery to Drug Development of BACE1 Inhibitor as Antialzheimerâ€™s: A Review. Current Topics in Medicinal Chemistry, 2023, 23, 77-97.	1.0	3
1798	Medicarpin and Homopterocarpin Isolated from Canavalia lineata as Potent and Competitive Reversible Inhibitors of Human Monoamine Oxidase-B. Molecules, 2023, 28, 258.	1.7	4
1799	Fc effector of anti-AÎ² antibody induces synapse loss and cognitive deficits in Alzheimerâ€™s disease-like mouse model. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	7
1800	Bloodâ€™brain barrier opening of the default mode network in Alzheimerâ€™s disease with magnetic resonance-guided focused ultrasound. Brain, 2023, 146, 865-872.	3.7	11
1803	Ameliorative Effect of Medicarpin on Scopolamine-Induced Cognitive Impairment in Mice. Processes, 2023, 11, 385.	1.3	0
1804	Drug Discovery and Development Targeting Dementia. Pharmaceuticals, 2023, 16, 151.	1.7	8
1805	8-Hydroxyquinolyl nitrones as multifunctional ligands for the therapy of neurodegenerative diseases. Acta Pharmaceutica Sinica B, 2023, 13, 2152-2175.	5.7	5
1806	Anti-amyloid antibody therapies in Alzheimerâ€™s disease. Brain, 2023, 146, 842-849.	3.7	50
1807	Deconvoluting binding sites in amyloid nanofibrils using time-resolved spectroscopy. Chemical Science, 2023, 14, 1072-1081.	3.7	2
1809	Antibodies as Therapeutic Agents. , 2023, , 131-161.		0
1810	Visualization of the functional neural circuit breakdown process in a mouse model of Alzheimerâ€™s disease and application to the development of new therapies. Folia Pharmacologica Japonica, 2023, 158, 144-149.	0.1	0
1811	Natural IgG antibodies to Î² amyloid are decreased in patients with Parkinsonâ€™s disease. Immunity and Ageing, 2023, 20, .	1.8	0
1812	Blood-Brain Barrier Dysfunction in Normal Aging and Neurodegeneration: Mechanisms, Impact, and Treatments. Stroke, 2023, 54, 661-672.	1.0	16
1814	Vascular Dysfunction in Alzheimerâ€™s Disease: Alterations in the Plasma Contact and Fibrinolytic Systems. International Journal of Molecular Sciences, 2023, 24, 7046.	1.8	5
1815	Aspirin Use and Risk of Alzheimerâ€™s Disease: A 2-Sample Mendelian Randomization Study. Journal of Alzheimer's Disease, 2023, 92, 989-1000.	1.2	4
1816	Adeno-Associated Virus-Mediated Immunotherapy Based on Bispecific Tandem scFv for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2023, , 1-14.	1.2	0
1817	Role of microbial dysbiosis in the pathogenesis of Alzheimer's disease. Neuropharmacology, 2023, 229, 109478.	2.0	10
1818	Newer modalities in the management of Alzheimer's dementia along with the role of aducanumab and lecanemab in the treatment of its refractory cases. Disease-a-Month, 2023, 69, 101547.	0.4	4

#	ARTICLE	IF	CITATIONS
1819	Biopharmaceutical applications of microbial polysaccharides as materials: A Review. <i>International Journal of Biological Macromolecules</i> , 2023, 239, 124259.	3.6	11
1820	Inhibition of ferroptosis through regulating neuronal calcium homeostasis: An emerging therapeutic target for Alzheimer's disease. <i>Ageing Research Reviews</i> , 2023, 87, 101899.	5.0	5
1821	Kaempferol as a therapeutic agent in Alzheimer's disease: Evidence from preclinical studies. <i>Ageing Research Reviews</i> , 2023, 87, 101910.	5.0	9
1822	Diagnosis of Alzheimer's disease: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. <i>Dementia E Neuropsychologia</i> , 2022, 16, 25-39.	0.3	2
1824	My Genome, My Right. , 0, , 183-199.		0
1825	Personalised Medicine and the Politics of Human Nuclear Genome Transfer. , 0, , 17-36.		0
1828	I Run, You Run, We Run. , 0, , 226-244.		0
1829	Personalising Future Health Risk through "Biological Insurance". , 0, , 52-76.		0
1830	"The Best Me I Can Possibly Be". , 0, , 200-225.		0
1831	When There Is No Cure. , 0, , 113-132.		0
1832	Targeting the Brain with Single-Domain Antibodies: Greater Potential Than Stated So Far?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2632.	1.8	5
1833	A Flower-like Brain Targeted Selenium Nanocluster Lowers the Chlorogenic Acid Dose for Ameliorating Cognitive Impairment in APP/PS1 Mice. <i>Journal of Agricultural and Food Chemistry</i> , 2023, 71, 2883-2897.	2.4	3
1834	Response adaptive randomization design for a two-stage study with binary response. <i>Journal of Biopharmaceutical Statistics</i> , 2023, 33, 575-585.	0.4	1
1835	New balance capability index as a screening tool for mild cognitive impairment. <i>BMC Geriatrics</i> , 2023, 23, .	1.1	4
1837	Translational molecular imaging and drug development in Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2023, 18, .	4.4	11
1838	Safety, Feasibility, and Potential Clinical Efficacy of 40â€ŠHz Invisible Spectral Flicker versus Placebo in Patients with Mild-to-Moderate Alzheimer's Disease: A Randomized, Placebo-Controlled, Double-Blinded, Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2023, 92, 653-665.	1.2	5
1839	Aducanumab for the treatment of Alzheimer's disease: a systematic review. <i>Psychogeriatrics</i> , 2023, 23, 512-522.	0.6	21
1840	Drug trial for Alzheimer's disease is a game changer. <i>Nature</i> , 2023, 615, 42-43.	13.7	7

#	ARTICLE	IF	CITATIONS
1841	Reduced secretion of LCN2 (lipocalin 2) from reactive astrocytes through autophagic and proteasomal regulation alleviates inflammatory stress and neuronal damage. <i>Autophagy</i> , 2023, 19, 2296-2317.	4.3	7
1842	Preclinical Research on Focused Ultrasound-Mediated Blood-Brain Barrier Opening for Neurological Disorders: A Review. <i>Neurology International</i> , 2023, 15, 285-300.	1.3	5
1843	In vivo characterization of cerebrovascular impairment induced by amyloid β peptide overload in glymphatic clearance system using swept-source optical coherence tomography. <i>Neurophotonics</i> , 2023, 10, .	1.7	2
1844	CSF biomarker concordance with amyloid PET in Phase 3 studies of aducanumab. <i>Alzheimer's and Dementia</i> , 2023, 19, 3379-3388.	0.4	1
1845	Lessons from anti-amyloid- β immunotherapies in Alzheimer's disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2023, , 267-291.	1.0	7
1846	Geschlechtsspezifische Besonderheiten zu ausgewählten Gesundheitsthemen. , 2023, , 85-123.		0
1847	Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method. <i>Antibody Therapeutics</i> , 2023, 6, 76-86.	1.2	0
1848	Protein Interactome of Amyloid- β as a Therapeutic Target. <i>Pharmaceuticals</i> , 2023, 16, 312.	1.7	4
1849	Frauengesundheit "Frauenmedizin. , 2023, , e1-e39.		0
1850	Plant-derived peptides for the improvement of Alzheimer's disease: Production, functions, and mechanisms. <i>Food Frontiers</i> , 2023, 4, 677-699.	3.7	4
1851	Roles of Microglia in AD Pathology. <i>Current Alzheimer Research</i> , 2023, 19, 854-869.	0.7	2
1852	Aducanumab "Hope or Disappointment for Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4367.	1.8	19
1853	Identification of Chromatin Regulatory Factors Related to Immunity and Treatment of Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2023, 73, 85-94.	1.1	0
1854	Diagnóstico da doença de Alzheimer: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. <i>Dementia E Neuropsychologia</i> , 2022, 16, 25-39.	0.3	5
1855	Impacts of FDA approval and Medicare restriction on anti-amyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development. <i>The Lancet Regional Health Americas</i> , 2023, 20, 100467.	1.5	5
1856	Mechanistic Insight into the Amyloid Fibrillation Inhibition of Hen Egg White Lysozyme by Three Different Bile Acids. <i>Journal of Physical Chemistry B</i> , 2023, 127, 2198-2213.	1.2	3
1857	Metal-mediated nanobody assemblies as potent alleviators of human islet amyloid polypeptide aggregation. <i>Materials Chemistry Frontiers</i> , 2023, 7, 2068-2077.	3.2	4
1858	RyR2-dependent modulation of neuronal hyperactivity: A potential therapeutic target for treating Alzheimer's disease. <i>Journal of Physiology</i> , 0, , .	1.3	1

#	ARTICLE	IF	CITATIONS
1859	Modifying Dietary Protein Impacts mTOR Signaling and Brain Deposition of Amyloid β in a Knock-In Mouse Model of Alzheimer Disease. <i>Journal of Nutrition</i> , 2023, 153, 1407-1419.	1.3	1
1860	β -Carotene, a Potent Amyloid Aggregation Inhibitor, Promotes Disordered $A\beta$ Fibrillar Structure. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5175.	1.8	1
1861	Commentary: A nearly forgotten class of anti-inflammatory lipid molecules in central nervous system. <i>Acta Pharmaceutica Sinica B</i> , 2023, , .	5.7	0
1862	Metal-Organic Frameworks as Sensors for Human Amyloid Diseases. <i>ACS Sensors</i> , 2023, 8, 1033-1053.	4.0	14
1863	β -Glucan attenuates cognitive impairment of <i>APP/PS1</i> mice via regulating intestinal flora and its metabolites. <i>CNS Neuroscience and Therapeutics</i> , 2023, 29, 1690-1704.	1.9	10
1864	Disturb mitochondrial associated proteostasis: Neurodegeneration and imperfect ageing. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	4
1865	Alleviating the unwanted effects of oxidative stress on $A\beta$ clearance: a review of related concepts and strategies for the development of computational modelling. <i>Translational Neurodegeneration</i> , 2023, 12, .	3.6	2
1866	Lecanemab Ushers in a New Era of Anti-Amyloid Therapy for Alzheimer's Disease. <i>Annals of Neurology</i> , 2023, 93, 877-880.	2.8	3
1867	Effectiveness and safety of monoclonal antibodies against amyloid-beta vis-à-vis placebo in mild or moderate Alzheimer's disease. <i>Frontiers in Neurology</i> , 0, 14, .	1.1	1
1868	The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders. <i>Advances in Neurobiology</i> , 2023, , 255-285.	1.3	0
1869	Assessing preparedness for Alzheimer disease-modifying therapies in Australasian health care systems. <i>Medical Journal of Australia</i> , 2023, 218, 247-249.	0.8	1
1870	ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2023, 9, .	1.8	22
1871	Oligomerization by co-assembly of β -amyloid and τ -synuclein. <i>Frontiers in Molecular Biosciences</i> , 0, 10, .	1.6	0
1872	Alpha Synuclein: Neurodegeneration and Inflammation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5914.	1.8	11
1873	Amyloid inhibition by molecular chaperones <i>in vitro</i> can be translated to Alzheimer's pathology <i>in vivo</i> . <i>RSC Medicinal Chemistry</i> , 2023, 14, 848-857.	1.7	10
1874	Immunotherapy targeting plasma ASM is protective in a mouse model of Alzheimer's disease. <i>Nature Communications</i> , 2023, 14, .	5.8	4
1875	Dendrimers and Derivatives as Multifunctional Nanotherapeutics for Alzheimer's Disease. <i>Pharmaceutics</i> , 2023, 15, 1054.	2.0	6
1876	Insulin-like growth factor-2 is a promising candidate for the treatment and prevention of Alzheimer's disease. <i>CNS Neuroscience and Therapeutics</i> , 2023, 29, 1449-1469.	1.9	2

#	ARTICLE	IF	CITATIONS
1877	Profiling and Cellular Analyses of Obesity-Related circRNAs in Neurons and Glia under Obesity-like In Vitro Conditions. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6235.	1.8	0
1878	Clinical Management in Alzheimer's Disease in the Era of Disease-Modifying Therapies. <i>Current Treatment Options in Neurology</i> , 2023, 25, 121-133.	0.7	1
1880	Extravasation of biodegradable microspheres in the rat brain. <i>Drug Delivery</i> , 2023, 30, .	2.5	1
1881	A new class of monoclonal A β 2 antibodies selectively targets and triggers deposition of A β 2 protofibrils. <i>Journal of Neurochemistry</i> , 2023, 165, 860-873.	2.1	2
1882	Structural and molecular insights into tacrine-benzofuran hybrid induced inhibition of amyloid- β 2 peptide aggregation and BACE1 activity. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 13211-13227.	2.0	0
1883	Ketogenic Diet as a Promising Non-Drug Intervention for Alzheimer's Disease: Mechanisms and Clinical Implications. <i>Journal of Alzheimer's Disease</i> , 2023, 92, 1173-1198.	1.2	3
1884	New Insights into Alzheimer's Disease: Novel Pathogenesis, Drug Target and Delivery. <i>Pharmaceutics</i> , 2023, 15, 1133.	2.0	2
1885	Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid- β 2 monoclonal antibodies in dominantly inherited Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 2669-2682.	3.3	1
1886	Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. <i>Journal of Clinical Apheresis</i> , 2023, 38, 77-278.	0.7	81
1887	Antibody-guided proteases enable selective and catalytic degradation of challenging therapeutic targets. <i>Journal of Biological Chemistry</i> , 2023, 299, 104685.	1.6	2
1888	Lama2 And Samsn1 Mediate the Effects of Brn4 on Hippocampal Neural Stem Cell Proliferation and Differentiation. <i>Stem Cells International</i> , 2023, 2023, 1-21.	1.2	0
1889	Biomarkers of Alzheimer's disease: Past, present and future clinical use. <i>Biomarkers in Neuropsychiatry</i> , 2023, 8, 100063.	0.7	3
1890	Five-mer peptides prevent short-term spatial memory deficits in A β 25-35-induced Alzheimer's model mouse by suppressing A β 25-35 aggregation and resolving its aggregate form. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	3.0	4
1891	Discoveries and future significance of research into amyloid-beta/ β 7-containing nicotinic acetylcholine receptor (nAChR) interactions. <i>Pharmacological Research</i> , 2023, 191, 106743.	3.1	3
1892	Carriers of the p.P522R variant in PLC β 2 have a slightly more responsive immune system. <i>Molecular Neurodegeneration</i> , 2023, 18, .	4.4	4
1893	Leveraging the glymphatic and meningeal lymphatic systems as therapeutic strategies in Alzheimer's disease: an updated overview of nonpharmacological therapies. <i>Molecular Neurodegeneration</i> , 2023, 18, .	4.4	5
1894	Women and Alzheimer's disease. , 2023, , 273-305.		0
1895	Informatics and computational methods in natural product drug discovery. , 2023, , 147-166.		0

#	ARTICLE	IF	CITATIONS
1917	Therapy and diagnosis of Alzheimer's disease: from discrete metal complexes to metal-organic frameworks. <i>Journal of Materials Chemistry B</i> , 2023, 11, 7024-7040.	2.9	2
1929	The impact of systemic inflammation on neuroinflammation. , 2023, , 169-188.		0
1930	Amyloid- β^2 Can Form Fractal Antenna-Like Networks Responsive to Electromagnetic Beating and Wireless Signaling. <i>Lecture Notes in Networks and Systems</i> , 2023, , 323-344.	0.5	0
1934	Amyloid β^2 -based therapy for Alzheimer's disease: challenges, successes and future. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	49
1938	Effects of adenosine A2A receptors on cognitive function in health and disease. <i>International Review of Neurobiology</i> , 2023, , .	0.9	0
1942	Recent developments in the chemical biology of amyloid- β^2 oligomer targeting. <i>Organic and Biomolecular Chemistry</i> , 2023, 21, 4540-4552.	1.5	5
1946	Detection and treatment of Alzheimer's disease in its preclinical stage. <i>Nature Aging</i> , 2023, 3, 520-531.	5.3	12
1952	Microtechnologies for single-cell and spatial multi-omics. , 2023, 1, 769-784.		2
1954	Recent Advances in Computational Modeling of BACE1 Inhibitors as Anti-Alzheimer Agents. <i>Neuromethods</i> , 2023, , 73-97.	0.2	0
1955	Understanding the Mechanisms of Amyloid Beta ($A\beta^2$) Aggregation by Computational Modeling. <i>Neuromethods</i> , 2023, , 51-71.	0.2	0
1961	TRP (transient receptor potential) ion channel family: structures, biological functions and therapeutic interventions for diseases. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	20
1963	Cognitive Enhancers and Treatments for Alzheimer's Disease. , 2023, , 1-42.		0
1968	Role of neuroinflammation in neurodegeneration development. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	62
1970	Alternative Hypotheses and Observations that Were Somehow Lost on the Way. , 2023, , 385-449.		0
1971	The Amyloid Cascade Hypothesis Has to Deliver, Finally. , 2023, , 309-350.		0
1973	Driving Forces of Alzheimer's Research Directions. , 2023, , 471-526.		0
1983	Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update. <i>Neurotherapeutics</i> , 2023, 20, 914-931.	2.1	22
1986	TO MARKET, TO MARKET-2021: MACROMOLECULAR THERAPEUTICS. <i>Medicinal Chemistry Reviews</i> , 0, , 733-805.	0.1	0

#	ARTICLE	IF	CITATIONS
1988	POSITRON EMISSION TOMOGRAPHY NEUROIMAGING IN DRUG DISCOVERY AND DEVELOPMENT. Medicinal Chemistry Reviews, 0, , 61-90.	0.1	0
1992	Pathological Roles of INPP5D in Alzheimer's Disease. Advances in Experimental Medicine and Biology, 2023, , 289-301.	0.8	0
2005	Traits and Trammels of Tau Tracer Imaging. , 2023, , 85-107.		0
2015	Recent progress of small-molecule-based theranostic agents in Alzheimer's disease. RSC Medicinal Chemistry, 0, , .	1.7	0
2020	The use of neuroimaging techniques in the early and differential diagnosis of dementia. Molecular Psychiatry, 2023, 28, 4084-4097.	4.1	2
2022	Emerging diagnostics and therapeutics for Alzheimer disease. Nature Medicine, 2023, 29, 2187-2199.	15.2	20
2029	Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer's disease treatment. Inflammation Research, 2023, 72, 1873-1876.	1.6	0
2036	Simultaneous PET/MR Imaging of Dementia. , 2023, , 241-253.		0
2037	Clinical efficacy and controversies of aducanumab. , 2023, , .		0
2043	Co-pathology may impact outcomes of amyloid-targeting treatments: clinicopathological results from two patients treated with aducanumab. Acta Neuropathologica, 2023, 146, 777-781.	3.9	2
2050	Electrochemical Biosensors for Drugs Detection. , 2023, , 101-118.		0
2057	Emerging Stem Cell Therapy and Tissue Engineering-Based Approaches in Neurodegenerative Diseases. , 2023, , 1-49.		0
2080	Inhibitors of Oxytosis/Ferroptosis: A New Class of Therapeutics for Alzheimer's Disease. , 2023, , 461-490.		0
2087	Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease. BioDrugs, 2024, 38, 5-22.	2.2	5
2097	Neuroimaging Biomarkers in Alzheimer's Disease and Related Disorders. , 2023, , 163-188.		0
2123	Microbubbles-based drug delivery for antiAlzheimer's drugs. , 2024, , 403-419.		0
2131	A new era in Alzheimer's disease management: exploring aducanumab's potential. , 2024, , .		0
2135	Current trends and updates in the treatment of Alzheimer's disease. , 2024, , 373-390.		1

#	ARTICLE	IF	CITATIONS
2138	Metabolomic of neurodegenerative disorder: Alzheimer's disease. Comprehensive Analytical Chemistry, 2024, , 183-215.	0.7	0
2152	Acid sphingomyelinase as a pathological and therapeutic target in neurological disorders: focus on Alzheimer's disease. Experimental and Molecular Medicine, 2024, 56, 301-310.	3.2	0
2157	Anti-amyloid Antibody Therapies for Alzheimer's Disease. Nuclear Medicine and Molecular Imaging, 0, , .	0.6	0